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RESUMO GERAL 
 
Galacto-oligosacarídeos (GOS) são prebióticos obtidos via 
transgalactosilação enzimática da lactose. Dentre os vários benefícios associados 
ao consumo de GOS destaca-se a capacidade de estimular o crescimento e 
atividade de bactérias benéficas no cólon. O objetivo deste estudo foi avaliar as 
propriedades prebióticas dos GOS sintetizados, a partir da lactose, por β-
galactosidase de Scopulariopsis sp. A digestibilidade e a fermentabilidade foram 
avaliadas in vitro, enquanto os efeitos prebióticos foram avaliados in vivo em um 
conjunto de experimentos com ratos Wistar. Os resultados observados in vitro 
demonstraram que os GOS produzidos neste estudo são indigeríveis, altamente 
fermentáveis e convertidos em ácidos graxos de cadeia curta (acetato, propionato 
e butirato). Estudos in vivo demonstraram que o consumo de diferentes doses de 
GOS por 42 dias não produziu efeitos tóxicos nos animais, evidenciado a partir de 
avaliações clínicas, exames hematológicos, bioquímicos, necroscópicos e 
histológicos. Os ratos suplementados com GOS apresentaram maior (p<0.05) 
população cecal de bifidobactérias (log10 10,05 ± 0,27 UFC/g) e lactobacilos (log10 
8,92 ± 0,16 UFC/g). Para os ratos não suplementados com GOS estas proporções 
foram de log10 8,22 ± 0,33 e 7,2 ± 0,15 UFC/g, para bifidobacterias e lactobacilos, 
respectivamente. Por outro lado, a população de Escherichia coli foi 
significativamente reduzida (p<0.05), sendo 24,75% menor, quando comparada ao 
grupo controle sem GOS. Além disso, a fermentação dos GOS pelas bactérias 
intestinais resultou em um aumento na produção de ácidos graxos de cadeia curta 
de 2,73 vezes, em relação aos animais sem acréscimo de GOS na dieta. 
xii 
 
Observou-se, ainda, que o grupo suplementado com GOS apresentou maiores 
valores de espessura total da mucosa, altura dos vilos e profundidade das criptas, 
evidenciado pela maior relação altura de vilosidades:profundidade de cripta em 
relação ao grupo controle.  
 
Palavras-chave: Galacto-oligossacarídeos, digestibilidade, fermentação, ácidos 
graxos de cadeia curta, microbiota intestinal, morfometria intestinal. 
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ABSTRACT 
 
Galacto-oligosaccharides (GOS) are prebiotics obtained via 
transgalactosylation enzymatic of lactose. Among the many benefits associated 
with consumption of GOS stands the ability to stimulate growth and activity of 
beneficial bacteria in the colon. The objective of this study was to evaluate the 
properties of prebiotic GOS synthesized from lactose by β-galactosidase from 
Scopulariopsis sp. The digestibility and fermentability were evaluated in vitro, while 
the prebiotic effects were evaluated in vivo in a series of experiments with Wistar 
rats. The results observed in vitro showed that the GOS produced by this study are 
indigestible highly fermentable and converted into short-chain fatty acids (acetate, 
propionate and butyrate). In vivo studies have showed that consumption of 
different doses of GOS for 42 days produced no toxic effects in animals, as 
evidenced from clinical, hematological, biochemical, and histological necropsy. The 
rats supplemented with GOS had higher (p<0.05) cecal populations of 
bifidobacteria (log10 10.05 ± 0.27 UFC/g) and lactobacillus (log10 8.92 ± 0.16 
UFC/g).  For rats not supplemented with GOS these proportions were log10  8.22 ± 
0.33 and 7.2 ± 0.15 UFC/g, for bifidobacteria and lactobacillus, respectively. 
Furthermore, the population of Escherichia coli was significantly reduced (p<0.05) 
and 24.75% less when compared to controls without GOS. Furthermore, the GOS 
fermentation by intestinal bacteria resulted in an increase in the production of short 
chain fatty acids from 2.73 times in compared with those without the addition of 
GOS diet. 
xiv 
 
It was observed also the supplemented group with GOS showed higher values of 
total mucosal thickness, villous height and crypt depth, evidenced by the higher 
ratio of villus height: crypt depth in the control group. 
 
Keywords: Galacto-oligosaccharides, digestibility, fermentation, short chain fatty 
acids, intestinal microbiota, intestinal morfometric. 
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ESTRUTURA DA TESE 
 
 
 
Esta tese está estruturada em sete capítulos. Nos Capítulos I e II são 
apresentados uma revisão da literatura sobre produção, aplicação e efeitos 
benéficos do prebióticos galacto-oligosacarídeos (GOS) na saúde humana. No 
Capítulo III são apresentados os resultados obtidos ao testar o potencial 
prebióticos in vitro dos GOS produzidos por Scopulariopsis sp. No Capítulo IV 
apresentam-se os resultados obtidos in vivo ao testar a segurança toxicológica 
dos GOS em ratos. No Capítulo V são apresentados os resultados obtidos ao 
testar os efeitos prebióticos dos GOS sobre a microbiota cecal, características das 
fezes e função intestinal em ratos. No Capítulo VI são apresentados os resultados 
obtidos ao testar os efeitos dos prebióticos GOS e FOS sobre a morfologia 
intestinal de ratos. O Capítulo VII descreve os resultados obtidos ao testar os 
efeitos prebióticos de diferentes oligossacarídeos. Os capítulos foram mantidos na 
forma de artigos e formatados de acordo com as normas das revistas os quais 
serão submetidos.  A tese também fornece um resumo dos principais resultados 
obtidos nos experimentos.  
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INTRODUÇÃO GERAL 
 
 
 Consumidores preocupados com a saúde estão buscando cada vez mais 
alimentos saudáveis que possam contribuir com a saúde e o bem-estar. Este 
crescente interesse por uma alimentação equilibrada tem incentivado pesquisas 
de novos componentes naturais biologicamente ativos e tem mudado o 
entendimento do papel da alimentação sobre a saúde (THAMER & PENNA, 2006;  
ARAÚJO, 2007). Neste contexto, os alimentos funcionais vêm ganhando posição 
de destaque na alimentação humana (SAAD, 2006) 
  A Portaria n.º 398, de 30 de abril de 1999, do Ministério da Saúde, define 
alimento funcional como sendo “todo aquele alimento ou ingrediente que, além 
das funções nutricionais básicas, quando consumido como parte da dieta usual, 
produza efeitos metabólicos e/ou fisiológicos e/ou efeitos benéficos a saúde, 
devendo ser seguro para consumo sem supervisão médica” (BRASIL, 1999, 
CRAVEIRO & CRAVEIRO, 2003). 
Atualmente, os grupos biologicamente ativos mais conhecidos, que agem 
como ingredientes funcionais, são:  fibras solúveis e insolúveis, flavonóides, 
carotenóides, fotosteróis, fitostanóis, ácidos graxos (ômega 3 e ômega 6),  
probióticos e prebióticos (TORRES, 2001; MERINO, 2006; BORTOLOZO &  
QUADROS, 2007; ABREU et al., 2011).  
A literatura científica sobre probióticos e prebióticos apresentou crescimento 
expressivo nos últimos 10 anos. Seus mecanismos de ação vêm sendo 
investigados experimentalmente (MORAIS & JACOB, 2006; ROBERFROID, 
GIBSON, HOYLES, 2010). Os prebióticos têm sido estudados como ingredientes 
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em vários alimentos, entre eles bebidas lácteas funcionais ou simbióticas (SILVA 
& STAMFORD, 2000; ABREU et al., 2011). 
Os prebióticos são componentes alimentares não-digeríveis que afetam 
beneficamente o  hospedeiro, por estimularem seletivamente a proliferação ou 
atividade de populações de bactérias desejáveis no cólon. Adicionalmente, os 
prebióticos podem inibir a multiplicação de patógenos, garantindo benefícios 
adicionais à saúde do hospedeiro (GIBSON & ROBERFROID, 1995; 
ROBERFROID, 2007, ROBERFROID, GIBSON, HOYLES, 2010). 
 Entre as substâncias prebióticas, destacam-se a Inulina, fruto-
ologosacarídeos (FOS), galacto-oligosacarídeos (GOS), soja-oligosacarídeos, xilo-
oligosacarídeos, isomalto-oligosacarídeos, e lactulose entre outros (SAKI, 
MATSUMOTO, TANALA, 1999; CHEN &  WALKER, 2005). 
Porém, segundo ROBERFROID et al. (2010) somente dois tipos de 
oligossacarídeos são considerados prebióticos, ou seja, frutanos  do tipo inulina e 
os galacto-oligossacarídeos (GOS). Estes têm demonstrado repetidamente a 
capacidade seletiva de estimular o crescimento de bifidobactérias e, em alguns 
casos, os lactobacilos levando a uma significativa mudança na composição da 
microbiota intestinal. 
Em relação à estrutura química, os fruto-oligossacarídeos (FOS) são 
oligômeros de frutose compostos por moléculas de sacarose às quais adicionaram 
uma, duas ou três unidades de frutose através de ligações glicosídicas β(2,1) à 
subunidade frutose da sacarose. As estruturas resultantes são denominadas: 1-
kestose (GF2), nistose (GF3 ) e 1F β-frutofuranosil nistose (GF4), e possuem a 
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seguinte distribuição percentual: 34% de 1-kestose, 53% de nistose e 10% de 1F 
β-frutofuranosil nistose (FORTES & MINIZ, 2009).  
Os FOS podem ser encontrados naturalmente em alguns alimentos de 
origem vegetal como frutas e hortaliças, também podem ser obtidos 
enzimaticamente a partir de enzimas vegetais e microbianas. Dependendo da 
fonte enzimática os FOS podem diferir-se pelo tamanho da cadeia e pela ligação 
entre as moléculas de açúcares (YUN, 1996; BOSSCHER, LOO, FRANCK, 2006). 
Os GOS são uma mistura de oligossacarídeos encontrados naturalmente 
no leite humano e pode ser produzido através da ação da enzima β-galactosidase 
utilizando a lactose como substrato (MACFARLENE, STEED, MACFARLENE, 
2008; SANTOS, SIMIQUELI,  PASTORE, 2009; MARTINS &  BURKERT, 2009). 
 São oligossacarídeos resistentes à ação hidrolítica das enzimas intestinais 
atingindo o cólon praticamente intacto, onde são seletivamente fermentados pelas 
bifidobactérias (CHUNG & DAY, 2004, BÚRIGO et al., 2007), permitindo o 
crescimento da flora bifidogênica, reduzindo a colonização de patógenos 
(ROBERFROID, 2007). 
 Os aumentos dos níveis de bactérias benéficas no intestino resultantes do 
consumo dos GOS são associados a uma serie de efeitos positivos nos sistemas 
digestório e imunológico. Estes incluem o desenvolvimento da barreira da mucosa, 
ativação do sistema imunológico, metabolismo dos ácidos biliares, síntese de 
vitaminas do complexo B, maior absorção de cálcio da dieta (BRUZZESE et al., 
2006; DUARTE et al., 2010, SANGWAN et al., 2011). 
  A fermentação dos GOS através das bactérias resulta em um aumento na 
produção de ácidos graxos de cadeia curta (AGCC), especialmente acetato, 
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propionato e butirato (CUMMINGS, MACFARLANE, ENGLYST, 2001; GIBSON et 
al., 2004; DUARTE et al., 2010, SANGWAN et al., 2011).  A taxa e a quantidade 
da produção dos AGCC depende das espécies e as quantidades da microbiota 
presente no cólon, a fonte de substrato e do tempo de trânsito do intestino (WONG 
et al., 2006). 
OS AGCC têm importante papel na fisiologia do intestino, é reconhecido 
como principal fonte de energia para o enterócito; estimula a proliferação celular 
do epitélio; melhora o fluxo sanguíneo; aumentam a absorção de água e sódio, 
diminui o pH intraluminal (LAJOLO et al., 2001, ROBERFROID, GIBSON, 
HOYLES,  2010), favorecendo a  absorção de vitamina K, magnésio e de cálcio no 
colon (DONATTO et al., 2006).  Além disso, os AGCC têm sido associados com a 
redução do risco de desenvolver algumas doenças, como a síndrome do colon 
irritável, doença inflamatória intestinal, câncer de cólon e redução de colesterol 
(HIJOVA  & CHMELAROVA , 2007; TOPPING & CLIFTON, 2008 ). 
 Os GOS também têm sido associados com a melhoria dos hábitos 
intestinais. Seu efeito na melhoria da obstipação é largamente atribuído ao 
aumento da biomassa microbiana que resulta de sua fermentação, bem como 
promovem um aumento na freqüência de evacuações (NIITTYNEN, KAJANDER,  
KORPELA  et al., 2007),  efeitos estes que confirmam a sua classificação no 
conceito atual de fibras da dieta (ROBERFROID, 2002; KAUR & GUPTA, 2002; 
COSTALOS et al., 2008). 
 Dentre os prebióticos os GOS tornaram-se foco de atenção na área de 
compostos bioativos em alimentos, devido aos seus benefícios de saúde e 
potenciais para melhorar a qualidade dos alimentos (DUARTE et al., 2010). 
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Em virtude dos efeitos benéficos produzidos pelo GOS, tem havido um 
considerável interesse por parte das indústrias em desenvolver produtos 
alimentícios que contenham estes ingredientes funcionais (GIBSON, FULLER, 
2000; ROBERFROID, 2000; ROBERFROID, 2007; DUARTE et al., 2010; RAIZEL 
et al., 2011).  
Com isso, se faz necessário a realização de pesquisas, com o intuito de 
comprovar os reais benefícios do seu consumo. Nesse sentido, este trabalho teve 
como objetivo avaliar in vitro e in vivo os possíveis efeitos prebióticos dos GOS 
produzido pela β-galactosidase por Scopulariopsis sp. 
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JUSTIFICATIVA 
 
    
 
Este trabalho se propôs a investigar as possíveis propriedades funcionais e 
os efeitos prebióticos relacionados com os galacto-oligossacarídeos (GOS) 
produzidos pela atividade enzimática da β- galactosidase pelo fungo 
Scopulariopsis sp. Pouca investigação tem sido documentada na literatura 
científica a respeito da atividade prebióticas frente aos parâmetros fermentativos e 
ao efeito bifidogênico dos GOS produzido por Scopulariopsis sp. Neste contexto, 
faz-se necessário, investigar seus efeitos prebióticos in vitro e in vivo. 
Evidências científicas têm demonstrado que os GOS são capazes de atuar 
no organismo humano, produzindo efeitos metabólico e/ou fisiológicos benéfico à 
saúde humana, mas a contribuição mais importante destes açúcares está 
associada a uma melhora na composição da microbiota intestinal, devido às 
características fermentativas especiais que estes compostos apresentam no 
organismo humano. 
 Diante dos benefícios da ingestão dos GOS demonstrados por meio de 
pesquisas e pouco trabalhos que avaliou as propriedades funcionais e os efeitos 
prebióticos dos GOS produzido por Scopulariopsis sp, justifica-se a realização 
deste estudo. 
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OBJETIVOS 
 
Objetivos Gerais: 
 
Avaliar in vitro a digestibilidade a fermentabilidade de um novo galacto-
oligosacarídeos produzido pela atividade enzimática da β-galactosidade derivada 
do fungo Scopulariopsis sp, bem como avaliar  in vivo os efeitos da 
suplementação dos GOS  sobre os parâmetros histopatológicos, hematológicos, 
bioquímicos, microbiota intestinal, produção de ácidos graxos de cadeia curta  
(AGCC) de cadeias curtas. Valores de pH e efeitos tróficos sobre o intestino 
delgado utilizando ratos Wistar como modelo animal.  
 
Objetivos Específicos: 
 
Capítulo 1 - Realizar levantamento bibliográfico abordando as propriedades físico-
químicas e tecnológicas dos GOS; 
 
Capítulo 2- Realizar levantamento bibliográfico com ênfase nos principais efeitos 
benéficos dos GOS para a saúde humana; 
 
Capítulo 3- Avaliar a digestibilidade e a fermentabilidade in vitro dos GOS 
utilizando enzimas digestivas e inoculo fecal de ratos; 
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Capítulo 4- Avaliar os efeitos da suplementação dos GOS sobre os parâmetros 
histopatológicos, hematológicos e bioquímicos em ratos Wistar; 
 
Capítulo 5- Avaliar os efeitos da suplementação dos GOS sobre a microbiota 
intestinal, produção de ácidos graxos de cadeia curta  (AGCC) de cadeias curtas e 
valores de pH em ratos Wistar; 
 
Capítulo 6- Avaliar os efeitos da suplementação dos GOS sobre a produção de 
ácidos graxos de cadeia curta (AGCC), valores de pH e os possíveis efeitos 
tróficos no intestino delgado de ratos Wistar; 
 
Capítulo 7- Avaliar os efeitos da suplementação de diferentes oligossacarídeos 
sobre a produção de ácidos graxos de cadeia curta (AGCC), valores de pH cecal e 
fecal, microbiota intestinal e morfologia intestinal utilizando ratos Wistar como 
modelo animal e comparar os efeitos prebióticos dos GOS com os prebióticos 
comerciais.  
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Abstract 
 
 
Galacto-oligosaccharides (GOS) are naturally-occurring oligosaccharides in human 
milk and can be produced through the action of β-galactosidase using lactose as 
substrate. In recent years, some of the most significant developments in functional 
food have related to development new product   containing prebiotic GOS.  The 
number of total launches in prebiotic products was five times higher in 2011 than in 
2005. The major growth was observed in products containing GOS. On average 
every three days a new product with GOS was launched in the world. Factors 
driving growth of the GOS in prebiotic products was the growth in awareness of the 
health benefits    of prebiotics. The GOS can be incorporated in to a wide variety of 
products, ranging from infant milk formula, yogurts, energy drinks, beverages (fruit 
juices and other acid drinks), fermented milks, flavored milks, and confectionery 
products. The increased interest of the consumers for these products heightened 
the need for the development in new biotechnological methods   efficient and 
inexpensive GOS production. This article presents a review of the literature on the 
production, applications and physiological effects of prebiotics GOS.   
 
 
Keywords: Galacto-oligosaccharides, β-galactosidase, prebiotics, technological 
properties, transgalactosylation. 
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Resumo 
 
Galacto-oligosacarídeos (GOS) são oligossacarídeos de ocorrência natural 
no leite humano e podem ser produzidos através da ação da β-galactosidase 
usando lactose como substrato. Nos últimos anos, alguns dos desenvolvimentos 
mais significativos em alimentos funcionais têm relacionado ao desenvolvimento 
de novos produtos contendo os prebióticos GOS. O número total de lançamentos 
de produtos prebióticos foi cinco vezes maior em 2011 do que em 2005. O maior 
crescimento foi observado em produtos que continham GOS. Em média a cada 
três dias um novo produto com GOS foi lançado no mundo. Fatores que 
impulsionam o crescimento dos GOS em produtos prebióticos foi o crescimento da 
consciência dos benefícios de saúde dos prebióticos. Os GOS podem ser 
incorporados em uma grande variedade de produtos, que vão desde fórmula de 
leite infantil, yogurts, bebidas energéticas, bebidas (suco de fruta e bebidas ácidas 
e outros), leites fermentados, leites aromatizados e produtos de confeitaria. O 
aumento do interesse dos consumidores para estes produtos aumentaram a 
necessidade do desenvolvimento de novos métodos biotecnológicos eficientes e 
de baixo custo para a produção de GOS. Este artigo apresenta uma revisão da 
literatura sobre a produção, aplicação e efeitos fisiológicos do prebióticos  dos 
GOS. 
 
Palavras-chave: Galacto-oligosacarídeos, β-galactosidase,  prebioticos, 
propriedades tecnológicas, transgalactosilação.  
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1 – Introduction 
 
Galacto-oligosaccharides (GOS) are oligosaccharides that consist mainly of 
galactose monomers linked together through several different structural 
configurations (PLAYNE; CRITTENDEN, 2009). They are classified as prebiotic 
food because they can selectively stimulate the growth of bifidobacteria and 
lactobacilli in the lower intestine (SANZ-VALERO, 2009). 
 
GOS have been established as prebiotic ingredients in vitro and in vivo 
studies (animal and human). Currently, GOS are produced by β-Galactosidase   
using lactose as substrate (DUARTE et al., 2010). GOS is a promising food 
additive because it is stable in acidic and high- temperature conditions. Therefore, 
GOS can be applied in a wide variety of foods such as fermented milk products, 
breads, jams, confectionaries, beverages, etc. (SAKO et al., 1999).  
 
The production of GOS, like other oligosaccharides, is becoming of 
increasing interest, as their beneficial effects on human health effects and wide 
applications as prebiotic food, new biotechnological capabilities promise to expand 
of the GOS market exponentially. (YANG; BEDNARCIK, 2001; NERI et al., 2011). 
 
The composition of the obtained GOS mixture and, above all, its chemical 
and structural composition will contribute not only to the development of advanced 
fractionation/separation processes of the different GOS but will also play an 
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important role in the understanding of the mechanisms associated with the 
prebiotic properties of the GOS (NERI et al., 2011). 
 
Recent evidence suggests that the GOS stimulates the growth of 
bifidobacteria and lactobacilli and reduces the growth of pathogens, modulation of 
the immune system, relief of constipation, reduction in the risk of colon cancer, 
increased absorption of minerals, improved synthesis of vitamins of the B-complex, 
reduction in serum total cholesterol and lipids (SANGWAN  et al., 2011). 
 
Despite the increasing number of publications documenting the production 
and application the GOS, several studies have shown that the main problem for 
your production is purification. Therefore, there is now considerable interest in new 
biotechnological methods to enhance production and yield of the GOS. This review 
focuses on production, applications and physiological effects of the GOS prebiotic 
are summarized. 
 
 
2 - Galacto-oligosaccharides: Definition, Composition and Properties 
  
 The GOS were recently defined as “a mixture of oligosaccharides occurring 
naturally in human milk and can be produced from lactose. GOS generally 
comprise a chain of galactose units that arise through consecutive 
transgalactosylation reactions, with a terminal glucose unit. The degree of 
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polymerization of GOS can vary quite markedly, ranging from 2 to 8 monomeric 
units (SANTOS; SIMIQUELI; PASTORE, 2009). 
 
 The GOS are characterized by their indigestible nature, therefore they 
belong  to the group of prebiotics, which are defined as a “selectively fermented 
ingredient that allows specific changes, both in the composition and/or activity in 
the gastrointestinal microbiota that confers benefits upon host well-being and 
health”(PETROVA; KUJUMDZIEVA, 2010). For this reason, GOS are also known 
as ‘Bifidus growth factors’ for their ability to stimulate the growth of Bifidobacteria in 
the human body ” (MAHONEY, 1998). 
 
 The GOS composition fraction can varies in chain length and β-glycosides 
linkages of the interconnection monomeric units, depending on the enzyme source 
(TOBA; ADACHI,1978). Quantitatively, the amount  of the different GOS products 
apparently follow the order: di-, tri- tetra-saccharides and the linkages synthesized 
are predominantly β-(1→6) > β-(1→3) and β-(1→2) (MARTÍNEZ-VILLALUENGA et 
al., 2008).   
 
There has been considerable interest in supplementing foods with prebiotic 
ingredients because the levels of naturally-occurring oligosaccharides in diets are 
considered inadequate to produce substantial effects on health (MANNING; 
GIBSON, 2004).  In this context, GOS should be considered as foodstuff valuable 
additives, as they have numerous dietetic benefits (ANGUS; SMART; SHORTT, 
2005). 
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 GOS are stable compounds, and they remain unchanged even after high 
temperature treatment and are also quite stable during long-term storage at room 
temperature. It has been suggested that their stability is better than fructo-
oligosaccharides (SAKO; MATSUMOTO; TANAKA, 1999; CRITTENDEN;  
PLAYNE, 1996). This property allows their use in thermally treated foods. Thus, 
there is no concern for potential decomposition of GOS during typical food 
processing conditions (PLAYNE; CRITTENDEN, 1996).  
 
GOS is an ideal ingredient to formulate in healthy products targeting specific 
groups such as infants, children, women, and the elderly (SANGWAN et al., 2011). 
Because of their stability, in addition to infant foods, GOS can also be incorporated 
into a wide variety of other foods.  
 
Recently, they have been used in beverages (fruit juices and other acid 
drinks), meal replacers, fermented milks, flavored milks, and confectionery 
products (DUARTE et al., 2010). Specialized foods for the elderly and hospitalized 
people are also promising fields of application of GOS (SAKO; MATSUMOTO; 
TANAKA, 1999; DUARTE et al., 2010). Besides the food sector, other areas, such 
as the cosmetic and pharmaceutical industries, can also exploit the 
physicochemical and physiological properties of GOS (BOCKMUHL et al., 2007; 
KRUTMANN, 2009).  
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3 - Production and Structure of GOS 
 
 3.1 - Enzymatic Synthesis of GOS 
 GOS have been produced by β-galactosidases that have 
transgalactosylation activities (Figure 1), which result  in the formation of 4’- or 6’-
galactosylactose, longer oligosaccharides, transgalactosylated disaccharides and 
nonreducing oligosaccharides(ANGUS; SMART; SHORTT, 2005).     
 
Figure 1- Chemical Structure of GOS produced through the transgalactosylation 
reaction catalyzed by lactase (MARTINS; BURKERT, 2009) 
 
The β-galactosidase can catalyze the transgalactosylation reaction as well 
as the hydrolysis of lactose (Figure 2) (ANGUS; SMART; SHORTT, 2005; 
MANUCCI, 2009). Depending of the lactose concentration, the proportion of 
transgalactosylation to hydrolysis reaction varies (GOULAS; TZORTZIS; GIBSON, 
2007). When water concentration in the system is high, the hydrolysis of lactose 
occurs predominantly. The transgalactosylation reaction increases with a decrease 
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in water activity (ZÁRATE; LÓPEZ-LEIVA, 1990). Apart from lactose concentration, 
other factors influence the reaction, such as: reaction conditions temperature, pH 
and the presence of specific inhibitors or activators for the enzyme (TZORTZIS; 
VULEVIC, 2009).   
 
 
 
 
 
 
 
Figure 2 - Trans-galactosylation proposed reaction mechanism by β-galactosidase 
on lactose (GOULAS et al., 2007).  
 
 
Converting lactose into GOS by β-galactosidase is a kinetically controlled 
reaction by means of the competition between hydrolysis and transgalactosylation. 
Specifically during this conversion is thermodynamically favored lactose hydrolysis 
which generates D-galactose and D-glucose, competes with the transferase 
activity that generates a complex mixture of various galactose-based di- and 
oligosaccharides of different structures (DUARTE et al., 2010).   
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 The knowledge of the reaction time course (or lactose conversion) is 
required to determine the point of maximum yield of the desired product (DUARTE 
et al., 2010; PLACIER et al., 2009). The final product obtained during lactose 
conversion and the glycosidic linkage between the monomers depends on the 
enzyme source and the physicochemical conditions in the catalytic environment 
(PLACIER et al., 2009).    
 
 Transgalactosylation involves both intramolecular and intermolecular 
reactions. Intramolecular or direct galactosyl transfer to D-glucose yields regio-
isomers of lactose. Intermolecular or indirect transgalactosylation is the route by 
which disaccharides, trisaccharides, and tetrasaccharides, and eventually longer 
GOS, are produced from lactose (PLACIER et al., 2009).   
 
 The proportion of transgalactosylation to hydrolysis reactions varies 
depending on enzymes different sources (PLAYNE; CRITTENDEN, 1996). The 
commercial products are manufactured using β-galactosidase isolated from several 
sources such as bacteria and fungi (BODUN et al., 2001; CRITTENDEN; PLAYNE, 
2001).   
 
 Considering that the β-galactosidase enzymes from different 
microorganisms display different rate constants for hydrolysis for specific glycosidic 
linkages and that synthesis of  GOS is kinetically controlled, synthetic product 
mixtures made with different enzymes are likely to contain different profiles of 
glycosidic linkages (CRITTENDEN; PLAYNE, 2001). In this context, these 
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enzymes fundamentally differ in their ability to catalyze the transgalactosylation 
reaction relative to hydrolysis, and in their affinity for the GOS synthesized 
compared to the affinity for lactose (PLACIER et al., 2009).  
 
 The main problem for GOS production is purification, since GOS mixtures 
produced by transgalactosylation always contain considerable amounts of non 
reacted lactose and monosaccharide (PLAYNE; CRITTENDEN, 1996; 
MONTAÑÉS et al., 2009). Purified products with more than 90% (w/w) of GOS are 
available from some manufacturers (PLACIER et al., 2009).   
 
  Besides the differences in the purity among commercially available 
products, there are differences also in the linkages of the oligosaccharide chain 
due to the different enzymes used in their production. Moreover,  depending on 
their oligosaccharide composition, GOS products vary in terms of their bifidogenic 
and other protective actions (PLACIER et al., 2009).  
 
 GOS have been manufactured and commercialized by very few companies 
around the world. GOS production was estimated in 1995 in Europe was about 
15,000 tones (TANAKA et al., 1983). Examples of companies that are currently 
involved in GOS production is shown in Table 1. These GOS products usually 
contain 24–55% oligosaccharides, and smaller amounts of lactose, glucose and 
galactose (PLAYNE; CRITTENDEN, 1996).  
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Table 1 - Companies that are currently involved in GOS Production 
Manufacturer Trade name 
Friesland Foods Domo (The Netherlands) Vivinal GOS 
Yakult Honsha (Japan) Oligomate 
GTC Nutrition (United States) Purimune 
Dairygold Food Ingredients (Ireland) Dairygold GOS 
First milk ingredients Promovita 
Nissin Sugar Manufacturing Company (Japan) Cup-Oligo 
Snow Brand Milk Products (Japan) P7L 
Clasado Ltd. (UK) Bimuno 
(SANGWAN  et al.,2011) 
 
 
4 - Physicochemical Properties of GOS 
 
 The prebiotic properties of the galacto-oligosaccharides have been 
established in several studies, both in vitro (ITO et al., 1990) and in vivo (GIBSON; 
FULLER, 2000). During the last years, galacto-oligosaccharides were reported to 
be beneficial for human health and they are now recognized as prebióticos 
(MACFARLANE; STEEDS; MACFARLANE, 2008).   
 
Because of the configuration of their osidic bonds, GOS resist hydrolysis by 
salivary and intestinal digestive mammals’ enzymes. Therefore they reach the 
colon virtually intact (MACFARLANE; STEEDS; MACFARLANE, 2008), where they 
are then fermented selectively by beneficial intestinal bacteria (Figure 3)   including 
Lactobacillus and Bifidobacterium (GOPAL et al., 2001). This fermentation that’s 
  
27 
helps to create an environment unfavorable to the growth of some pathogenic 
bacteria (BRUZZESE et al., 2006).   
 
GOS are not hidrolyzed by 
salivary enzymes
Are not digested in the 
stomach
Pass into the large
bowel virtually intact
Are selectively 
fermented in the colon
Increased beneficial 
bacteria in the large 
bowel lead to a variety
of health effects
 
Figure 3 -   Behavior of GOS in the human digestive tract (Adapted from TUOHY 
et al., 2005)  
 
 
The major products of fermentation includes carbon dioxide, hydrogen, short 
chain fatty acids (SCFA) and bacterial cell mass (CUMMINGS; MACFARLANE; 
ENGLYST, 2001).   
 
 GOS have been classified as one of the few prebiotics that follow three 
criteria:  (i) resistance to gastric acidity, hydrolysis by mammalian enzymes and 
gastrointestinal absorption; (ii) fermentation by intestinal microflora; and (iii) 
selective stimulation of the growth and/or activity of intestinal bacteria associated 
with health and well-being (GIBSON et al., 2004; IQBAL et al., 2011).  
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  Many in vivo studies have assessed the GOS effect on intestinal microbiota 
and they showed significant increases in the bifidobacteria population (MALINEN 
et al., 2002; DEPEINT et al., 2008; VULEVIC et al., 2008), whereas in other 
investigation a bifidogenic effect of GOS was not detected (DAVIS et al., 2010).
  
 
  Differences in the type, purity, and composition of the GOS used in these 
studies, as well as differences in experimental design and methods of analysis, 
have likely contributed to these varying outcomes (MACFARLANE; STEED; 
MACFARLANE, 2008).  
 
 However, it has previously been suggested that the daily dose of a prebiotic 
is not a determinant of the prebiotic effect (DAVIS et al., 2010; ROBERFROID, 
2007). According to this argument, the prebiotic effect is influenced by the starting 
number of bifidobacteria in the subjects prior to administration of the prebiotic, 
which means that the larger the number of initial fecal bifidobacteria present in an 
individual, the greater  the potential for a bifidogenic effect (DAVIS et al., 2010).  
 
The increased activity of these health-promoting bacteria results in a 
number of health-related benefits both directly by the bacteria themselves and 
indirectly by the organic acids that they produce via fermentation. Examples of 
potential health-promoting benefits are inhibition of the growth of harmful bacteria 
(MACFARLANE; STEED; MACFARLANE, 2008).  
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5 - GOS and Health Benefits 
 
 Several mechanisms that GOS elicit beneficial effects have been described.  
Mechanisms related to microflora modification to a more-healthy are linked to 
selective proliferation of beneficial bacteria especially Bifidobacterium and 
Lactobacillus in the gut (Figure 4). The increased levels of beneficial bacteria in the 
gut resulting from the consumption of GOS are associated with a number of 
positive effects in the digestive and immune systems.  These effects include the 
development of the mucosal barrier, production of short-chain fatty acids, pH 
reduction, immune system activation, synthesis of vitamins of the B-complex and 
enhanced absorption of dietary calcium (HUGHES; HOOVER, 1991; ONISHI; 
YAMASHIRO; YOKOZEKI, 1995; BRUZZESE et al., 2006).   
GOS
Increased Beneficial Bacteria 
Positive effects
on GI
Increased SCFA
production
Decreased 
pathogenic
bacteria
Lower pH
Immune 
modulation
Nutrition to
enterocytes
Improvement of
mineral absorption
 
 Figure 4 - Different mechanisms that GOS elicit beneficial effects (Adapted from  
DONOVAN et al., 2009).  
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Another mechanism promoted by GOS is associated with the production of 
the short-chain fatty acids (SCFA). GOS are not digested and absorbed in the 
small intestine, but are available for colonic bacterial fermentation resulting in the 
production of SCFAs (i.e., acetate, propionate, and butyrate). The SCFAs are 
produced in varying amounts depending on the diet and the composition of the 
intestinal microbiota. However, highest concentrations of SCFA are found in the 
proximal part of the colon (SANGWAN et al., 2011).  
 
 Acetate is a fuel for the skeletal and cardiac muscle, the kidneys, and the 
brain. Butyrate is the preferred fuel of the colonic epithelium, in particular the distal 
colon and rectum. Propionate is metabolized by the liver and play a role in 
cholesterol lowering (HIJOVA; CHMELAROVA, 2007). Another benefit of SCFAs is 
that they increase growth of intestinal epithelial cells and control their proliferation 
and differentiation (TOPPING; CLIFTON, 2001).  
 
The rate and amount of SCFA production depends on the species and 
amounts of microflora present in the colon, the substrate source and the gut transit 
time. SCFAs are readily absorbed and this colon absorption is a very efficient 
process with only 5–10% being excreted in the feces (GUARNER; MALAGELADA, 
2003).   
 
  The SCFAs have been associated with reduced risk of some diseases as 
colon cancer, increased dietary mineral absorption, improvement in bowel habit, 
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might reduce or lower serum cholesterol levels and serum lipid (HIJOVA; 
CHMELAROVA, 2007; WONG; JENKINS, 2007). 
 
6 - Applications of Galacto-oligosaccharides  
  
There has been considerable interest in supplementing foods with prebiotic 
ingredients because the levels of naturally-occurring oligosaccharides in diets are 
considered inadequate to produce substantial effects on health (MANNING;  
GIBSON, 2004).  In this context, GOS should be considered as foodstuff valuable 
additives, as they have numerous dietetic benefits (ANGUS; SMART; SHORTT,  
2005).   
 
 GOS are stable compounds, and they remain unchanged even after high 
temperature treatment and are also quite stable during long-term storage at room 
temperature. It has been suggested that their stability is better than Fructo-
oligosaccharides (CRITTENDEN; PLAYNE, 1996; SAKO; MATSUMOTO; 
TANAKA, 1999). This property allows their use in thermally treated foods. Thus, 
there is no concern for potential decomposition of GOS during typical food 
processing conditions (MONTAÑÉS et al., 2009).  
 
GOS is an ideal ingredient to formulate in healthy products targeting specific 
groups such as infants, children, women, and the elderly (SANGWAN et al., 2011).   
Because of their stability, in addition to infant foods, GOS can also be incorporated 
into a wide variety of other foods. Recently, they have been used in beverages 
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(fruit juices and other acid drinks), meal replacers, fermented milks, flavored milks, 
and confectionery products (DUARTE et al., 2010).   Specialized foods for the 
elderly and hospitalized people are also promising fields of application of GOS 
(SAKO; MATSUMOTO; TANAKA, 1999; DUARTE et al., 2010).    
  
Besides the food sector, other areas, such as the cosmetic and 
pharmaceutical industries, can also exploit the physicochemical and physiological 
properties of GOS (BOCKMUHL et al., 2007; KRUTMANN, 2009).   
 
7 – Conclusions 
 
 
 
In conclusion, development of functional food products will continue to grow 
in the future as consumer demand for healthful products. In this context, the GOS 
have attracted the interest of pharmaceutical and food industries due to their 
functional properties. However, the main problem for GOS production is low-
yielding. Therefore, are still required the development of cheap and efficient 
production techniques 
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Abstract 
 
 
Galacto-oligosaccharides (GOS) are prebiotic functional foods that have many 
health benefits by stimulating the growth and/or activity of bifidobacteria in the 
colon. The present review summarizes the physiological effects and health benefits 
of the prebiotics GOS. In vivo experiments have demonstrated that the GOS 
stimulates the growth of bifidobacteria and lactobacillus, reduces the growth of 
pathogens, modulation of the immune system, relief of constipation, reduction in 
the risk of colon cancer, increased absorption of minerals, improved synthesis of 
vitamins of the B-complex, promotes the reduction of total cholesterol and lipids. In 
conclusion, several experimental and clinical data demonstrate that the GOS are 
selectively fermented ingredient, modulate the gut microbial ecosystem and 
confers benefits health in animals and humans.  
 
 
Keywords: Galacto-oligosaccharides, prebiotic, functional foods, health benefits. 
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Resumo: 
 
 
 Galacto-oligossacarídeos (GOS) são alimentos funcionais prebióticos que têm 
muitos benefícios de saúde por estimular o crescimento e/ou atividade de 
bifidobactérias no cólon. A presente revisão resume os efeitos fisiológicos e os 
benefícios de saúde do prebióticos GOS. Experiências in vivo demonstraram que 
os GOS estimulam o crescimento de lactobacilos e bifidobactérias, reduz o 
crescimento de patógenos, modula do sistema imune, alivia a constipação, reduz 
do risco de câncer do cólon, aumenta a absorção de minerais, melhora à síntese 
de vitaminas do complexo B, promove a redução do colesterol total e lipídeos. Em 
conclusão, vários dados experimentais e clínicos demonstraram que os GOS são 
ingredientes seletivamente fermentados, que modulam o eco-sistema microbiano 
intestinal e confere benefício de saúde em humanos e animais. 
 
 
 
 
 
 
Palavras-chave: galacto-oligosacarídeos, prebiotico, alimentos funcionais, 
benefícios à saúde. 
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1 – Introduction 
 
 
 Consumers are increasingly interested in the health benefits of foods and 
have begun to look beyond the basic nutritional benefits to the potential disease 
prevention and health enhancing compounds contained in many foods (1).  This 
interest combined with a more widespread understanding of how diet affects 
disease, rising health-care costs and an aging population are driving a growing and 
robust market for functional foods and natural health products (2).  
“Functional foods” are generally defined as a food that due to their 
physiologically active substances, benefit health in addition to providing basic 
nutrition, and is demonstrated to have physiological benefits and/or reduce the risk 
of chronic disease (3-4-5).  The prebiotics have assumed the status of “functional’ 
foods”, capable of providing additional health benefits like prevention or delaying 
onset of chronic diseases (6).  
  A prebiotic was originally defined in 1995 as a “non-digestible food 
ingredient that beneficially affects the host by selectively stimulating the growth 
and/or activity of one or a limited number of bacteria in the colon, and thus 
improves host health” (7-8). However, a more recent definition described prebiotic 
as “a selectively fermented ingredient that allows specific changes, both in the 
composition and/or activity in the gastrointestinal microbiota that confers benefits 
upon host wellbeing and health” (8).  
 Common prebiotics in use include inulin, fructo-oligosaccharides (FOS), 
galacto-oligosaccharides (GOS), soya-oligosaccharides, xylo-oligosaccharides, 
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pyrodextrins, isomalto-oligosaccharides and lactulose. The majority of the studies 
have so far focused on inulin, FOS and GOS (9-10-11-12-13).  
 Galacto-oligosaccharides (GOS) have become the focus of a great deal of 
attention in the field of functional foods, owing to their known health benefits and 
potential to improve the quality of many foods (14-15). Numerous studies in both 
animals and humans have demonstrated the health benefits of GOS. This article 
presents the literature review of the physiological effects and human health 
benefits of GOS. 
 
2- Galacto-oligosaccharides: Physiological Effects and Health Benefits 
 
GOS resist breakdown by human digestive secretions and arrive relatively 
unchanged in the lower regions of the intestinal tract where they can be utilized as 
an energy source by the resident microflora, selectively stimulate the growth and/or 
metabolic activity of only beneficial microbiota organisms (16). 
 GOS provide their health benefits by 2 main mechanisms, one is by 
selective proliferation of beneficial bacteria especially bifidobacteria and 
lactobacillus in the gut, which provide resistance against colonization of pathogens 
thereby reducing exogenous and endogenous intestinal infections (17).  
These organisms provide specific health benefits for the host that include 
normalization of colonic transit time, increased production of short-chain fatty 
acids, improved pathogen resistance, enhanced mineral absorption, favorable 
modulation of blood lipids, reduce cancer risk improved gut mucosal barrier and 
immune function (17-18). 
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2.1 - Bifidogenic Activity in the Colon 
 
 The bifidogenic effects of GOS are attributed to non-digestibility and 
selective fermentation in the colon by beneficial bacteria, particularly bifidobacteria 
and lactobacillus (19). The bifidogenic effect is often associated with a reduction of 
the pH and changes in the SCFA pattern (20).  
 The proposed mechanism: GOS are not digested and absorbed in the small 
intestine, but are available for colonic bacterial fermentation resulting in the 
production of SCFAs, as end-products of fermentation (20). These molecules 
decrease the intraluminal pH, directly inhibiting the growth and activities of harmful 
microorganism, and contributing to stimulation of the growth of Bifidobacteria (21). 
 The health promoting attributed to bifidobacteria and other beneficial 
bacteria is due to the growth inhibition of harmful bacteria, stimulation of immune 
functions, lowering of gas distention problems, improved digestion/absorption of 
essential nutrients and synthesis of vitamins (21).    
 
2.2 - Relief of Constipation 
 Constipation is a frequent problem, particularly among the elderly and 
pregnant women. For these individuals, consumption of GOS can offer relief to 
their constipation (19-20).  The effect of GOS on fecal characteristics has been 
evaluated in a number of studies (Table 1). GOS consumption is associated with a 
softening effect on feces in healthy adults, and may relieve the symptoms of 
constipation in adults and elderly people (23).  
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 The proposed mechanism:  GOS pass undigested into the large intestine 
and stimulate bacterial fermentation in the colon. The bacterial fermentation of 
GOS increases bacterial mass, which in turn increases fecal bulk (24). Undigested 
oligosaccharides and fermentation products may also produce an osmotic effect in 
the gut, which increases the water content of feces (25). The increased bowel 
content stimulates peristalsis in the colon (26).  However, the laxative effect of 
GOS varies from patient to patient, as does the effect of any other fiber (27).  
 
 
2.3 - Maintenance of Normal Intestinal Balance of Microflora 
 
 The human digestive tract plays host to some five hundred or more species 
of bacteria which is made up of both beneficial and harmful bacteria. Intestinal 
infection may occur by an overgrowth of harmful bacteria in the gut (28).  
  The prebiotics may be able to alter the composition of the microflora in 
different segments of the gastrointestinal tract and can also affect other intestinal 
characteristics influencing intestinal health, such as increased fecal bulk, shortened 
colonic transit time, changes in the composition of the gut microbiota, lowered 
intraluminal pH and changed bile acid profiles (29). Another important role of 
helpful gut flora is that they prevent species that would harm the host from 
colonizing the gut, an activity termed the "barrier effect" (30).    
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The proposed mechanism: The process of fermentation of prebiotic GOS 
since it produces lactic acid and different fatty acids, also serves to lower the pH in 
the colon, preventing the proliferation of harmful species of bacteria and facilitating 
that of helpful species (31-32). Metabolism of GOS leads to the production of 
SCFA, which are important for supporting a healthy intestinal barrier (particularly in 
the lower GI tract) and also inhibits the growth of harmful bacteria (32).   
 
2.4- Reduction in Serum Cholesterol   
 
 Several studies have suggested that ingestion of GOS is effective in 
improving lipid profiles, including the reduction of serum/plasma total cholesterol, 
LDL-cholesterol and triglycerides or increment of HDL-cholesterol (33).   
 The proposed mechanism:  prebiotics have been suggested to reduce 
cholesterol via various mechanisms; one of the purported mechanisms has been 
mainly attributed to SCFAs. Prebiotics are fermented in the colon by large bowel 
bacteria, yielding short-chain fatty acids (SCFAs) such as butyrate, acetate and 
propionate (33).  
 Butyrate is known to inhibit liver cholesterol synthesis and provide a source 
of energy for human colon epithelial cells, meanwhile propionate may inhibit the 
synthesis of fatty acids in the liver, thereby lowering the rates of triacylglycerol 
secretion (31). Propionate is also involved in the control of hepatic cholesterol 
synthesis and it reduces the rate of cholesterol synthesis which could lead to the 
lowering of plasma cholesterol levels (34-35).  
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 Another possible mechanism by which prebiotics could reduce cholesterol 
level is by selective proliferation of beneficial bacteria especially bifidobacteria and 
lactobacillus in the gut. The lowering of the cholesterol could be attributed to 
assimilation of cholesterol in the diet by some strains of Lactobacillus (36).   
 The animal studies have shown some evidence for the lipid-lowering effects 
of the GOS however, there are difficulties   in demonstrating equivalent effect in 
humans.  The number of human studies is, however, limited and results concerning 
effects on plasma cholesterol and triacylglycerol are not conclusive (37-38).  
 
 
2.5 - Increase in Absorption of Different Minerals in the Intestine  
 
 There is extensive evidence in experimental animals that prebiotics can 
increase the absorption of a variety of minerals, including calcium, magnesium, 
iron, and zinc (39). Several theories have been proposed to explain the stimulatory 
effect of prebiotic substances on intestinal calcium absorption.  
 The proposed mechanism: Most of the proposed mechanisms are that 
prebiotic substances that escape digestion in the small intestine are substrates for 
the formation of short-chain fatty acids (SCFAs), essentially acetate, propionate, 
and butyrate). These SCFAs contribute to a reduced luminal pH in the large 
intestine, increase solubility of calcium in the luminal contents and so increase 
passive concentration-dependent calcium absorption in the colon (40).  
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 Studies in humans and in animals  has demonstrated that administration of 
GOS resulted in more efficiently absorbed calcium and increased bone density, 
indicating the prevention of bone losses (17-41-42-43).   Although the majority of 
studies on calcium metabolism have so far been performed on rats, experimental 
evidence indicates that GOS have a role to play in increasing bioavailability of this 
mineral (Table 1), but as yet, these results have been translated into only a few 
human trials.  
  
2.6- Improved Synthesis of B-Complex Vitamins  
 
 
 There is evidence that prebiotics contributes to synthesis of the vitamins of 
the B-complex and Vitamin K. 
  The proposed mechanism:  The fermentation of prebiotics on the colon 
leads to the selective stimulation of growth of the bifidobacteria population. The 
Bifidobacteria, are known to produce B-complex vitamins (B1, B2, B3,  B6, B9, 
B12) and vitamin K, which are important for various metabolic, mucosal and nerve 
functions within the body (44).  
 
2.7 - Prevent Colon Cancer 
 
 
 Studies in vitro and in vivo, together with a few human trials, have been 
conducted to try to establish whether the GOS in general have an anticarcinogenic 
activity. The anticarcinogenic effect might be exerted by several possible 
mechanisms: 
  
52 
 The proposed mechanism: Most of the proposed mechanisms are that 
metabolism of GOS leads to the production of SCFA (acetate, propionate and 
butyrate). The three main acids stimulate colonic sodium and fluid absorption and 
exert proliferative effects on the colonocyte (45).   SCFA contribute to normal large 
bowel function and prevent pathology through their actions in the lumen and on the 
colonic musculature and vasculature and through their metabolism by colonocytes 
(46).  Anti-carcinogenic activity has been mainly attributed to SCFAs in particular 
butyrate (47).  
 Butyrate is the preferred “fuel” for colonocyte function in the healthy gut 
epithelium, but is thought to exert certain effects on pre-neoplastic or neoplastic 
colonocytes. These may include the induction of apoptosis, modulation of 
oncogene expression (e.g., inhibition of proto-oncogenes), induction of certain 
differentiation markers and regulation of systems involved in cellular adhesion 
and/or migration (48).    
 Total and relative molar concentrations of the main SCFA, acetate, 
propionate and butyrate produced in the human intestine, depend on the site of 
fermentation, diet and composition of the intestinal microbiota (46).   
 The other proposed mechanisms is by selective proliferation of beneficial 
bacteria especially bifidobacteria and lactobacillus in the gut. Attention has already 
been directed to the potential of bifidobacteria to influence the bacterial enzymes 
involved in potential mutagenic and carcinogenic activity (49). More direct evidence 
for protective properties of prebiotics against cancer has been obtained by 
assessing the ability of cultures to prevent DNA damage and mutations (50). 
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2.8 - Effect on the Immune System  
 
 Several experimental and clinical data demonstrate that the prebiotics can 
influence the intestinal microbiota and modulate the immune response. Increased 
SCFA production, and increase in immunogenic bacteria such as lactobacillus and 
bifidobacteria are the two main methods by which prebiotics can exert their effects 
on the immune system (49).   
 In vitro and animal studies have suggested that the addition of complex 
fermentable carbohydrates to the diet can modulate the type and function of cells 
from different regions of the gut-associated lymphoid tissue (51), increase 
immunoglobulin production in the small intestine and cecal mucosa, and alter the 
profile of inflamatory cytokines in plasma and intestinal cells (52-53).  
  The proposed mechanisms:  GOS stimulate the growth beneficial bacteria 
and decreases the population of potentially pathogenic bacteria in the 
gastrointestinal tract, resulting in reduced quantity of   harmful toxins produced by 
pathogens in the gut, and helps to support the immune system (54). Although the 
mechanisms underlying the effects of dietary GOS (either from human milk or 
alternative sources) are not fully understood, the development of a balanced 
intestinal flora is obviously a key element in this relationship (55).  
 Another mechanism proposed is by production of SCFAs (acetate, 
propionate and butyrate) which enhance immune protection by promoting the 
production of T helper cells, antibodies, leukocytes, and cytokines, stimulate lymph 
mechanisms (48-49 -56). 
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 Butyrate, which serves as a fuel for colonic epithelial cells, stimulates 
apoptosis suppress both cytokine-induced and constitutive expression of the 
transcription factor NF-κB in HT-29 cell lines (57). One of the proposed beneficial 
effects of butyrate on human intestinal health is the prevention and inhibition of 
colon carcinogenesis (58-59-60).  
 
Table 1 - Summary of Studies Designed to Determine the Prebiotic Effects of GOS  
Prebiotics/  
Oligosaccharides 
Experimental  
design 
Animals/  
Subjects 
Dose;  
duration of  
the study 
Effects Ref. 
 
GOS 
 
single-blinded 
study 
 
18 elderly 
volunteers 
 
0, 2.5, 5.0, 
and 10.0g. 
dose for 3 
weeks, 
treatment 
period 
 
GOS revealed an 
increase in 
bifidobacteria 
populations, dosage 
to 5 or 10g 
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GOS multicenter, 
double-blind 
study, 
159 healthy 
infants, 
formula 
supplemented 
with (GOS) (77 
infants), or to a 
standard follow-
on formula 
(control, 82 
infants). 
supplemented 
with 5 g/L 
(GOS) for 6 
weeks, 
treatment 
period 
addition of GOS (5 
g/ L) to a follow-on 
formula positively 
influences the 
bifidobacteria flora 
and the stool 
consistency in 
infants 
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GOS Randomized, 
Placebo 
controlled, 
double-blind 
44 elderly 
volunteers  with 
Rome II positive 
IBS 
7 g/d prebiotic 
GOS or 7 g/d 
placebo, for 
12-week, 
treatment 
Period 
GOS stimulating gut 
bifidobacteria in IBS 
patients 
56 
GOS Randomized, 
Placebo 
controlled, 
double-blind, 
crossover 
44 elderly 
volunteers 
(16 men & 28 
women); 
64-79 years old. 
5.5 g/d, two 
10 
weeks 
treatment 
period 
B-GOS significantly 
increased the 
numbers of 
beneficial bacteria, 
especially 
bifidobacteria, at the 
expense of less 
beneficial groups 
compared with the 
baseline and 
placebo. 
48 
GOS double-blind, 
placebo-
controlled, 
Rats 4 g kg(-1) day 
for 10 days 
before colitis 
induction. 
later 
Assessed 
72 h 
 
GOS stimulate the 
growth of 
bifidobacteria in 
rats. No reduction in 
IBD inflammation. 
 
57 
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GOS double-blind, 
randomized 
crossover 
study 
Huamns (n=12) 20g Increased Ca 
absorption in 
menopausal women 
58 
GOS double-blind, 
placebo-
controlled, 
Rats 5 g/100 g of 
diet 
Increased Ca and 
Mg absorption 
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GOS 
 
 
 
 
double-blind, 
placebo-
controlled 
 
 
Rats 
(overiectomized) 
 
 
 
 
5 g/100 g of 
diet 
 
 
 
 
Stimulated Ca 
absorption. 
Reduced loss of 
bone mass and 
calcium content 
59 
 
 
 
 
GOS double-blind, 
placebo-
controlled, 
ovariectomized 
(OVX) Wistar 
rats 
5g/100g  
of diet 
for 20 days 
GOS produced a 
significant 
hypocholesterolemic 
effect in the OVX 
rats 
59 
GOS Double-blind 
randomized 
controlled trial, 
two-period 
cross-over 
study 
Humans 
14 elderly 
subjects (mean 
age 80 years), 
suffering from 
constipation 
9 g of GOS 
per day) or a 
placebo  for 
6 weeks 
 
 
 
The weekly 
defecation 
frequency was 
higher during the 
GOS period (mean 
7.1, range 3–15) 
than during the 
control period 
(mean 5.9, range 1–
14) 
62 
GOS 
 
single-blind 
cross-over 
study 
Human  (12 
volunteers) 
dose  0, 2.5, 
5.0 or 10.0 g 
of GOS, 
respectively, 
for 7 d 
GOS increase the 
multiplication of 
bifidobacteria and 
lactobacilli in the 
human intestinal 
microflora. 
No significant 
change on stool 
weight 
63 
GOS double-blind, 
placebo-
controlled, 
Rats (n= 344) 
 
 
 
 
 
 
 
5%  or 20% 
w/w of  GOS 
for 
6 weeks 
 
The aberrant crypt 
multiplicity and the 
colorectal tumor 
incidence in rats 
fed an HGOS (20%, 
w/w) were 
significantly lower 
than those in rats 
fed an LGOS (5% 
w/w) diet. 
64 
GOS  with 4 
probiotic 
organisms 
randomized, 
double-blind, 
placebo-
controlled trial 
Humans 
(children) 
GOS (n = 461) 
or a placebo (n 
= 464) 
GOS + 4 
probiotics 
for  2 to 4 
weeks 
Significant reduction 
in IgE-associated 
diseases, eczema 
and atopic eczema 
65 
GOS double-blind, 
placebo-
controlled, 
mice (5% w/w) for 
4 weeks 
GOS has no 
detectable effect on 
the intestine villus 
height but increased 
the total protein 
GOS was also able 
to increase sucrase 
activity in cultured 
Caco-2 cells 
66 
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Inulin, FOS and 
GOS, controls 
 
 
controlled trial 
randomized 
Double-blind 
 
Humans 15 g, Patients  
treatment 
periods of 3 
weeks 
lipids or glucose 
absorption No 
significant changes 
in blood 
67 
GOS  randomized,     
double-blind, 
placebo-
controlled                   
Humans 
(n=18) 
GOS (2.5;5.0 
or10g/d) 
For 16 week 
GOS (5.0g/d) 
significant 
bifidogenic shifts in 
the fecal microbial 
community of  
healthy human 
adults 
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3 - Possible Adverse Effects of Galacto-oligosaccharides 
 
 
The bacterial fermentation of the GOS increases the production of gases in 
the colon and may cause adverse gastrointestinal symptoms such as flatulence 
and transient osmotic diarrhea, which are common side-effects of increasing fiber 
intake (69).  
   Usually, tolerance to GOS depends on the amount of the product eaten (23-
70). Similarly, the frequency of gastrointestinal symptoms increases when the dose 
of GOS increases (21- 63). In most of the studies, amounts of 12g of GOS or less 
daily were well tolerated (25-27), but 15g of GOS per day increased flatulence (22). 
However, individuals vary considerably in their response to GOS (24), as with their 
response to any other easily fermented fiber (23-70).  
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4 – Conclusions 
 
 
 In conclusion, several experimental and clinical data demonstrate that the 
prebiotic GOS are selectively fermented ingredient, modulate the gut microbial 
ecosystem and confers benefits health in animals and humans. In addition, GOS 
can be incorporated in different types of food products.  
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Significance and Impact of the Study: This is the first study reporting of a 
potential prebiotic mode of activity for Galacto-oligosaccharides (GOS) synthesized 
by β-galactosidase for Scopulariopsis sp. The GOS produced by Scopulariopsis 
sp. demonstrated prebiotic effects in vitro, are not digestible by digestive enzymes, 
fermented by cecal bacteria and converted to short chain fatty acids in rat large 
intestine. The fermentation patterns obtained in vitro might be used to predict 
behavior in vivo. The type of oligosaccharide fermented influences the nature of 
the fermentative end products. Short chain fatty acids are considered to be 
beneficial to health. 
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ABBREVIATIONS 
DP - Degree Polymerization  
FOS - Fructo-oligosaccharides  
GOS - Galacto-oligosaccharídes 
GIT - GastroIntestinal Tract 
HPLC - High-performance Liquid Chromatography  
SCFA - Short-Chain Fatty Acid  
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Abstract 
 
 
Digestibility and fermentation properties of galacto-oligosaccharídes (GOS) by β-
galactosidase from Scopulariopsis sp were assessed in vitro. The GOS digestibility 
was assessed by using a full model of gastrointestinal digestion, including gastric 
and small intestinal environments, simulation physiological digestion conditions. 
Fermentation properties were estimated under anaerobic conditions in mixed fecal 
bacterial, quantified at 0, 4, 8, 12, 24 and 48 h. GOS were resistant to human 
salivary enzymes,  gastric juice, porcine pancreatic enzymes and rat intestinal 
mucous enzymes, decreased intestinal  pH and resulted in higher (p<0.05) total 
short-chain fatty acid (SCFA) concentrations. The GOS produced by β--
galactosidase from Scopulariopsis sp demonstrated prebiotic effects in vitro, once 
that they are non digestible, fermented by cecal bacteria and converted to short 
chain fatty acids in the large intestine and potential benefit on health. The results 
from the current study indicate that GOS produced by β-galactosidase from 
Scopulariopsis sp has future perspectives promising for applications in food 
industry. 
 
 
Keywords: Galacto-oligosaccharides, prebiotic, digestibility, fermentation, in vitro, 
short chain fatty acid, Scopulariopsis sp. 
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1 - Introduction  
 
 
The concept of colonic health has become a target for the development of 
functional foods such as “probiotics, prebiotics and synbiotics” and other dietary 
components that target the colon and affect its environment, composition of the 
microflora, as well as the physiology of the colon, and display distinct health 
benefits (Roy et al., 2006). 
 
“A prebiotic is a selectively fermented ingredient that allows specific changes, both 
in the composition and/or activity in the gastrointestinal microbiota that confers 
benefits upon host wellbeing and health” (Gibson  & Roberfroid, 1995; Gibson et 
al., 2004; Roberfroid, 2007 ). The principal concept associated with both of these 
definitions is that the prebiotic has a selective effect on the microbiota that results 
in an improvement in the health of the host (Gibson et al., 2004). 
 
For a dietary substrate to be classed as a prebiotic, at least three criteria are 
required: (1) the substrate must not be hydrolysed or absorbed in the stomach or 
small intestine, (2) it must be selective for beneficial commensal bacteria in the 
large intestine such as the bifidobacteria, (3) fermentation of the substrate should 
induce beneficial luminal/systemic effects within the host. (Gibson and Roberfroid, 
1995; Gibson, 1999; Manning and Gibson, 2004). 
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Based on these criteria listed, only a few groups of food ingredients qualify to be 
used. A good number of food materials because of their chemical   structure are 
not absorbed in the upper part of the gastrointestinal tract (GIT) or hydrolyzed by 
the digestive enzymes in humans.  Such foods have been called “colonic foods”, 
foods entering the large intestine which also serve as food for the endogenous 
micro-organisms (Gibson and Roberfroid, 1995; Gibson et al., 2004). 
 
Intake of prebiotics can significantly modulate the colonic microflora by increasing 
the number of specific bacteria and thus changing the composition of the 
microbiota (Gibson & Roberfroid, 1995).  Many of these microflora-associated 
activities have a direct impact on host health. Short chain fatty acids (SCFA) are 
the major bacterial fermentation products in the large intestine. Up to 95% of the 
SCFA (acetate, propionate and butyrate) produced during carbohydrate 
fermentation may be taken up and utilized by the host (Cummings et al., 1987; 
Tuohy et al., 2005). 
 
Common prebiotics in use include inulin, fructo-oligosaccharides (FOS), 
galactooligosaccharídes (GOS), soya-oligosaccharides, xylo-oligosaccharides, 
pyrodextrins, isomalto-oligosaccharides and lactulose. The majority of studies have 
so far focused on inulin, FOS and GOS (Macfarlane et al., 2008). 
Galacto-Oligosaccharides (GOS) are classified as prebiotics, defined as non-
digestible food ingredients that beneficially affect the host by stimulating the growth 
and/or activity of beneficial bacteria in the colon. The increased activity of these 
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health-promoting bacteria results in a number of health-related benefits both 
directly by the bacteria themselves or indirectly by the organic acids they produce 
via fermentation (Gibson, 1998; Roberfoid, 200; Macfarlane,et al., 2008).  
GOS naturally occurs in human milk and can be commercially produced from 
transgalactosylation reaction of B-galactosidase from lactose (Boon  et al., 2000; 
Hung and Lee, 2002). GOS are broadly used in food for both infants and adult 
(Duarte et al., 2010). Besides the food sector, other areas, such as the cosmetic 
and pharmaceutical industries, can also exploit the physicochemical and 
physiological properties of GOS (Bockmuhl et al., 2007; Krutmann, 2009). 
Different oligosaccharides with prebiotic properties, such as inulin, 
fructooligosaccharides (FOS), galacto-oligosaccharides, and lactulose, are 
commercially available, but currently there is increasing interest in the identification 
and development of new prebiotic compounds, perhaps with added functionality 
(Mandalari et al., 2007; Menne et al., 2000; rao, 2001). 
However, the wide variety of new candidate prebiotics becoming available for 
human use requires that a manageable set of in vitro tests be agreed on so that 
their nondigestibility and fermentability can be established without recourse to 
human studies in every case (Cummings et al., 2001;) 
Many different techniques have been used to evaluate the prebiotic potential of 
carbohydrates.  In vitro techniques using   fecal inoculum and fermentation 
systems designed to model the gut are A more useful initial test for evaluate 
prebiotic potential.  
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Oligosaccharides are attracting increasing interest as prebiotic functional food 
ingredients. In this context, GOS produced by β-galactosidase from Scopulariopsis 
sp are novel candidate prebiotics of interest great for the development of functional 
food.  For this reason, we will initially evaluate your   prebiotic activity using in vitro 
methods. 
This study we investigated the digestibility and fermentation products of GOS 
produced by  β-galactosidase from Scopulariopsis sp in vitro,  using a full model of 
GastroIntestinal Tract (GIT) digestion, including gastric and small intestinal 
environments and a colonic model consisting of in vitro fermentation systems using 
fecal inoculum from rats to predict the fate of the GOS in the digestive tract.   
 
2 – Materials and Methods 
 
 
2.1 - GOS Substrate: The fungi Scopulariopsis sp ATCC 44206 isolated 
previously from soil by Pastore & Park (1979) was used to produce β-
galactosidase in this study. Scopulariopsis sp fresh spores were inoculated in 
wheat bran medium (Koji process) and incubated at 30ºC for 5 days. Then the 
enzyme was extracted by mixing water to culture of Scopulariopsis sp on wheat 
bran and concentrated by precipitation with ethanol (70% of final concentration) at 
4ºC. The resulting precipitate was centrifuged, the solids were lyophilized and the 
dry powder used as crude β-galactosidase enzyme. Activity of β-galactosidase was 
estimated using O-nitrophenyl-β D-galactopyranoside (ONGP) as substrate. 
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Enzyme activity was defined as the amount of enzyme that liberated 1 µmol of O-
nitrophenol (ONP) per minute under the standard assay conditions. To synthesis 
galactooligosaccharides, crude β-galactosidase enzyme at a concentration of 10 
U.mL–1 were added to a 40% (w/v) lactose solution in a 200mM potassium acetate 
buffer (pH 5.0) and incubated on a reciprocal shaker at 45°C/12h/150rpm. The 
reaction was stopped in boiling water bath for 10 minutes to inactivate the enzyme, 
then diluted, and filtered through a 0.45 µm membrane to remove insoluble 
particles. Oligosaccharides formed were analyzed by high-performance liquid 
chromatography (HPLC) (Waters 600E) with a refractive index detector as 
described previously (Santos et al., 2009). This fraction contained mono-, di-, tri- 
and tetrasaccharides as follows (%w/w):   50% lactose, 15% glucose, and 7% 
galactose, in this fraction GOS represent 28%.  
 
2.2 - In Vitro Digestion:  In vitro digestibility of GOS synthesized by  β-
galactosidase from Scopulariopsis sp was investigated according the method 
described by Asano et al. (2003). These investigators simulated gastric and small 
intestinal (hydrolytic) digestion. The commercial GOS prebiotic were chosen as a 
positive control (Oligomate 55 - Yakult Pharmaceutical Ind. Co. Ltd. Tokyo, 
Oligomate 55, contains 55% GOS) for in vitro digestibility studies, while maltose 
(Wako Pure Chemicals, Osaka), a non prebiotic carbohydrate, was used as a 
nonselective control (0.2g of substrate was weighed in triplicate and incubated with  
artificial human saliva - Sigma Chemical, St. Louis, MO), artificial gastric juice 
prepared according to Lian et al. (2003), porcine pancreatic enzymes (Wako Pure 
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Chemicals) and digestion by rat intestinal mucous enzymes (Sigma Chemical), 
each substrate solution in a test tube and incubated at 37°C for 4 h.  
Tubes containing reagents, but no substrate, were run as blank. The tubes were 
analyzed after simulated hydrolytic digestion, at each fermentation sampling time 
(0 and 4 h). 
 
2.3 - Analysis: Oligosaccharides remaining after digestion were measured by 
HPLC and the results again shown as the average of three experiments. After 
deactivation of digestive enzymes, the incubation solutions were diluted 100 fold 
with water and centrifuged at 5200xg for 10 min. The supernatant was used for 
HPLC analysis after filtering through a 0.45 µm membrane filter (Advantec, Tokyo). 
HPLC was performed with a Shimadzu LC-10 (Kyoto) device and a pulsed 
amperometric detector (Dionex, Sunnyvale, USA). A CarboPac PA1  
 
(Dionex) column was used with 100 mM  NaOH elution and the flow rate 
maintained at 1.0 ml/min. The hydrolysis rate was calculated from the following 
formula: Hydrolysis rate (%) = 100 -100 (Sa/Sb), in which Sa represents samples 
after treatment and Sb represents samples before treatment (Suzuki, 2004) 
 
2.4- Fermentation by Fecal Flora:  
 
2.4.1- Substrates: The galactooligosaccharídes synthesized by β-
galactosidase from Scopulariopsis sp were used as substrates. The Commercial 
GOS Oligomate® was used as positive control and it was purchased from Yakult 
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Pharmaceutical Ind. Co. Ltd. (Tokyo).  Each substrate was dissolved in deaerated 
0.1 M phosphate buffer (pH 7.0) at a concentration of 10.0%. 
 
2.4.2 - Fecal incubation: Rat cecal contents (n=3) were pooled to serve as 
the source of inoculum for the in vitro fermentation experiment.  Male Wistar rats 
(14 weeks of age) were anesthetized by intraperitoneal injection of a mixture of 
ketamine (150 mg/kg) and xylazine (10 mg/kg). The gut was removed and the 
contents were collected in a plastic bag, packed with an Anaero- Pack (Mitsubishi 
Gas Chemical Inc., Tokyo).  Fecal samples were maintained at 37°C until inoculum 
was prepared (within 10 min).  The experimental protocol was approved by the 
Animal Experimentation Ethics Committee of University of Campinas. 
 
2.4.3 - In Vitro Fermentation Model: The composition and the preparation 
of the in vitro medium have been described in detail Flickinger et al (2000), and the 
composition are shown in Table 1. All components except vitamin and SCFA mixes 
were added before autoclave medium sterilization. Filter-sterilized vitamin solution 
was added just before dispensing the medium that was maintained under 
anaerobic conditions at all the time after preparation.  
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Table 1 - Microbiological  Medium Composition of Used in Vitro Experiments. 
component concentration in 
medium, mL/L 
solution Aa 330.0 
solution Bb 330.0 
trace mineral solutionc 10.0 
water-soluble vitamin solutiond 20.0 
olate:biotin solutione 5.0 
riboflavin solutionf 5.0 
hemin solutiong 2.5 
short-chain fatty acid mixh 0.4 
resazurini 1.0 
distilled H2O 296.1 
  
Na2CO3 4.0 
cysteine HCl-H2O 0.5 
trypticase 0.5 
yeast extract 0.5 
a
 Composition (g/L): NaCl, 5.4; KH2PO4, 2.7; CaCl2-H2O, 0.16; MgCl2-6H2O, 
0.12; MnCl2-4H2O, 0.06; CoCl2-6H2O, 0.06; (NH4)2SO4, 5.4. b Composition (g/ 
L): K2HPO4, 2.7. c Composition (mg/L): ethylenediaminetetra acetic acid (disodium 
salt), 500; FeSO4-7H2O, 200; ZnSO4-7H2O, 10; MnCl2-4H2O, 3; H3PO4, 30; 
CoCl2-6H2O, 20; CuCl2-2H2O, 1; NiCl2-6H2O, 2; Na2MoO4-2H2O, 3. d Composition (mg/L): 
thiamin-HCl, 100; D-pantothenic acid, 100; niacin, 100; pyridoxine, 100; p-aminobenzoic acid, 5; 
vitamin B12, 0.25. e Composition (mg/L): folic acid, 10; D-biotin, 2; NH4HCO3, 100. f Composition: 
riboflavin, 10 mg/mL in 5 mmol/L of Hepes. g Composition: hemin, 500 mg/mL in 10 mmol/L of 
NaOH. h Composition: 250 mL/L each of n-valerate, isovalerate, isobutyrate, and DL-R-
methylbutyrate.  
i
 Composition: resazurin, 1 g/L in distilled H2O. 
 
An aliquot (16 mL) of the medium was aseptically transferred to tubes containing 
the substrate and control tubes. Each substrate was dissolved at 10.0% (w/v). All 
the tubes were stored at 4ºC for approximately 12 h to enable hydration of the 
substrates before initiation of fermentation. After that, the tubes were placed in a 
water bath 37ºC approximately 30 min before inoculation (Faber, 2010). 
 
Fecal inoculum (10% w/v) was prepared using fresh feces from three healthy rats. 
Feces were mixed together and diluted 1:10 (w/vol) in phosphate buffer (pH7.0). 
These fecal sample dilutions were filtered through four cheesecloth four layers. 
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Appropriate samples and blank tubes were aseptically inoculated with 1.5 mL of 
diluted fecal. Tubes were incubated at 37°C with pe riodic mixing for 4, 8, 12, 24 
and 48 h. (Hernot et al., 2009). In a control experiment, the substrate solution was 
replaced by the bicarbonate buffer.  First, the pH of the tubes was measured with a 
standard pH-meter (Pack pH 21- Hanna Instruments). Then, 2 mL sample was 
taken from each tube for SCFA analyses. Finally, 1 mL of sample was taken and 
frozen at -80°C for carbohydrate analyses of the cu lture medium (Faber et al., 
2010). 
 
2.3- Carbohydrate Analysis:  carbohydrate contents in the cultures were 
measured to determine the time that oligosaccharides disappear in the  samples 
and compared GOS with FOS prebiotic. Samples were removed (1 mL) from the 
batch culture fermentation diluted 100 fold with water, centrifuged at 5200 x g for 
10 min and they were filtered (0.25 µm) with membrane filter (Advantec, Tokyo). 
The carbohydrate content in the culture was measured by HPAEC-PAD (Dionex 
Bio-LC DX 300) with a CarboPac PA-100 carbohydrate column (Dionex). Control 
experiment was prepared by adding each sugar.  
 
2.4 – Short Chain Fatty Acids Analysis: The fluid (2 mL) removed from the 
sample tubes for SCFA was immediately added to 0.5 mL of 25% metaphosphoric 
acid, precipitated for 30 min, and centrifuged at 20000g for 20 min.  
The supernatant was decanted and frozen at -20 °C i n microfuge tubes. After 
freezing, the supernatant was thawed and centrifuged in microfuge tubes at 
10000g for 10 min. Acetate, propionate, and butyrate concentrations in the 
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supernatant were determined using a Agilent GC (Model 7890A) equipped with a 
flame ionization detector (FID) and Nukol columm (Supelco, 30 m x 0.320 mm i.d, 
x 0.25µm film thickness). The injection was performed in the splitless mode for 1 
min at 220°C. Oven temperature was programmed at 10 0°C for 5 min, then 
increase to 200°C at 8°C.min -1 and held for 1 min at the end temperature. Nitrogen 
was used as the carrier gas with a flow-rate of 60 mL.min-1. Injector and detector 
were kept at 220°C. Short-chain fatty acid concentr ation values also were 
corrected for blank tube production of SCFA. All samples were run in triplicate and 
an error of 5% was considered acceptable.  
 
2.5 - Statistical Analysis: The statistical analyses were performed using the 
GRAPHPAD PRISM 5.0 software. All values are given as means ± SEM. The 
results were analyzed using a paired Student’s t-test. Probability value of p< 0.05 
was considered statistically significant. 
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3- Results  
 
3.1 - pH Values: Figure 1 presents the pH change after 4, 8, 12, 24 and 48 h in 
vitro fermentation. All substrates had similar pH values (7.0) at 0 h. The GOS 
synthesized by β-galactosidase from Scopulariopsis sp fermentation resulted in the 
most rapid decline in pH and the lowest pH values (p<0.05) at 4, 8 and 12 h. 
Conversely, Oligomate GOS had the slowest decline in pH and the highest pH 
values (p<0.05) at 4, 8, 12 and 24 h of fermentation.  The pH decrease was greater 
at 12 h for these two substrates. However, the GOS synthesized by Scopulariopsis 
sp resulted in the greatest (p<0.05) pH decrease (-1.5) compared with Oligomate 
GOS (-1.0) after in vitro fermentation. The pH values after 24 h and 48h of in vitro 
fermentation were not significant (p>0.05) from each group.  
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Figure 1- The pH values of GOS synthesized by β-galactosidase from 
Scopulariopsis sp and GOS Commercial after different time of in vitro fermentation 
using rat’s cecal microflora. Values are mean (SEM), result of the paired Student’s 
t test compared to pH. 
 
3.2 - In Vitro GOS Digestibility: Digestibility of GOS synthesized by β-
galactosidase from Scopulariopsis sp was carried out in vitro digestion experiments 
and compared with commercial GOS prebiotic; control experiment was carried out 
using maltose. Initially we examined the decomposition of oligosaccharides by 
saliva using human salivary α-amylase. GOS synthesized by β-galactosidase from 
Scopulariopsis sp and commercial GOS were not digested by human salivary α -
amylase (Figure 2) during 4h incubation. But maltose was decreased by about 32 
% after 4h. 
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Next we examined digestibility of GOS produced by β-galactosidase from 
Scopulariopsis sp and commercial GOS by artificial gastric juice (Figure 3), both 
showed resistance to this juice after 4h incubation. Similarly, maltose showed 
resistance to artificial gastric juice after 4h incubation. 
 
GOS produced by  β-galactosidase from Scopulariopsis sp and commercial GOS 
were not decomposed during 4h incubation by porcine pancreatic enzymes, but 
maltose was decreased by about 16% after 4h (Figure 4). 
 
Finally, our examination of the decomposition of GOS produced by β-galactosidase 
from Scopulariopsis sp and commercial GOS by intestinal mucous enzymes using 
rat intestinal acetone powder (Figure 5) showed that two were not decomposed 
during 4h incubation. About 92% of maltose was hydrolyzed by rat intestinal 
mucous enzymes after 3h incubation and about 96% of maltose was hydrolyzed 
after 4h. 
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Figure 2- GOS digestion by human 
salivary α-amylase after 4h incubation. 
Figure 2- GOS digestion by human 
salivary α-amylase after 4h incubation. 
Figure 4 - GOS digestion by porcine 
pancreatin after 4h incubation. 
Figure 4 - GOS digestion by porcine 
pancreatin after 4h incubation. 
A B 
C D 
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3.3 - Carbohydrate Analysis: Carbohydrate contents in the cultures were 
measured after 0, 4, 8, 12 and 24h to determine the time oligosaccharides 
disappeared (Figure 6). The GOS produced by Scopulariopsis sp mixture the 
carbohydrate disappeared after 12h incubation period. The commercial GOS 
mixture the carbohydrate   disappeared in the cultures after 24h under this 
experimental condition. When compared the commercial GOS and GOS produced 
by Scopulariopsis sp. The GOS produced by Scopulariopsis sp was broken down 
faster than commercial GOS. The FOS disappeared after 8h incubation period. 
 
 
Figure 6 - Disappearance of GOS in the culture during the in vitro cecal incubation. 
Values are means ± SEM (n=6). 
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3.4 - Concentration Short Chain Fatty Acids: Determination of short chain fatty 
acids as the fermentation end products is showed  in  Table 2. Acetic, propionic 
and butyric acids were the main fatty acids in the fecal content with GOS produced 
by β-galactosidase from Scopulariopsis sp or commercial GOS. In vitro GOS 
fermentation produced by β-galactosidase from Scopulariopsis sp resulted in the 
greatest (p<0.05) SCFA concentration including acetate, propionate and butyrate 
when compared to commercial GOS. 
 
Concentration of acetate, propionate and butyrate (p<0.05) after 48h fermentation 
were 29.75; 4.16 and 1.49 µmolg, respectively for GOS produced by  β-
galactosidase from Scopulariopsis sp and 25.57; 2.85 and 1.19 µmol/g for 
commercial GOS (p<0.05). The molar ratio of acetate:propionate:butyrate was 
72:16:12, respectively for GOS synthesized by β-galactosidase from 
Scopulariopsis sp and 67:18:15, respectively, for  commercial GOS after 48h 
fermentation. 
 
Fermentation of GOS produced by β-galactosidase from Scopulariopsis sp resulted 
highest (p<0.05) SCFAs total concentration (155.03 µmol/g) after 48h when 
compared with commercial GOS (101.43 µmol/g). GOS produced by β-
galactosidase from Scopulariopsis sp, resulted in the most rapid accumulation of 
organic acids, achieving 78% of total organic acids production after 12h 
fermentation. The interaction of the substrate and the time that it was significant 
(p<0.01) for acetate and attained a maximal rate of SCFA production in time 48h. 
Propionate and butyrate attained a maximal rate in time 12h.  After 12h of 
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fermentation, propionate and butyrate had lowest rates of production GOS 
produced by β-galactosidase from Scopulariopsis sp and commercial GOS. 
 
Table 2 - Concentrations at 0, 4, 8, 24 and 48h of short-chain fatty acids produced 
during fecal fermentation 
Values for individual acids are means ± standard deviations of the results.  
Results sharing the same superscript in the same row   are not significant different (p<0.005). 
1GOS, produced by Scopulariopsis sp; 2GOS, commercial Oligomate. 
 Total SCFA = (acetate+propionate+butyrate).  
Amounts of generated of SCFA (µmol) from 1.0g of each oligosaccharides. N.D. (not detected). 
 
Fatty acid(s) Incubation 
time (h) 
1GOS  2GOS 
 
 
µmol /g substrate 
0 N.D N.D 
4 9.78±1.44a 3.59±1.22b 
8 17.73±1.71a 7.82±0.64b 
12 23.94±1.27a 12.97±1.72b 
24 29.54±1.42a 27.32±1.89b 
Acetic acid 
48 29.75±2.25a 25.57±2.32b 
0 N.D N.D 
4 2.83±0.94a 2.06±0.38a 
8 6.35±0.87a 3.65±0.010b 
12 7.35±1.72a 6.31±0.92b 
24 4.49±2.06a 3.68±1.75b 
Propionic acid 
48 4.16±1.67a 2.85±1.49b 
0 N.D N.D 
4 2.79±1.53a 2.25±1.74a 
8 5.37±0.56a 3.98±0.72b 
12 5.60±1.71a 4.87±0.58b 
24 3.86±1.19a 3.32±1.51a 
Butyric acid 
48 1.49±0.45a 1.19±0,89a 
0 0 0 
4 15.40±4.024a 7.90±0.83b 
8 29.45±6.871a 15.45±1.31b 
12 36.89±10.12a 24.15±2.32b 
24 37.89±14.65a 24.32±4.30b 
Total SCFAs 
48 35.40±15.60a 29.61±7.41b 
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4- Discussion 
 
After 48h of fermentation, GOS produced by β-galactosidase from Scopulariopsis 
sp resulted in the lowest pH values. The change of pH was probably caused by 
highest total SCFA productions. 
 
These data indicate that bacteria present in the large intestine of rats may   ferment 
these substrates. Similarly, Flickinger et al. (2000) reported 17% decrease in pH 
values when short-chain fructo-oligosaccharides were fermented for 11h by canine 
fecal microflora.  
 
The test substrate was not degraded by digestive enzymes after 4h the incubation.  
These results suggested that GOS produced by β-galactosidase from 
Scopulariopsis sp were confirmed as non-digestible.  Therefore, it was expected 
that GOS reached the large intestine following the digestive tract without digestion 
and in the colon content fermented by the colonic microbiota.  
 
The non-digestibility of prebiotics can be demonstrated in vitro by treatment with 
pancreatic and other gastrointestinal digestive enzyme. In the GOS, several in vitro 
experiments have shown its non-digestibility and stability to hydrolysis enzyme. 
Van Loo et al. (1999) studied the effects of various non-digestible oligosaccharides 
and concluded that more than 90% of GOS arrives into the colon. 
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Similar finding was observed by  Asano et al. (2003) examined by in vitro digestion 
method and observed that mannooligosaccharides were resistant to human 
salivary  α-amylase, artificial gastric juice, porcine pancreatic enzymes and rat 
intestinal mucous enzymes, but maltose was hydrolyzed after 4h. 
 
  
The non-digestible oligosaccharides are connected by β-2, 1 bonds and they are 
not hydrolyzed by digestive enzymes in the upper gastrointestinal tract and, 
therefore, reach the colon intact. Reach the colon intact, they are fermented by 
beneficial bacteria commensal to the colon, e.g. bifidobacteria, lactobacillus, which 
are stimulated to grow and/or are metabolically activated. However, only a few 
non-digestible oligosaccharides have been identified which can be classified as 
prebiotics (Gibson and Roberfroid, 1995). 
 
In the cultures with GOS produced by β-galactosidase from Scopulariopsis sp the 
oligosaccharides disappeared after a 12h incubation period and commercial GOS 
oligosaccharides disappeared in the cultures after 24h. GOS produced by β-
galactosidase from Scopulariopsis were more selectively utilized than commercial 
GOS, This can be attributed to the fact that there are differences also in the 
composition of the oligosaccharides and differences in the position of the glycosidic 
linkages occur, due to the different enzymes used in their production (Duarte et al. 
2010). 
 
The time of GOS produced by β-galactosidase from Scopulariopsis sp and 
commercial disappearance in the culture was different from that of 
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fructooligosaccharides.   FOS disappeared after 8 h incubation period, it must be 
inferred that FOS (long-chain), were more rapidly fermented by bacteria of the 
colonic than GOS (short-chain). Thus, it is possible that the utilization more 
selective of the FOS by bacteria consist on its structure of the carbohydrate and 
the bacterial species present in the ecosystem.  
 
Results similar were reported by Asano et al. (2003) that investigated the utilization 
of fructooligosaccharides by an anaerobic incubation with human feces in vitro; 
these investigators reported that carbohydrate was not detected in the fecal culture 
with fructo-oligosaccharides after 8h of incubation. Fructooligosaccharides were 
broken down faster than manno-oligosaccharides by fecal flora. The difference of 
the time course seemed to be due to differences in species and quantity of bacteria 
in the feces which utilized each oligosaccharide. 
 
A more meaningful in vitro method for studying prebiotic oligosaccharides is the 
use of mixed culture (faecal inocula). Study of the changes in populations of 
selected genera or species can then establish whether the fermentation is 
selective. The use of faecal inocula probably gives a representation of events in 
the distal colon (Gibson and Rastall, 2006). 
 
GOS produced by β-galactosidase from Scopulariopsis sp resulted in greater 
fermentation as indicated by greater acetate, propionate, butyrate and total SCFA 
production compared to substrate evaluated. The GOS commercial produced 
much less acetate (approximately 77µmol/g) compared to the GOS produced by β-
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galactosidase from Scopulariopsis sp (approximately 110µmol/g). Differences in 
composition of oligosaccharides may have been a factor. The commercial GOS 
contains 55% GOS with glucose, galactose and lactose making up the remaining 
45%.  GOS produced by β-galactosidase from Scopulariopsis sp contains 28% 
GOS, 50% lactose, 15% glucose, and 7% galactose. 
 
 
 Compositions of short chain fatty acids showed variance in individual composition 
and it was apparently due to the difference of intestinal microflora. The potential for 
maximal SCFA production at 12h of fermentation, indicate that fermentation is 
occurring for simply breakdown of oligosaccharides. However, after 24h of 
fermentation substrates decreased production of propionate and butyrate for two 
substrates.  The progressive decline in total SCFA concentrations coupled with the 
rise in pH suggests that the amount of substrate available for fermentation is 
limiting. 
 
After 48h of fermentation, the molar ratios of acetate, propionate, and butyrate 
were 67:18:15 for the GOS commercial and 72:16:12 to GOS produced by   β-
galactosidase from Scopulariopsis sp. These variations may be due to disparities 
in the molecular structure of substrates used.  
 
Any food ingredient that enters the large intestine is a candidate prebiotic. 
However, to be effective, selective fermentation by the colonic microbiota is 
required; much evidence supports the belief that the currently identified prebiotics 
are fermented (Molis et al., 1996; Alles et al., 1996) 
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Prebiotics have been shown to be a source of SCFAs both in vitro and in vivo, but 
in vivo, the study of SCFAs is more difficult and relies mostly on determination of 
the concentrations in feces (Gibson et al., 1995). Study in vitro using fecal 
inoculum from 6 healthy volunteers, compared production of SCFAs from 17 
different carbohydrate sources, only FOS and inulin were established as prebiotics 
(Wang  and Gibson ,1993). 
 
Smiricky-Tjardes et al. (2003) evaluated the   fermentative characteristics of the 
galacto-oligosaccharídes in vitro and in vivo and reported that the GOS   increased 
beneficial bacteria in vivo and SCFA concentrations both in vitro and in vivo. 
Results similar were reported by Vickers et al. (2001) these investigators described 
an increased SCFA production as a result of fermentation of short-chain fructo-
oligosaccharides and long-chain fructo-oligosaccharides with canine fecal 
microflora. Therefore, substrates that produce high amounts of SCFA in vitro, 
namely the fructans, xylo-oligosaccharides, and the galacto-oligosaccharides, may 
do the same in vivo. 
 
The nature of the carbohydrate determines its fermentability, both the structure of 
the carbohydrate and the bacterial species present in the ecosystem are probably 
important factors in controlling the fermentation of short-chain carbohydrates 
(SCCs) (Van Laere et al., 1997; Cummings et al., 2001). 
 
Van Laere et al. (1997) produced a range of different SCCs with widely different 
sugar compositions and molecular sizes and tested their breakdown by several 
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strains of Bifidobacterium, Clostridium, Bacteroides, and Lactobacillus. 
Fermentability differed with oligosaccharide structure. The fructans were 
extensively fermented, except by clostridia, whereas few species were able to 
break down arabinoxylan under the conditions of the experiment. 
Xylooligosaccharides were well fermented. Linear oligosaccharides were 
catabolized to a greater degree than were those with branched structures. 
Bifidobacteria utilized low degree of polymerization (DP) carbohydrates first and 
bacteroides utilized those with a high DP. Metabolic collaboration among species 
was evident in carbohydrate breakdown. 
 
An acidic pH optimizes the growth conditions for acidophilic bacteria. These 
include the large group of lactic acid bacteria, e.g. lactobacillus and bifidobacteria. 
In contrast, an acidic milieu provides only suboptimal conditions for pathogenic 
microorganisms. Lowering the pH thus reduces colonization by pathogenic 
microbes and promotes mineral absorption (Rémésy et al., 1993; Chonan & 
Watanuki, 1995)  
 
The major products of prebiotic metabolism are SCFAs, the gases hydrogen and 
carbon dioxide, and bacterial cell mass. Much has been written about SCFA 
production in the hindgut and about the differing metabolic significance of the 
individual acids (Cummings, 1995).  
 
 
 SCFA produced by bacterial fermentation contribute to normal large bowel 
function and prevent pathology through their actions in the lumen and on the 
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colonic musculature and vasculature and through their metabolism by colonocytes. 
Approximately 95-99% of the short chain fatty acids produced during bacterial 
fermentation are absorbed rapidly from the intestinal lumen.  Butyrate is the 
preferred energy source for the epithelial cells in the large intestine and supplies up 
to 70 % of their total energy requirements (Scheppach, 1994). Propionate has 
been suggested to spare amino acids that would be used in gluconeogensis in the 
post absorptive state (Demigne and Remesy, 1991). 
 
The GOS produced by β-galactosidase from Scopulariopsis sp are indigestible, 
were fermented by rat cecal bacteria and the products of fermentation were short 
chain fatty acids. To study these physiological functions of GOS in vivo, 
experiments with animals and human are in progress. 
 
To be classified as a prebiotic, the substrate must “be a selectively fermented 
ingredient that allows specific changes, both in composition and/or activity, in the 
gastrointestinal microflora that confers benefits upon host well-being and health”. 
(Roberfroid et al.1998).  On the basis of this definition, GOS produced by β-
galactosidase from Scopulariopsis sp has prebiotic potential based on its 
indigestibility and SCFA production. GOS was highly fermentable and may 
positively affect large bowel health. 
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5- Conclusion  
 
In conclusion, GOS synthesized by β-galactosidase from Scopulariopsis sp 
resisted hydrolytic digestion and they were well fermented as indicated by a 
decrease in pH, increased SCFA production or concentration. Thus, GOS exhibited 
prebiotic effects. However, these effects need to be performed using human 
volunteers.  
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Abstract 
 
 
Galacto-oligosaccharides (GOS) are nondigestible oligosaccharides occurring 
naturally in human milk and can be manufactured by enzymatic 
transgalactosylation from lactose using β-galactosidase, are of great interest for 
food and feed applications because of their beneficial effects on health. Some 
beneficial effects attributed to consumption of GOS include reduced risk of cancer 
of the colon, increased in mineral absorption, control serum cholesterol levels and 
immune modulation of the gastrointestinal tract. The present study aims at 
investigating the effects of oral administration of GOS produced by β-galactosidase 
from Scopulariopsis sp on hematological and biochemical blood parameters in rats.  
Male albino-Wistar rats weighing between 365 to 375g were supplemented with 
different doses of GOS in a 42 -days experiment. The result shows that the body 
weight, feed intake and water consumption was not statistically significant when 
compared with the control (p<0.05). Hematologic and biochemical variables were 
not affected by the supplementation with GOS.  Histopathologic examination of the 
organs obtained at autopsy did not reveal any alterations. The data obtained 
showed that consumption of GOS produced by β-galactosidase derived from 
Scopulariopsis sp for 42 days is safe and does not have of harmful effects 
variables tested in rats. 
 
Keywords: Galacto-oligosaccharides, haematology, Clinical biochemistry, 
Pathology, rats. 
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Resumo 
 
Galacto-oligossacáridos (GOS) são oligossacáridos não digeríveis que ocorrem 
naturalmente no leite humano e podem ser produzidos por transgalactosilação 
enzimática a partir de lactose utilizando β-galactosidase, são de grande interesse 
para aplicações na alimentação humana e animal devido aos seus efeitos 
benéficos para a saúde. Alguns efeitos benéficos atribuídos ao consumo de GOS 
incluem o risco reduzido de cancer de cólon,  aumento na absorção de minerais, 
controle dos níveis de colesterol sérico e  e modulação imunológica do trato 
gastrointestinal. O presente estudo tem como objetivo investigar os efeitos da 
administração oral dos GOS produzidos pela β-galactosidase a partir de 
Scopulariopsis sp sobre os parâmetros sanguíneos hematológicos e bioquímicos 
em ratos. Ratos machos Wistar albinos pesando entre 365 a 375g foram 
suplementadas com diferentes doses de GOS em um experimento de 42 dias. O 
resultado mostra que o peso corporal,consumo de ração e água não foi 
estatisticamente significativo quando comparado com o controle (p <0,05). 
Variáveis bioquímicas e hematológicas não foram afetados pela suplementação 
com GOS. O exame histopatológico dos órgãos obtidos na autópsia não revelou 
quaisquer alterações. Os dados obtidos mostraram que o consumo de GOS 
produzidos por β-galactosidase derivada de Scopulariopsis sp por 42 dias foi 
seguro e não teve efeitos nocivos nas variáveis testadas em ratos. 
 
Palavras-chave: galacto-oligosacarídeos, hematologia, bioquímica clínica, 
patologia, ratos 
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1 - Introduction 
 
 
Galacto-oligosaccharides (GOS) is a collective term for a group of carbohydrates 
composed of oligo-galactose with some lactose and glucose. GOS were recently 
defined as “a mixture of those substances produced from lactose, comprising 
between 2 and 8 saccharide units, with one of these units being a terminal glucose 
and the remaining saccharide units being galactose and disaccharides comprising 
2 units of galactose” (Tzortzis and Vulevic 2009; Torres et al, 2010).  
 
Galacto-oligosaccharides are naturally occurring in human milk; however, 
commercial preparations are produced by enzymatic activity of β- galactosidase on 
lactose in a reaction known as transgalactosylation (Sako et al, 1999; Angus et al., 
2005 ; Macfarlane et al.2006 ; Maischberger et al., 2008 ; Sangwan et al.2011). 
Converting lactose into GOS by glycoside hydrolases (GH) results in mixtures 
containing GOS of different degrees of polymerization (DP), unreacted lactose, and 
monomeric sugars (glucose and galactose) (Torres et al, 2010).  
 
GOS are non-digestible oligosaccharides and they pass on the colon where they 
are fermented selectively by beneficial intestinal bacteria, which implicate a 
balanced and advantageous microbiota (Sako et al., 1999 ; Cummings et al, 2001; 
Boehm et al. 2007; Mischberger et al., 2008), belong, because of their indigestible 
nature, to the group of prebiotics (Schaafsma 2008, Sangwan  et al. 2011). 
 
Several microbial glycoside hydrolases have been proposed for the synthesis of 
GOS from lactose. In this context, these enzymes fundamentally differ in their 
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ability to catalyze the transgalactosylation reaction relative to hydrolysis, and in 
their affinity for the GOS formed as compared to the affinity for lactose. (Torres et 
al, 2010).  Mixtures of oligossacharides of various chain length and glycosidic 
bonds are formed during production (Tannock et al., 2004; Neri et al., 2011). 
 
 Besides the differences in purity of GOS mixtures, differences in the position of the 
glycosidic linkages occur, because different enzymes have different regiochemical 
selectivity. Depending on oligosaccharide composition, GOS products will vary in 
terms of prebiotic activity, as well as other physiological effects (Torres et al., 
2010). 
 
Many beneficial effects on health have been attributed to GOS including: 
improvement of defecation, stimulation of mineral absorption, elimination of 
ammonium, colon cancer prevention, as well as protection against certain 
pathogenic bacteria infections (Hopkins et al. 2003; Shoaf et al., 2006; Macfarlane 
et al., 2008). 
 
Because of their known health benefits, GOS have become the centre of a great 
deal of attention in the field of functional foods (Sako et al. 1999, Angus et al., 
2005). There is continuous interest in finding microorganisms with adequate 
properties for industrial uses and able to produce specific GOS mixture with better 
yields (Torres et al., 2010). 
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Intake of GOS produced by β-galactosidase from Scopulariopsis sp as a dietary 
supplement requires a safety assessment because its potential use as a prebiotic 
ingredient is of great interest. Therefore, the purpose of this study is to evaluated 
the toxic effects resulting from the supplementation of GOS orally in rats, focus on 
weight parameters, clinical hematological, biochemical and histological necropsy.  
 
2 – Material and Methods   
 
2.1 - Test Substance 
GOS syrup used in this study was produced by transgalactosylation from lactose 
using β-galactosidase derived from Scopulariopsis sp produced in the Bioaromas 
laboratorie   (Department of Food Science, School of Food Engineering, University 
of Campinas, São-Paulo-Brazil). The GOS syrup containing approximately 28% 
GOS,  50 % lactose,   15% glucose and 7% galactose (Santos et al., 2009).  
 
Reference controls were provided as white powder.  The FOS (Raflitose P95) 
contain 95% oligofructose with degree of polymerization (DP) between 2 and 8 and 
5% of glucose, fructose and sucrose were obtained from ORAFTI (Belgium).  The 
FOS was prepared weekly (50%w/v) in suspension in deionized water. This 
mixture was stored refrigerated and a sufficient amount was removed each day for 
supplementation of the control animals. 
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 2.2 - Animals and Treatment 
Thirty-two (32) male wistar albino rats (Rattus Wistar) weighing 365–375 g, were 
obtained the Center of Multidisciplinary investigation in Biology (CEMIB) of the 
University of Campinas, São-Paulo-Brazil). The rats were given 1 wk to acclimatize 
during which time they consumed the basal diet ad libitum. After  acclimatization, 
the rats were  housed in cages (n= 1/cage) kept at 22 ± 3°C, with 40–70% relative 
humidity and controlled lighting that provided a 12-h light:dark cycle.  
 
2.3 - Acute Toxicity 
During the whole experiment, the animals received water and commercial Labina-
Purina chow (23.5% protein, 6.5% fat, 70.0% carbohydrate, Purina 5008, St. Louis, 
Mo.) ad libitum. The rats were randomly assigned to four groups (n=8 per group). 
Group reference control supplemented with FOS (Orafti®P95) 1000mg/kg/bw/day. 
Groups supplemented with different doses of GOS at 300, 500 and 
1000mg/kg/bw/day (OECD Category 4>300-2000mg/kg/bw). Dose volume was 
calculated based on a density determination performed at the laboratories of Food 
Engineering (1mL/500mg GOS).  Individual doses were based on the most recent 
body weights. 
 
The GOS syrup was administered orally by intragastric cannula insertion for 42 
consecutives days. Oral administration was selected as the route of administration 
as this is the potential route of exposure to humans; gavage was chosen due to 
potential palatability issues. All animal manipulations were carried out in the 
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morning to minimize the effects of circadian rhythm. The protocol was approved by 
Animal Experimental Ethics Committee of the University of Campinas.  
 
Parameters Evaluated 
 
2.4 - Clinical Observations: The animals were observed daily twice a day for 42 
days to assess general health (mortality and morbidity). Detailed clinical 
observations were performed once weekly prior to dosing and prior to scheduled 
euthanasia. The visual observations included changes in skin and fur (hair), eyes 
and mucous membranes and also respiratory, circulatory system, as well as body 
weight of each animal at the beginning and 42 days of the trial. 
 
2.5 - Body Weights and Food Consumption: Body weight, as well as food and 
water consumption, was recorded daily. Feed efficiency was calculated as the 
weekly body Weight gain divided by the food consumption. 
 
2.6 - Hematology and Clinical Chemistry:  At the end of the experiment, rats 
were deprived of food overnight, anesthetized with ether and blood was collected 
by cardiac puncture (1 mL into EDTA for hematology and 2 mL into sodium heparin 
for blood clinical chemistry). Blood was centrifuged at 1500 x g (model TJ-6 
centrifuge, rotor TH-4 with buckets, Beckman Coulter, Fullerton, CA) for 15 min. 
and the plasma was immediately removed from the cells. The plasma was stored 
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in a freezer at -20 ºC for later biochemical analyses. All samples were processed 
within 4–6h. 
Auto haematological analyzer Hemo 960V (Shinova Systems Co., Ltd.) was used 
to analyse the following blood parameters: erythrocyte count, hemoglobin, 
hematocrit, mean corpuscular volume, mean corpuscular hemoglobin, mean 
corpuscular hemoglobin concentration, total and differential leukocyte count and 
platelet count. Prothrombin time and fibrinogen were assessed with the 
Coagulation analyzer (Coagulometro Drake, model Quik Timer SL0055). 
 
The biochemical constituents as glucose, cholesterol, triglycerides, HDL, LDL, total 
proteins, albumin, amylase and Gamma glutamyl-transferase (GGT), were 
measured by enzymatic methods using (Labtest®) reagents according to the 
manufacturer's instructions. All tests were performed at the Laboratory of Analyses 
Clinical of Medicine Veterinary. 
 
Pathology 
 
2.7 - Gross Necropsy: Detailed gross necropsy, including careful examination of 
the body external surface, orifices and cranial, thoracic and abdominal cavities and 
their contents was performed in both groups. The organs (spleen, liver, thymus and 
pancreas) were evaluated macroscopically according to color, size and texture. 
After the necropsy the organs were weighed and their wet weights immediately 
recorded. Results were expressed as organ weight relative to 100g body weight. 
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2.8 - Histopathology: All tissues examined in the study were fixed in 1.23 mol/L 
buffered formalin (pH 7.4) and the samples were sent to the Laboratories of 
Histopathology, University of Adamantina – FAI (Adamantina – SP, Brazil) for 
histopathologic study. The tissues were then treated with graded alcohol, 
embedded in paraffin, sectioned in 5 µm slices and stained with hematoxylin and 
eosin for examination under the light microscope. The tissues were examined 
microscopically by a board-certified veterinary pathologist. 
 
2.9 - Statistics Methods: Results were expressed as the mean ± SEM. Statistical 
differences between means were compared using Tukey´s multiple range test. 
Differences over time were analyzed using one way analysis of variance. All 
statistical analyses were performed with GraphPad Prism version 5.0 (GraphPad 
software, Inc.; La Jolla, CA, USA). The p <0.05 level was taken as significant. 
 
3 - Results 
 
3.1 - Survival and Clinical Observations 
In study, no mortality was observed in rats after 42 days of daily oral ingestion of 
different doses of the GOS (300, 500 and 1000mg/kg/bw).During the daily 
observation of the occurrence of toxic signs on the different systems (autonomic, 
behavioral, sensory, neuromuscular, cardiovascular, respiratory, ocular, 
gastrointestinal, genitourinary, skin) did not show toxic signs in the treated groups 
during the trial period.  From the clinical point view the animals maintained a 
normal appearance corresponding to their species. 
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3.2 - Body Weight, Food and Water Consumption 
No significant differences were found (p≥ 0.05) between the initial and final body 
weight of rats supplemented with GOS and the control rats (Table 1). The 
cumulative balance in grams of body weight in relation to the initial weight of the 
animals behaved similarly in groups  supplemented with different concentrations of 
GOS  and control group, which is  indicative of the not occurrence of changes in 
this parameter. 
 
 Similarly, the groups supplemented with GOS and control did not differ in food or 
water consumption. Feed efficiency remained constant until the end of the study 
did not differ between groups GOS and control (Table 1). We considered the 
gain/feed ratio as the most sensitive measure of growth performance. 
 
Table 1 - Effect of GOS supplementation on body weight, gain, feed and water 
intakes in rats after 42 days. 
Variables Treatment 
 
 
Control GOS 
300mg/kg 
GOS 
500mg/kg 
GOS 
1000mg/kg 
SEM 
 
p-Value 
 
 
 
  
 
 
  
Initial body 
weight (g) 
365.3± 0.26 368.4± 0.27 370.9± 0.34 367.6± 0.29 0.89 0.835 
Final body 
weight (g) 
538.8±3.18  
 
539.2±2.80  
 
542.4±2.77  
 
544.5±3.00  
 
0.78 0.875 
Total weight 
gain (g) 
192.50± 0.50 189.92± 0.62 190.50± 0.55 192.20± 0.58 0.96 0.653 
Total feed 
intake 
767.76±1.24  
 
753.06±1.29  
 
755.16±1.68  
 
768.60±1.48  
 
0.96 0.735 
water (ml/d) 47.5±0.36  
 
48.5±0.39  
 
48.7±0.21  
 
47.9±0.39  
 
0.52 0.530 
2FCE 0.26±0.52  
 
0.25±0.56  
 
0.25±0.44  
 
0.25±0.41  
 
0.63 0.665 
1
 Results are expressed as means ± SEM. (n = 8). Groups did not differ, p>0.05. 
2Feed efficiency conversion – FCE (weight gain/food consumed ratio g/g).  
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3.3 - Hematological and Biochemical Parameters 
 The effects of the GOS on the hematological and biochemical parameters of the 
male Wistar rats were investigated. There were no significant changes in blood 
parameters between groups supplemented and control group (Table 2). These 
values are within physiological limits established for the species (Charles River 
Laboratories; 2006).  
 
There were no changes in blood parameters in the rats supplemented with   
different doses of GOS (300; 500 and 1000 mg/kg/bw/d). These values are with in 
limits established for the species (Charles River Laboratories; 2006). No 
statistically significant differences were noted in blood parameter between rats 
supplemented with   different doses of GOS and control group (Table 2). 
Therefore, the supplementation with different doses of GOS not was considered 
toxicological. 
 
The supplementation of different doses of GOS did not affect serum lipids, glucose 
and enzymes (Table 2). No significant differences were observed in clinical 
chemistry in the 300, 500 and 1000 mg/kgbw/day groups when compared to the 
control.  
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Table 2- The effects of different doses of GOS on the hematological and 
biochemical parameters in Wistar rats1 
Hematological variables Control GOS 
300mg/kg 
GOS 
500mg/kg 
GOS 
1000mg/kg 
Red blood cells     
Erythrocytes (106/ml) 8.34±0.43 8.39±0.36 8.35±0.28 8.27±0.33 
Hemoglobin (g/dL) 15.80±0.65 15.50±0.34 14.80±0.72 15.60±0.87 
Hematocrit (%) 42.80±1.50 43.30±1.60 44.90±1.30 42.60±1.90 
MCV, fL 55.50±0.90 52.40±1.20 53.90±1.55 55.70±1.67 
MCH 18.40±0.92 17.90±0.74 18.20±0.86 18.70±0.98 
MCHC (%) 33.80±0.84 35.40±0.92 33.40±0.65 34.80±0.66 
PT (s) 13.20±1.25 13.50±0.56 12.80±0.94 12.90±1.32 
Fibrinogen (mg/dL) 334±35.26 328±42.46 326±38.92 338±40.84 
     
White blood cells     
Leukocytes (103/mm3) 10.97±2.43 10.83±2.64 10.57±3.37 11.34±3.40 
Neutrophils % 17.92±5.20 18.36±3.40 17.62±6.20 18.26±8.70 
Lymphocytes, % 80.39±5.40 84.42±5.70 83.38±6.30 80.73±4.70 
Monocytes, % 0.92±1.78 0.98±1.58 0.88±1.68 0.94±1.54 
Eosinophils, % 1.20±1.80 1.30±1.90 1.50±1.20 1.30±1.70 
Basophils, % 0.00±0.00 0.00±0.00 0.00±0.00 0.00±0.00 
     
Platelets     
Platelets (103/mL) 475±47.30 494±56.39 482±44.56 479±6.85 
Mean platelet volume, fL 6.65±0.43 5.38±0.57 6.66±0.41 5.91±0.38 
 
Clinical biochemistry 
 
   
Glucose mgl/dL 135.0±24.0 128.0±18.0 132.0±26.0 123.0±22.0 
CT mgl/dL 63.0±18.0 62.0±12.0 59.0±10.0 65.0±16.0 
TG mgl/dL 78.0±33.0 75.0±28.0 82.0±32.0 80.0±26.0 
HDL-C  mgl/dL 52.0±12.0 58.0±18.0 55.0±24.0 59.0±23.0 
LDL- C mgl/dL 19.3±24.0 18.6±22.0 19.0±19.0 18.9±21.0 
Total protein g/dL 6.7±1.6 6.5±0.9 6.7±1.4 6.2±0.6 
Albumin g/dL 3.3±0.6 4.0±0.2 3.6±1.3 3.5±1.5 
Globulin g/dL 3.4±0.2 3.6±0.3 3.4±0.5 3.6±1.1 
Amylase U/dL 228.0±32.0 232.0±24.0 226.0±38.0 230.0±17.0 
GGT2  U/L 236.3±0.8 232.1±1.4 230.9±0.6 233.5±0.4 
1Values are means ± SEM, n = 8. Groups did not differ, p >0.05. 
MCV: Mean Corpuscular Volume; MCH: Mean Corpuscular Hemoglobin; MCHC: Mean Corpuscular 
Hemoglobin Concentration; PT: Prothrombin Time. 
CT, Cholesterol Total; TG – Triglycerides; GGT, Gamma glutamyl-transferase. 
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Pathology 
 
3.4 - Gross Necropsy: At the end of the study, rats were subjected to detailed 
post-mortem examinations of internal organs, which did not show macroscopic 
differences in size, color or texture. Necropsy did not reflect any damage in the 
organs examined. The organs (liver, spleen, thymus and pancreas) examined 
macroscopically showed no pathological changes for any of the animals 
supplemented orally with GOS, behaving in all cases equal to the control. 
 
3.5 - Relative Organ Weights  
 Table 4 one can see the quotients of organ weights (spleen, liver, thymus and 
pancreas)/ body weight. For these variables did not show any significant difference 
(p>0.05) between the treated and control groups after 42 days of supplementation. 
The repeated oral administration of different doses of GOS did not affect the mean 
relative in the organ weights. 
 
Table 3 – Relative organ weights (liver, spleen, thymus and pancreas) of rats  
after 42 days of daily oral administration of different concentrations of GOS1 
Parameters Control GOS 
300mg/kg 
GOS 
500mg/kg 
GOS 
1000mg/kg 
     
Liver  0.67±0.70 
 
0.65±0.50 0.68±0.40 0.67±0.80 
Spleen 0.27±0.11 
 
0.28±0.17 0.24±0.15 0.24±0.12 
Thymus 0.17±0.80 
 
0.16±0.30 0.15±0.80 0.15±0.50 
Pancreas 0.07±0.21 0.09±0.32 0.08±0.28 0.09±0.23 
1Values are means ± SEM, n = 8. Groups did not differ, p>0.05. 
Organs weight was expressed in percentage related to animal body weight.  
Relative weight (%) = absolute organ weight/body weight X 100% 
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3.6 - Histopathology Parameters 
 Histopathology showed no change in cell morphology of the organs examined 
(spleen, liver, thymus and pancreas) and no evidence of toxicity was observed. 
These results were positively correlated with the results of the hematological and 
biochemical parameters. 
 
4 - Discussion 
There has been a number of studies that reveal the prebiotic potential of GOS as 
health promoting in man and animals (Chonan et al., 1995; Teuri et al., 1998; 
Chonan et al., 2001; Vulevic et al., 2008; Fanaro  et. Al, 2009; Silk  et al., 2009; 
Davis et al., 2010 ). This compound as food ingredients are of great interest as 
potential ingredients for functional foods. In this study the toxicological effect of 
GOS produced by β-galactosidase from Scopulariopsis sp in experimental animals 
were analyzed. 
 
The results of individual clinical examinations in both the treated and control 
groups of the male Wistar rats indicate that GOS was well tolerated during the 
treatment period (42-days), with no mortality or signs of morbidity observed. In 
addition, observations were made daily during the study and no differences among 
the groups supplemented with different doses of GOS  and controls rats in 
changes in skin, eyes, and mucous membranes,  as well as in behavioral changes. 
From the clinical point of view the animals maintained mainteda normal 
appearance corresponding to their species. 
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The 42-d oral administration doses of 300, 500 and 1000 mg/kg did not affect the 
body weight, food and water consumption. These results indicate that GOS 
showed no toxicity at the doses and routes of administration tested.   
 
There was no significant difference in the organ weights (liver, thymus, spleen, and 
pancreas) between control and experimental animals supplemented with different 
doses of GOS. 
 
Histological evaluation of tissues belonging to all structures of the supplemented 
animals showed normal results (no changes considered to be indicative of 
pathology), or revealing of important functional and structural damage that could be 
associated with GOS supplementation at the dosages and periods. 
 
Analysis of blood parameters is a relevant risk assessment; any change in the 
hematological system has a high predictive value of the toxicity in the humans and 
in animals. The results of the hematological parameters shows that the rats 
supplemented with different doses of GOS did not show variations of importance of 
a biological standpoint. No changes were observed in the red series and also the 
values of hematocrit and hemoglobin and the counts of white blood cells, since the 
values are within the normal range for the species (Charles River Laboratories, 
2006).  
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The coagulation time was not changed in groups supplemented with GOS 
compared with the control. The biochemical analysis showed no statistically 
significant differences among the groups supplemented with different doses of  
GOS. Cholesterol and triglycerides were not altered, indicating no role in lipid 
metabolism of the GOS. Also no changes were observed in blood glucose. 
 
Several studies have showed that the administration of prebiotics are effective in 
improving lipid profiles, including the reduction of serum/plasma total cholesterol, 
LDL-cholesterol and triglycerides (Trautwein et al., 1998; Letexier et al., 2003; Hsu 
et al., 2004; Li et al., 2007). GOS have also been shown to decrease serum 
cholesterol and triglycerides, respectively, in animal models (Chonan et al., 1995; 
Beylot, 2005). 
 
In this study, there were no significant differences in (p≤0.05) serum lipids in 
groups supplemented with GOS when compared with control group. The GOS 
supplementation not reduced serum total cholesterol, LDL-cholesterol and 
triglycerides or increment of HDL-cholesterol. However, studies have shown 
hypocholesterolemic effects in rats (Chonan, 1995). 
 
The animal studies have shown some evidence for the hypocholesterolemic effects  
of the GOS however, there are difficulties   in demonstrate  equivalent effect  in 
humans (Vulevic et al. 2008)   The number of human studies is, however, limited 
and results concerning effects on plasma cholesterol and triacylglycerol are not 
conclusive (Roberfroid et al., 2010).  
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Many of the proposed mechanisms and experimental evidence specifically 
targeting cholesterol-lowering effects remain controversial. Additionally, little 
information is available on the effective dosage of prebiotics needed to exert 
hypocholesterolemic effects (Ooi  et al., 2010). 
 
Although animal studies have demonstrated significantly lower blood glucose 
concentrations with prebiotics (Delzenne et al., 2007). In this study, GOS 
supplementation had no effect on glucose. 
 
However, studies in humans have yielded conflicting data. Consumption of 20 
grams/day of inulin-type fructans by healthy volunteers did not modify fasting 
plasma glucose and insulin concentrations after 4 weeks (Luo et al., 1996).  
Consumption of 8 grams/day of inulin-type fructans in non-insulin-dependent 
diabetic reported significantly lower blood glucose levels after 4 weeks. (Yamashita 
et al., 1994). 
 
 Another study examining the effects of chronic consumption of FOS by type 2 
diabetics on plasma glucose showed that consumption of 20g FOS/d for 4 weeks 
had no effect on fasting plasma glucose or insulin levels (Luo et al., 2000).  
 
In relation to the hematological parameters, similar data were observed for the 
values of the control group. The study results indicate that the GOS syrup 
produced by β-galactosidase from Scopulariopsis sp administered orally at a dose 
of 1000mg/kg does not produce any signs of toxicity or death in rats. Similar results 
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were reported by Anthony et al. (2005) when syrup GOS vivinal was administered 
to rats by gavage at 2500 or 5000mg/kg/bw/day for 90 days no adverse 
toxicological effects attributable to treatment. 
 
The results of this study have established that the oral administration of GOS 
produced by β-galactosidase from Scopulariopsis sp was safe up to 1000 mg/kg, 
and the intake of different concentrations 300, 500, 1000 mg/kg of GOS was found 
to be safe and has no adverse effect on the evaluated parameters. However, the 
dosage level 1000mg/kg/bw/day not were considered sufficient for conventional 
acute toxicity test. 
 
On the basis of all these results and under conditions in which the study was 
conducted was not possible to estimate the LD50 in rats after 
administration GOS oral. Pursuant to the provisions in the OECD, the 
substances that exhibit an LD50 greater than 5000 mg / kg by mouth may be 
considered practically non-toxic or unclassified.  
 
Therefore, this suggests that further studies should be performed in vivo LD50 dose 
levels; to ensure that oral administration of GOS produced by β-galactosidase from 
Scopulariopsis sp does not induce any toxic effect, which can be the beginning of 
the safer use of this compound as food ingredient on the future. 
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5 – Conclusion 
 
Comparing the effects physiological, biochemical analyses and the results of 
pathological examination, it was concluded that the syrup GOS obtained by the 
action of β-galactosidase derived from Scopulariopsis sp has no significant toxicity 
even at high doses in the experimental model used. However more studies are 
needed to confirm the safety of application of the GOS in human food products. 
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Abstract 
 
Galacto-oligosaccharides (GOS) are non-digestible oligosaccharides that have 
many health benefits on human health by stimulating the growth and/or activity of 
Bifidobacterium in the colon. This study evaluated the effects of Galacto-
oligosaccharides (GOS) produced by  β-galactosidase from Scopulariopsis sp on 
the alteration of cecal microbiota, cecal pH, cecal short-chain fatty acids (SCFAs) 
concentration, stool characteristics, pH fecal and bowel function in Wistar rats. The 
rats were randomly assigned to 2 groups: control and supplemented with GOS 
(250 mg/(kg body wt d) for 42 days.  After 42 day treatment, the rats supplemented 
with GOS presented higher humid, dried fecal weight and decreased the fecal pH, 
the feces contain no excess of undigested food (fat globules, starch granules and 
muscle fibers), protease activity was observed in the feces.The group that received 
supplementation of GOS presented a significant increase in the amount of 
Bifidobacterium and Lactobacillus (p<0.05), inhibited the growth of E.coli, and 
decreased the cecal pH. The SCFAs were significantly increased (P<0.05) by 
intake of GOS, indicating active fermentation. The potential physiological benefits 
of the GOS   appear to relate to colonic health in terms of effects on bowel 
function, cecal microflora and SCFA metabolism. These results suggest that the 
GOS produced by β-galactosidase from Scopulariopsis sp have a great prebiotic 
potential and may be beneficial to gastrointestinal health.  
Keywords: Galacto-loligosaccharides, Cecal microbiota, Trypsin fecal, Short-chain 
fatty acids (SCFAs), Rats. 
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Abbreviations: GI, gastrointestinal tract; FOS, fructooligosaccharides; GOS, 
galacto-oligosaccharides; SCFAs, Short-chain fatty acids; EPI, exocrine pancreatic 
insufficiency 
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1 - Introduction 
The mammals animals gut is populated by an array of bacterial species, which 
develop important metabolic and immune functions, with a marked effect on the 
nutritional and health status of the host (Ley and others 2008).The metabolic 
activity developed by the gut microbiota contributes to the digestion of dietary 
compounds, salvage of energy, supply of micro-nutrients and transformation of 
xenobiotics (Laparra and others 2010). 
 
A balanced gut microbiota composition confers benefits to the host, while microbial 
imbalances are associated with metabolic and immune-mediated disorders (Nadal 
and others 2007; Santacruz and others 2009). The development of the intestinal 
microflora provides the basis for a barrier that prevents pathogenic bacteria from 
invading the gastrointestinal tract. The composition of the intestinal microflora 
together with the gut immune system allows resident bacteria to exert a protective 
function. In addition gut bacteria are involved in vitamin synthesis (especially 
vitamins B and K) and in the metabolism of xenobiotics (Salminen and others 
1988). 
 
The composition of the gut microbiota is influenced by endogenous and 
environmental factors (diet, antibiotic intake, xenobiotics etc.). Of these factors, the 
diet is considered a major driver for changes in gut bacterial diversity that may 
affect its functional relationships with the host (Ley and others 2008). 
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Thus, modification of the flora by dietary means offers one of the most effective 
opportunities for development of functional foods (Salminen and others 1988).  In 
this context, prebiotics has stood out for its beneficial effects on the function and 
microbiota composition. 
 
Prebiotics are defined as “nondigestible food ingredients that beneficially affect the 
host by selectively stimulating the growth of one or a limited number of bacterial 
species in the colon. Modification by prebiotics of the composition of the colonic 
microflora leads to the predominance of a few of the potentially health-promoting 
bacteria, especially, but not exclusively, lactobacillus and bifidobacterium (Gibson 
and Roberfroid 1995). 
 
Researchers have suggested that these bacteria protect the host by competing 
with bacterial or fungal pathogens for available nutrients and space and modulating 
the immune system (Guarner and others 2003; Wagner 2008; Gaboriau-Routhiau 
and others 2009, Roberfroid and others 2010). In addition, it has been reported 
that some short chain fatty acids (SCFA) including acetic, propionic and butyric 
acids are released during the fermentation of the prebiotic. As a whole, SCFAs 
acidify the luminal pH which suppresses the growth of pathogens. They are rapidly 
absorbed by the colonic mucosa and contribute towards energy requirements of 
the host (Cummings 1991; Blaut 2002; Vogt and others 2003). 
 
Prebiotics are found naturally in many foods, and can also be isolated from plants 
(e.g., chicory root) or synthesized (e.g., enzymatically, from sucrose) ” In order for 
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a food ingredient to be classified as a prebiotic, it has to be demonstrated, that it: 
(a) is not broken down in the stomach or absorbed in the GI tract, (b) is fermented 
by the gastrointestinal microflora; and (c) most importantly, selectively stimulates 
the growth and/or activity of intestinal bacteria associated with health and wellbeing 
(Roberfroid 2007). 
 
Common prebiotics in use include inulin, fructo-oligosaccharides (FOS), galacto-
oligosaccharides (GOS), soya-oligosaccharides, xylo-oligosaccharides, 
pyrodextrins, isomalto-oligosaccharides and lactulose (Macfarlane and others 
2006; Macfarlane and others 2008). There is also a range of new prebiotic 
compounds emerging, and these include: pecticoligosaccharides, lactosucrose, the 
sugar alcohols, gluco-oligosaccharides, levans, resistant starch, xylosaccharides 
and soy-oligosaccharides (Hume and others 2011). 
 
Of the many prebiotics that are available, the only ones for which sufficient data 
have been generated to allow consideration of their potential for classification as 
functional food ingredients are the inulin, fructo-oligosaccharides (FOS) and 
galacto-oligosaccharides (GOS) (Roberfroid 2007). 
 
Galacto-oligosaccharides (GOS) are non-digestible carbohydrates, which are 
resistant to gastrointestinal digestive enzymes, but are fermented by specific 
colonic bacteria. They are classified as prebiotic food because they can selectively 
stimulate the growth of Bifidobacterium and Lactobacillus in the lower intestine 
(Sako and others 1999). 
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The health benefits of Galacto-oligosaccharides are  the increased presence of 
good bacteria ( Bifidobacterium and Lactobacillus, as a fermentative substrate and 
include protection against enteric infections; increased mineral absorption; 
immunomodulation for the prevention of allergies and gut inflammatory conditions; 
trophic effects of SCFAs on the colonic epithelium;  preventing of diarrhea and 
constipation,  and reduced toxigenic microbial metabolism that may reduce risk 
factors for colon cancer (Gibson and others 2004; Macfarlane and others 2008; 
Torres and others 2010). 
 
GOS produced by transgalactosylation from lactose using β-galactosidase and are 
of great interest for food and feed applications because of their prebiotic properties 
(Maischeberger 2007). GOS have been extensively studied for their physiological 
roles on the intestinal flora and functions (Sako and others 1999). 
 
The prebiotic concept is based on the selective stimulation of the host's own 
beneficial microbiota by   providing specific substrate for their growth and 
metabolism. Today, the effect is measured by using Bifidobacterium or 
Lactobacillus as markers (Roberfroid and others 2010).   
 
Therefore, the present study evaluated the effects of GOS produced by β-
galactosidase from Scopulariopsis sp on the cecal content microbiota, cecal and 
fecal pH values, short-chain fatty acids (SCFA) concentrations, stool 
characteristics and bowel function in Wistar rats.  
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2 - Material and Methods 
 
2.1 - GOS Production 
The GOS mixtures obtained by the action of the β-galactosidase synthesized by 
Scopulariopsis sp were investigated for their effects on the intestine physiology of 
rats. The GOS were prepared with 40%(w/v) of lactose solution (0,1 M of acetate 
buffer, pH 5.0), temperatures 45°C, were added  the  enzyme concentration ( 10 
U.mL–1), reaction time was 12 hours of reaction. Under these conditions, the 
enzyme converted 20% of lactose into oligosaccharide (80.8 mg.mL–1 de 
4'galactosyl-lactose). The mixture of contain 22% monosaccharides, 50% lactose 
and 28% GOS (Santos and others 2009).         
 
2.2 - Animals  
Twenty-four male Wistar rats weighing approximately 380g±20g were obtained 
from the Center of Multidisciplinary investigation in Biology (CEMIB) of the 
University of Campinas (São Paulo, Brazil). Animals were housed individually in 
plastic boxes with temperatures (21-24ºC), humidity (55%) under a 12h light-dark 
cycle. All animals were given ad libitum to diet and water.  The animal use protocol 
was reviewed and approved by Animal Experimental Ethics Committee of the 
University of Campinas (protocol n°1707-1). 
 
2.3 - Experimental Design 
Rats were assigned randomly in two groups (n = 12 per group), and they were fed 
with commercial diet (Purina Laboratory Animal Co., Ltd., Shanghai, China). 
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Control group were given gavage of maltodextrin (250mg/kg BW·d), and GOS 
groups were given gavage of (250mg/kg BW·d). The duration of the study was 42 
d. During the experimental period, rats were weighted every day before the 
supplementation. At the end of the experimental period, the rats were anesthetized 
with ketamine/xylazine (100:10 mg/kg) and euthanized by cardiac puncture. After 
necropsy, cecum were removed and immediately processed for microbial counts 
and analysis of SCFA.  
 
2.4 - Fecal Weight and Humidity  
Feces were collected for 3 days (72-hour) consecutives  beginning on 35, 36 and 
37 days and stored in a freezer (-20°C).  After the  third day of collection, we 
obtained the wet weight of feces in electronic analytical balance (Metla Toledo, 
model AB204) with a sensitivity of 0.0001g. Next the feces were dried in an oven at 
105 ºC. After 22 hours, weighings were begun at 30-minute intervals until two 
consecutive weights had differences of less than 1.0 mg.  The fecal humidity was 
calculated using the formula [(humid fecal weight - dry fecal weight) / humid fecal 
weight] x 100 (Freitas and others 2004). 
 
2.5 - Protease Activity in Feces 
Two tests were performed with fresh feces (15 minutes of defecation) to assess the 
presence of pancreatic enzymes in the feces. The x-ray film digestion test and the 
gelatin digestion test. A fecal sample was obtained from each of the clinically 
normal rats (n=24) for to evaluate the fecal protease activity. 
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The x-ray Film Digestion Test: The x-ray film digestion test is performed by 
mixing one part feces with nine parts 5% sodium bicarbonate solution in a test 
tube. A strip of x- ray film, were placed on a Kodak X-OMAT scientific imaging film 
with gelatin coating. Hydrolysis of the gelatin on the X-ray film was determined 
after four hours of incubation at 37ºC in a humid incubator by washing the film with 
distilled water.  At the end of the incubation period, the film is examined to detect 
digestion of the film coating. A positive reaction is indicated by a clear zone on the 
film after it has been rinsed with running water. If the coating has been digested, 
the feces are considered to be positive for protease activity. The assay was 
repeated three times. 
 
The Gelatin Digestion Test: The gelatin digestion test is performed by mixing 1ml 
of the described feces-bicarbonate solution with 2ml of melted 7.5%gelatin and 
incubating this mixture for 1 hour at 37ºC. After the incubation period, the tube is 
allowed to cool and then is checked for solidification. If the gelatin remains liquid, 
the feces are considered to be positive for protease activity (proteases in the feces 
digested the gelatin). 
 
2.6 - Microscopical Examination of the Feces  
Fecal sample is also examined for the presence of undigested food components, 
fat globules, starch granules and muscle fibers. Test is performed by mixing one 
part feces with nine parts of water. 
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Fecal Starch: non-digestible starch in the feces is detected by staining feces with 
lugol solution. A small amount of feces (1-2 drops) is mixed with one to two drops 
of lugol solution (2% iodine solution) on the surface of a microscopic slide. A 
covers lip is placed over the mixture, which then is observed microscopically. 
Undigested starch appears as dark, blue to black granules.  The presence of a 5 or 
more to blue granules in the feces per x 40 microscopic field is considered to be 
positive result. 
 
Fecal Fat: This test is performed to detect non-digestible fecal fat. The test is 
performed by mixing a small amount of feces (1-2 drops) with one to two drops of 
Sudan III stain on the surface of a microscopic slide. A cover slip is placed over the 
mixture, and the slide then is examined microscopically. Undigested fat appears as 
large orange-red droplets. The presence of a 10 or larger, refractive, orange 
droplets per x 40 microscopic field is considered to be a positive result, thereby 
indicating a deficiency of fat digestion enzyme (lipase). 
 
Fecal Muscle Fibers: The test is performed by mixing a small amount of feces (1-
2 drops) with one to two drops of staining Lugol's iodine on the surface of a 
microscopic slide. A cover slip is placed over the mixture, and the slide then is 
examined microscopically. Undigested, striated muscle fibers appear as stain light 
brown. Undigested fibers have visible striations (40x) running both vertically and 
horizontally. Partially digested fibers exhibit striations in only one direction, and 
digested fibers have no visible striations. Only undigested fibers are counted, and 
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the presence of more than 10 is reported as increased.  Five to 6 fields should be 
evaluated. 
 
2.7 - Microbiological Analysis  
The cecal contents were diluted 1:9 with distilled water. In duplicates, 0.05ml of 
each dilution was plated selective media.  The specific agar plates used were as 
follows: plate count agar – PCA (Merck; total aerobes) Wilkins –chalgren agar 
(Difico; total anaerobes), Mac-Conkey agar   (Merck; Enterobacteriaceae), eosine 
methylene blue agar (Oxoid, Escherichia coli), de Man, Rogosa and Sharp – MRS 
agar (Oxoid; Lactobacillus), and MRS agar (Oxoid; Bifidobacterium) 
 
Enumeration of Bifidobacterium was determined using the method   described by 
Moriya et al (2006). The Commercial MRS medium (Oxoid) was sterilized at 121ºC 
for 15min and was added the inhibitors and the aminoacid L-cysteine added. The 
inhibitors concentration in the final medium were: lithium chloride 3 mg/ mL, 
nalidixic acid 15 µ/mL, neomycin sulphate 100 µg/mL and paramomycin sulphate 
200 µg/mL. The L-cysteine concentration was 0.5 g/mL in the final medium. 
 
Plates were incubated at 37ºC aerobically or in anaerobic conditions (Anaerogen® - 
anaerobiosis generator from Oxoid), for 24 or 72 h as appropriate. After incubation, 
plates containing 20 to 200 colonies were enumerated, and the counts were 
expressed as log10cfu/g dry weight. The selectivity of the growth conditions was 
confirmed by microscopic examination. 
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2.8 - Determination of SCFAs  
Concentrations of short-chain fatty acids in cecal content sample were measured in 
duplicate as described by Smirick-Tjardes et al. (2003) with modifications. cecal 
sample were acidified with 250 g/L metaphosphoric acid using a mixture of 0.5 g 
sample:0.8 mL acid:2.8 mL distilled H2O, precipitated at room temperature for 30 
min, and then centrifuged at 25,900 × g for 20 min. The supernatant was decanted 
and frozen at −20°C in microfuge tubes. After freez ing, the supernatant was 
thawed and centrifuged in microfuge tubes at 13,000×g for 10min. The supernatant 
was used in GC/MS analysis. 
  
The SCFA concentration was analyzed with gas chromatography GC/MS (Agilent 
5975C, inert MSD) equipped with a Nukol   capillary columm (Supelco, 30m x 0.25 
mm x 0.25µm film thickness). The injection was performed in the splitless mode for 
1 min at 220°C. Oven temperature was programmed at 100°C for 5 min, then 
increase to 200°C at 8°C min -1 and held for 1 min at the end temperature. Injector 
and detector temperature was 200°C; the carrier gas  was nitrogen at a flow rate of 
25 mL/min. Volatile free acid standard mix (Supelco4697-U) was used as internal 
standard.  Short chain fatty acid concentrations were calculated by relative to the 
internal standard by the peak height ratio method. SCFA concentrations are 
expressed in units of µmol SCFA/g and all results given as the mean, standard 
errors (SEM).  
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2.9 - Fecal and Cecal pH 
At the end of the experimental period, 1g of feces were freshly collected from each 
rat and homogenized with 10 mL of distilled water (Brambillasca and others 2010), 
using a vortex shaker (Vortex, model QL-901,  Biomixer) and pH was immediately 
determined using a pH meter (Pack pH21). Cecal content pH was all determined in 
the undiluted cecal contents immediately after killing the animals. 
 
2.10 - Statistical Analyses 
Results were expressed as means with their Standard errors of the mean. Results 
were analysed by an unpaired Student’s t test to determine significant differences 
between control and experimental group. P values of <0·05 were considered 
significant, using GaphPad Prism 5.0 version (GrapPad software, Inc.; La Jolla, 
CA, USA). All microbiological concentration was subjected to log10 transformation 
before analysis. 
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3 - Results 
 
3.1 - Fecal Weight and Humidity 
The total quantities of feces excreted during the three days (72-hour) after 
supplementation of GOS are summarized in Table 1. When productions of humid 
feces   were compared, significant differences (p<0.05) were found between the 
groups. The group supplemented with GOS had greater production of humid feces 
than the control group. 
 
Significant differences (p<0.05) were also found between groups when dry weight 
of feces was compared.  The GOS group had greater dry weight of feces than the 
control group. The total quantity of feces (g), humid and dry, was significantly 
higher (p<0.05) in the group supplemented with GOS than the control group.  
 
The feces humidity of the total three days (72-hour) revealed significant differences 
between groups (p<0.05). Rats supplemented with GOS had a significant increase 
in humidity of feces.  Visually, differences in fecal volume are obvious between the 
groups (Table 1). 
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Table 1- Effect of GOS supplementation on the production of humid feces (g), dry 
feces (g) and humidity of feces (%) during the three days collection (72-hour). 
Production of 
feces 
Maltodextrin 
(n=12) 
GOS 
(n=12) 
p-value 
Humid weight (g) 24.35±0.90a 36.57±1.36b 0.0042 
Dry weight (g) 15.73±0.56a 19.49±0.44b 0.0039 
*Humidity (%) 31.66±3.04a 43.29±1.85b 0.0038 
Values are mean (SEM). Within rows, values with different letters indicates significant 
differences (p<0.05) between groups. 
*The humidity was calculated using the formula [(humid fecal weight - dry fecal weight)/wet 
fecal weight] X 100. 
 
3.2 - Protease Activity in Feces  
Protease activity could be detected using the X-ray film in all rats the control group 
and supplemented with GOS.  Results similar were observed with gelatin digestion 
test. The feces were considered to be positive in both groups for protease activity. 
Moreover, not differences were observed in protease activity in the two tests has 
were performed with fresh feces. 
 
3.3 – Non-digestible/Non-absorbed Food Particles 
Starch was usually present in small quantities and often visible macroscopically 
when stained with Lugol iodine. Undigested Starch ranged from none to five per 
low powered field. No Statistically significant differences (p<0.05) were found 
between groups (Table 2). 
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Table 2- Undigested food components (fat globules, starch granules and muscle 
fibers) in fecal sample in the rats supplemented with GOS for 42 consecutives day. 
Food components Maltodextrin 
(n=12) 
GOS 
(n=12) 
p-value 
 
Starch granules 4.63±0.47 4.52±0.32 0.0034 
Fat globules 3.45±1.45 4.69±1.15 0.0062 
Muscle fibers 1.58±0.56 1.32±0.62 0.0022 
Values are mean (SEM) There were no significant differences (p>0.05) between groups. 
Maltodextrin, GOS. 
 
The presence of small numbers of neutral fat were observed macroscopically when 
stained with Sudan III, usually contained at least 8 neutral fat droplets with 
diameters greater than 20 microns per high powered field. Results were similar in 
two groups. 
 
Undigested muscle fibers ranged from none to four per low powered field in both 
groups, generally, microscopic findings for undigested /unabsorbed food particles 
were similar in control groups and supplemented with GOS. No Statistically 
significant differences (p<0.05) were found for undigested /unabsorbed food 
particles between groups. 
 
3.4 - Microbiological Analysis 
According to the microbiological analyses statistically significant differences 
(p<0.05) were found in the bacteria population between groups. Compared with 
control group, the GOS supplementation significantly increased (p<0.05) the 
population of Bifidobacterium (Table 3). The cecal Bifidobacterium populations 
were inversely associated with cecal pH (p<0.05). The cecal population of 
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Lactobacillus was higher in the group supplemented with GOS. The concentration 
of total anaerobes was significantly higher   (p<0.05) in animals supplemented with 
GOS when compared to animals supplemented whit maltodextrin.  
 
However, the number of cecal Enterobacteriaceae and E. coli were significantly 
reduced (p<0.05) by oral administration of GOS. The total aerobes in the cecum 
were not significantly affected (p>0.05) after the supplementation of GOS. The total 
aerobes were similar in the animals the two groups (Table 3). 
 
Table 3- Microbiota population of the cecum contents of rats in the control and  
GOS group. 
 Maltodextrin 
 (n = 12) 
GOS group 
(n = 12) 
*Cecal microbiota   
 Total anaerobes 8.1±0.22a 10.8±0.26b 
 Bifidobacterium 8.2±0.33a 10.0±0.27b 
 Lactobacillus 7.2±0.15a 8.9±0.16b 
 Total aerobes 7.6±0.22a 7.2±0.25±a 
 Enterobacteriacea 8.9±0.14a 7.2±0.16b 
  Escherichia coli 8.9±0.26a 6.2±0.34b 
* Values are mean log colony-forming units (CFU)/g of cecal content, n = 12. 
a,bWithin rows, values with different letters indicates significant differences (p<0.05) 
between groups. 
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3.5 - Cecal Concentration of SCFAs 
 
Significant differences were detectable in the cecal concentration of SCFAs 
between control rats and rats supplemented with GOS. The supplementation of 
GOS resulted in higher (p<0.05) cecal acetate, propionate and butyrate 
concentrations compared with group control.  
 
The cecal SCFA pool, expressed as µmol/cecum, was altered by supplementation 
of GOS.  The supplementation of GOS resulted in higher (p< 0.05) cecal acetate, 
propionate and butyrate concentrations compared with maltodextrin. The 
maltodextrin substrate produced much less acetate (approximately 12.93 µmol) 
compared to the GOS (30.25µmol). GOS resulted in higher (p<0.05) cecal 
propionate concentrations (16.27µmol) compared with control (4.07 µmol).     Cecal 
concentrations of butyrate were higher (p< 0.05) for rats supplemented with GOS 
(8.05µmol) compared with maltodextrin (2.97µmol). Total SCFA production was 
greatest (p<0.05) for the GOS compared with control (Table 4). 
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Table 4 - Means of short-chain fatty acids (SCFA) in cecal contents of rats 
supplemented with GOS. 
Cecal SCFA 
 
Maltodextrin 
(n = 12) 
GOS 
(n = 12) 
p-value 
 
Cecum (µmol/g of content) 
 
 
 
Acetate 12.93±4.66a 30.25±1.55b p< 0.001 
Propionate 4.07±0.33a 16.27±1.20b p < 0.022 
Butyrate 2.97±0.57a 8.05±1.27b p< 0.005 
*Total SCFAs 19.97± 1.20a 54.57± 1.31b p< 0.001 
Values are means ± SEM, n =12. Results are expressed as µmol SCFA/g  
*Total SCFA = acetate + propionate + butyrate  
Means within a rows with no common superscript different significantly  
 (p<0.05)  
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3.6 - Fecal and Cecal pH 
In the rats supplemented with GOS we observed significantly lower cecal and fecal 
pH values (Figure1) compared with rats control. However, comparing fecal and 
cecal pH these differences were not significant for two groups. 
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Figure 1 - Fecal and cecal pH of rats supplemented with GOS or maltodextrin     
Values are means, ± SEM, n = 12.  *p< 0.05 
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4 - Discussion 
The supplementation with prebiotic GOS produced by β-galactosidase from 
Scopulariopsis sp may positively modulate gut microbiota composition, resulting in 
higher humid and dried fecal weight and caused higher fecal humidity than did 
maltodextrin, probably due to greater fermentation.  
 
The prebiotic reaches the large intestine completely intact, is fermented by the 
gastrointestinal microflora;   selectively stimulating the growth of Bifidubacterium 
and Lactobacillus in the lower intestine. (Tuohy and others 2005).  This bacterial 
growth leads directly to an increase in microbial biomass in the colon, resulting in 
increase in fecal weight (Cummings and others 1997).  
 
Undigested oligosaccharides and fermentation products may also produce an 
osmotic effect in the gut, which increases the water content of feces (Niittynen and 
others 2007). This increase in fecal bulk stimulates passage through the colon, 
shortening transit time. Colonic water resorption is reduced, stool becomes softer 
and heavier, and stool frequency increases.  Together these factors alleviate 
constipation and improve colon evacuation (Swennen and others 2006; Rose and 
others 2007).  
 
However, the extent of the effect depends on the chemical and physical nature of 
the oligosaccharides and the extent to which they are fermented in the colon. 
Fermentable oligosaccharides stimulate increases in microbial biomass in the 
colon, resulting in some increase in fecal weight (Cummings and others 1997). 
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All rats supplemented with GOS, produced feces of similar appearance. The stools 
were bulky, green-brown, well formed but soft.  They contained little starch, 
occasional undigested muscle fiber and moderate amounts of fat. The feces were 
considered to be positive in for protease activity.  Excess undigested or 
unreabsorbed material then appear in the feces, may provide indirect evidence of 
maldigestion and malabsorption (Strasinger and Di Lorenzo 2008).         
 
Malabsorption is defined as impaired absorption of nutrients and maldigestion is a 
consequence of impaired digestion of nutrients in the intestinal lumen, or at the 
terminal digestive site of the brush-border membrane of mucosal epithelial cells. It 
can occur because of congenital or acquired disease in which pancreatic enzyme 
activity, bile acid concentration, or small intestinal mucosal enzymes are decreased 
or absent (Dressman and Lennernäs, 2000).   Interference with food digestion in 
small animals is typically due to exocrine pancreatic insufficiency (EPI), whereas 
most cases of absorption failure are caused by small intestinal disease.  
 
The presence of excess undigested starch is suggestive of a deficiency in starch-
digesting enzyme or a increase intestinal transit time. Starch-digesting enzymes 
(i.e., α-amylase) are produced by the pancreas, and deficiency in these enzymes is 
suggestive of EPI (Thrall and others 2004). 
 
Excess of undigested fat in feces is suggestive of steatorrhea caused by neutral 
fats (triglycerides),   thereby indicating a deficiency of a fat-digesting enzymes (i.e., 
lipases). Detection of steatorrhea is useful for the diagnosis of EPI and small bowel 
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disorders that cause malabsorption. Absence of bile salts that assist pancreatic 
lipase in the breakdown and subsequent reabsorption of triglycerides produces an 
increase in stool fat (steatorrhea). Normal feces have few if any neutral fat droplets 
evident (Thrall and others 2004). 
 
Muscle fibers in the feces are suggestive of defective digestion of these fibers, 
most likely resulting from EPI (e.g., inadequate fecal protease activity). Muscle 
fibers also can be present in the feces because of increased intestinal motility and 
subsequente decrease in intestinal transit time (Thrall and others 2004). 
 
This test is designed to detect proteolytic activity in fresh stool samples, 
presumably of pancreatic origin.  The test evaluates the ability of a fresh fecal 
sample to digest off the gelatin coating of undeveloped radiographic film or to 
digest varying dilutions of gelatin in test tubes.  Unfortunately, a significant number  
of both false positive (proteolytic activity is present) and false negative reactions 
(no proteolytic activity is present) occur (Hardy 2010). 
 
False positive results can occur due to proteolytic activity present in normal fecal 
bacteria, and false negative secondary to bacterial degradation of pancreatic 
enzymes and having long delays between collection of the sample and 
performance of the test. Because of the non-specificity of the stool analysis tests, a 
number of other tests have been developed to lend better diagnostic sensitivity and 
specificity to the diagnosis of EPI (Hardy, 2010). 
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The cecal and fecal pH was significantly reduced with supplementation of GOS 
when compared to control. The acidic cecal and fecal pH resulting from ingestion 
of the oligosaccharide diets probably is caused by the greater level of total SCFA 
production (Campbell and others 1997).  A low intestinal pH is good for intestinal 
health, because the growth of many known pathogens is inhibited under such 
conditions (Gibson and others 1994; Gibson and others 1995; Asahara and others  
2001).  
 
 
This study shows that supplementation with GOS resulted in significant increases 
in cecal Bifidobacterium and lactobacillus concentration, indicating that the 
microbiota of the large intestine were capable of completely fermenting GOS. 
Bifidobacterium, together with lactobacillus, has an important function in the eco-
physiology of the colonic microbiota. These organisms have been linked to 
increased resistance to infection and diarrhoeal disease (Drakoularakou and others 
2009).                          
 
The bifidogenic properties of GOS were demonstrated in various animal and 
human study (Rowland and Tanaka, 1993; Moro and others 2002; Drakoularakou 
and others 2010). Davis and others (2010) studied the effects of GOS in healthy 
adults reported significant increases in Bifidobacterium. Other research has 
obtained similar results, elderly supplemented with GOS 5.5 g/d of GOS for 10 
wk, significantly increased the numbers of beneficial bacteria, especially 
Bifidobacterium (Vulevic and others 2008).  
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 The addition of GOS (5g/L) to a follow-on formula positively influences the 
Bifidobacterium flora and the stool consistency in infants during the 
supplementation period at weaning (Fanaro and others 2009).  Depeint and others 
(2008) showed that 7g/d of the GOS significantly increased the Bifidobacterium 
populationan in healthy human.   Smiricky-Tjardes and others (2003) demonstrated 
the effect of dietary with GOS on ileal and fecal bacterial communities in growing 
pigs. The authors found a significant increase in fecal Bifidobacterium and 
Lactobacillus for animals fed diets containing GOS.  
 
Rats fed diet containing s (4g kg-1days) increased the colonic levels of 
Bifidobacterium (Holma et al., 2002). Similar results were observed in vitro gut 
model, the prebiotic capacity of the GOS was further investigated in a pig feeding 
trial, a significant increased the density of Bifidobacterium were observed.(Tzortzis 
and others 2005).  However, recent studies also suggest that the bifidogenic effect 
of GOS is not only dose dependant, but relies on undefined host factors (Davis and 
others 2010). 
 
GOS are non-digestible carbohydrates, which are resistant to gastrointestinal 
digestive enzymes, in the colon; they are fermented by intestinal bacteria. This 
bacterial fermentation in the colon leads to the production of short chain fatty acids 
(SCFA), mainly acetate, propionate, butyrate, and lactate (Anderson and others 
1984; May and others 1994). 
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The GOS    tested in this experiment increased cecal concentration of SCFA 
(acetate, propionate and butyrate). Similar results were reported by Pan and others 
(2009) showed that the after 14 d. treatment, SCFA in mice cecum were 
significantly increased (p<0.05) by intake oligosaccharides, especially FOS and 
GOS.  
 
The present study demonstrated the cecal SCFA concentration in the rats 
supplemented with GOS are in the order from:  acetate >propionate> butyrate 
(30.25; 16.27 and 8.05 µmol) and control group: acetate >propionate> butyrate 
(12.93; 4.07 and 2.97 µmol) respectively. Survey data from various populations 
show that fecal SCFA are in the order predicted from that equation, i.e., acetate > 
propionate ≥ butyrate (Hoverstad 1984; Cummings 1991).  
 
The SCFAformed at fermentation is quantitatively and qualitatively influenced by 
the type and amount of carbohydrate substrate. Further, certain combinations of 
carbohydrates may have synergistic effects on the SCFA pattern and may also 
shift the site of fermentation (Henningsson and others 2001). 
 
The SCFA contribute to normal large bowel function and prevent pathology through 
their actions in the lumen and on the colonic musculature and vasculature and 
through their metabolism by colonocytes (David and others 2001). 
 
Production of SCFAs is one of the most important physiological actions mediated 
by the microbiota (Cummings 1995).  A great proportion (80-85%) of these SCFA 
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is absorbed by the mucosa of the colon and the other part is either evacuated in 
the feces or is used for growth and multiplication of bacteria (Guerin-Deremaux 
and others 2010).  
 
Another benefit of SCFAs is that they increase growth of intestinal epithelial 
cells and control their proliferation and differentiation (Guarner 2003). Acetate and 
propionate provide energy for brain, muscle and heart, while butyrate provides 
about 50% of the daily energy requirements of the gastrointestinal mucosa 
(Macfarlane and Gibson 1997; Roediger 1989). 
 
The butyrate was produced in a higher concentration when rats were 
supplemented with GOS (8,05 µmol) compared with  control (2,97 µmol). Butyrate, 
however, is a fatty acid of particular interest since is known to be the preferred 
energy substrate for colonocytes. In addition to the trophic effect of butyrate on the 
mucosa, it is an important source of energy for the colonic epithelium and can 
regulate both the growth and the differentiation of colonic cells (Williams and others 
2003; Rafter and others 2004; Tuohy and others 2005). 
 
Other researchers have demonstrated the trophic effects of SCFA on the intestinal 
epithelium in rats (Sakata, 19887; Koruda et al. 1988; Kripke et al. 1989).  A 
systemic mediatory mechanism that transmits the stimuli of SCFA to the epithelial 
cells is proposed for the trophic effect in vivo (Sakata 19887). 
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In humans, the results of the studies examining the effects of GOS on the 
concentration of SCFAs in the feces are contradictory (van Dokkum and others 
1999).  It should be noted that the increase in the production of SCFAs in the colon 
is difficult to determine in humans, because SCFAs are rapidly absorbed in the gut, 
and thus the amount of SCFAs in the feces does not necessarily correspond to 
their intracolonic production (Bouhnik and others 1997; Alles and others 1999). 
 
Analysis of intestinal contents and feces for SCFA concentration may not be a 
good indicator of production since less than 5% of the bacterially derived SCFA 
appears in feces due to efficient colonic uptake (Smiricky-Tjardes and others 
2003). 
 
The data indicate that GOS produced by β-galactosidase from Scopulariopsis sp 
was fermented by intestinal bacteria, significantly increased the Bifidobacterium 
and Lactobacillus population, increased SCFA production in a lower pH, produces 
health benefits related to their interactions with the GI, establishes this prebiotic as 
an attractive ingredient for foods and dietary supplements. 
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5 - Conclusion 
 
In conclusion, the GOS produced by β-galactosidase from Scopulariopsis sp show 
a great prebiotic potential as indicated by increased SCFA production and positive 
microbial modifications in rats. These physiological effects in conjunction with the 
physicochemical characteristics enable GOS to be promising prebiotic food 
ingredients. However, further studies of the effects of the GOS on intestinal 
microflora composition and the concentrations of SCFA are necessary to sustain 
their beneficial health effects. 
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Abstract 
 
Galacto-oligosaccharides (GOS) and Fructo-oligosacharides are nondigestible 
oligosaccharides confer beneficial health effects on animals and humans. The 
purpose of this study was to evaluate the effects of FOS and GOS produced by β-
galactosidase from Scopulariopsis sp on growth performance, cecal short-chain 
fatty acids, pH and small intestinal mucosal morphology in Wistar rats. The study 
was carried out on 36 wistar adult male rats, weighing 380 - 420g, were allocated 
equally to three groups (n=12). Rats were respectively give gavage of Fructo-
oligossacharides (FOS) and galacto-oligosaccharides (GOS) (250mg/Kg/day) for 
42 days. Food intake and body weight was determined daily during experimental 
period. At the end experimental period, cecal contents obtained post-mortem were 
collected, pH measured and processed for SCFA analysis and  small intestine 
were collected for analysis Morphometric.  In the present study, no significant 
differences (p>0.05) among experimental groups and control group in average 
weight, weight gain and food intake. The supplementation of GOS and FOS 
resulted in higher cecal butyrate concentrations compared with the control. The 
cecal SCFA were higher while pH was lower (p<0.05) in groups supplemented whit 
oligosaccharide (FOS and GOS). The supplementation with prebiotics increased 
(p<0.05) villus height, villus height/crypt depth ratio and decreased crypt depth in 
jejunum and ileum. The Oligossacharides FOS and GOS were   fermented, 
increased concentration of SCFA, low pH and exert trophic effects in the small 
intestine. The FOS and GOS exert protective effects in the colon. 
Keywords: Galacto-oligossacharides, Fructo-oligosaccharides, Short-Chain Fatty 
Acid, Intestinal Morfometric, Rats. 
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1 - Introduction  
Prebiotic is defined as "a nondigestible food ingredient that beneficially 
affects the host by selectively stimulating the growth and/or activity of one or a 
limited number of bacteria in the colon" [1].  Modification the composition of the 
colonic microflora by prebiotics leads to the predominance of a few of the 
potentially health-promoting bacteria, especially, but not exclusively, lactobacillus 
and bifidobacteria [1].  
The major fermentation products of prebiotic metabolism in large bowel are 
short-chain fatty acids (SCFA), which had different effects on colon morphology 
and function such as supply of energy to the intestinal mucosa, lowering of the pH, 
and stimulation of sodium and water absorption [2,3,4].  
Fructooligosaccharides (FOS) and galactooligosaccharides (GOS) are 
classified as non-digestible oligosaccharides (NDOs), have been demonstrated to 
possess prebiotic activity in human [5,6,7,8].  
FOS is short-chain polymers of b 1–2-linked fructose units, which are 
produced commercially by hydrolysis of inulin or by enzymatic synthesis from 
sucrose.  They are not hydrolyzed in the human small intestine, but degraded in 
the colon by the resident microflora [9].  They are mainly known for their ability to 
increase the endogenous growth of intestinal lactobacilli and bifidobacteria in 
humans and animals, which has long been regarded as beneficial to health [9, 10].  
GOS belong to the group of NDO, containing two to five molecules of 
galactose and one molecule of glucose connected through glycosidic bonds; they 
are produced commercially from lactose, which is abundant in cheese whey, by 
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enzymatic transgalactosylation with ß-galactosidase present in either free or 
immobilized form [11].  
  They are classified as prebiotic food because they are completely soluble 
and are fermented by specific bacteria present in the colon, resulting in the 
production of SCFA [12].  
  The modulation of the composition and metabolic activity of the intestinal 
microbiota through dietary interventions has aroused interest in the use of 
components that can beneficially on physiology intestinal [13].  
   Several authors have reported that prebiotics exert important trophic effects 
on the intestinal epithelium, stimulating the proliferation and differentiation of 
colonic epithelial cells [14, 15]. These studies opened up a whole new field of 
investigation in relation to gastrointestinal physiology and prebiotics. 
 We hypothesized that GOS produced by β-galactosidase from 
Scopulariopsis sp can act beneficially on the intestine physiology. Therefore, an 
experiment was carried out to investigate the effects of GOS and FOS 
supplementation on growth performance, cecal short-chain fatty acids, pH and 
intestinal morfometric in rats. 
 
 
 
 
 
 
  
179 
2 - Materials and Methods 
 
 2.1 - Composition of the GOS 
The GOS syrup was prepared by reaction a high concentration of lactose 
(40% wt/vol) with a β-galactosidase enzyme for 24 h at 37°C. The enzyme was 
produced from Scopulariopsis sp isolated by Pastore and Park [16], deposited at 
the American Type Culture Collection (ATCC), accession number 44206. 
 The GOS syrup was analyzed by HPLC as described previously [17]. This 
fraction contained mono-, di-, tri- and tetrasaccharides as follows (%w/w):   50% 
lactose, 15% glucose, and 7% galactose. In this fraction, GOS per se, i.e., except 
glucose, galactose and lactose represent 28% by weight. 
The commercial FOS used in the experiment was Raftilose® P95 (Orafti-
Active Food International, Tienen, Bélgica), a product provided by Clariant S.A., 
São Paulo, contains 95% oligofructose with a degree of polymerization (DP) 2~7 
and 5% of glucose, fructose and sucrose. 
 
2.2 - Animals and Treatments 
These experiments were conducted on 36 Wistar adult male rats, weighing 
380 - 420g, (3 - 4 mo of age) were obtained from the Vivarium Center- Campinas 
State University (CEMIB/ UNICAMP). The rats were randomized in  3 groups (n=12 
per group) a control group (no oligosaccharide), FOS group and GOS group 
(250mg/kg/day), respectively. Rats were housed in plastic cages in a temperature 
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controlled room with a 12h light/dark cycle. They were allowed ad libitum to 
commercial rat diet Labina® (Purina do Brazil Ltda. Ribeirão –Preto) and water.  
 The supplement was administered orally (oral gavage) for a period of 42 
consecutive days. Food intake and body weight was determined daily during 
experimental period. All procedures involving animals were reviewed and approved 
by the Animal Experimentation Ethics Committee (CEEA-IB-UNICAMP) at the 
University of Campinas (Brazil, SP), under the protocol number: 1707-1. 
 
2.3 - Experimental Design 
The ration consumption (food intake) and the body weight were recorded 
daily. The feed conversion ratio was calculated by the correlation between the 
weight gain and food intake at the end of the experimental period.  
At the termination of the experiment, the rats were anaesthetised with 
subcutaneous injection of ketamine-xylazine-acepromazine cocktail (1.4 ml/kg 
body wt) and killed by exsanguination through a cardiac puncture. After 
laparotomy, the cecum and colon with contents was removed. The Cecal contents 
were collected, pH measured, and a 0.5g aliquot immediately processed for SCFA 
analysis.  
The intestine was removed washed with sterile 0.9% (w/v) NaCl, and 
immersed in a fixing solution (formol 5%) for 24h for subsequent histological 
examination. The organs (thymus, spleen and liver)   were excised and weighed 
(Bel Mark 210A Model analytical balance, Capacity: 100 mg to 210g).   
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2.4 - Cecal SCFAs Analysis  
 
 Cecal content SCFA concentrations were determined in duplicate using the 
method   described by of Smirick-Tjardes et al. (2003) with modification. Cecal 
contents were acidified with 250 g/L metaphosphoric acid using a mixture of 0.4 g 
sample:0.8 mL acid:2.8 mL distilled H2O and centrifuged at 25,900 1 g for 20 min. 
2), precipitated at room temperature for 30 min, and then centrifuged at 25,900 × g 
for 20 min. The supernatant was decanted and frozen at −20°C in microfuge tubes. 
After freezing, the supernatant was thawed and centrifuged in microfuge tubes at 
13,000 × g for 10 min. The supernatant was used in GC/MS analysis. 
 The cecal content digesta was analysed for SCFA concentration with the 
gas chromatography GC/MS (Agilent 5975C, inert MSD) equipped with a Nukol  
capillary columm (Supelco, 30m x 0.25mm x 0.25µm film thickness). The injection 
was performed in the splitless mode for 1 min at 220°C. Oven temperature was 
programmed at 100°C for 5 min, then increase to 200 °C at 8°C.min -1 and held for 1 
min at the final temperature. Injector and detector temperature was 200°C; the 
carrier gas was nitrogen at a flow rate of 25 mL/min. Volatile free acid standard mix 
(Supelco4697-U) was used as internal standard. Cecal SCFA pool size was 
calculated as the product of SCFA concentration in cecal digesta mass. 
 
2.5 - Histological Analyses 
The histological cuts (duodenum, jejunum and ileum)  were dehydrated in a 
series of crescent concentrations of alcohol, diafinized in xylol, and immersed into 
paraffin. Cuts of 5 µm thickness were obtained. The slides obtained were stained 
with hematoxiline-eosin (H.E).  Three cross-sections for each intestinal sample 
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(total of 24 samples for each of the 3 intestinal segments per dietary treatment) 
were prepared after staining with H.E [19]. A total of 10 intact crypt-villus units were 
selected in triplicate for each intestinal cross-section (30 measurements for each 
sample).  
 
2.6 - Morphometric Analyses 
  The slides were evaluated by light microscopy (Carl Zeiss, Germany). The 
image of the material analyzed was magnified using 40X objective lens. Images 
were captured by a camera (Sony) coupled to the microscope and connected to an 
image analyzer and measured using   the ZoomBrowser EX software, ten  villus 
and crypts were scored for each rat, and means calculated were used in the 
statistical analysis. 
 After capturing the images, morphological indices were determined using an 
image Tool Software. The measurements were taken in millimeters (mm).  The 
variables studied in the small intestinal mucosa through the morphometric analysis 
were: height of the villus (VH), depth of the crypts (DC) and villus/crypt ratio 
(VH:DC). Villus height was measured from the tip of the villus to the villus-crypt 
junction; crypt depth was defined as the depth of the invagination between 
adjacent villi [19].  The results expressed mean ± SD 
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2.7 - Statistical Analyses  
  One-way ANOVA was used to study differences in Weight gain, feed intake, 
organ weight and structure of the small intestine. The differences were compared 
by Tukey multiple comparison test (parametric data). All data are expressed as 
means and standart deviation (SD), and the level of statistical significance was 5% 
(p<0.05). The data were processed and analyzed using the GRAPHPAD PRISM 
5.0 software. 
 
3 - Results  
 
3.1 - Growth Performance and Absolute Weight of Organs 
Body weight (BW) body weight gain, feed intake and feed conversion ratio of 
rats the control group and supplemented with prebiotics are presented in Table 1. 
The initial BW of rats did not differ (p>0.05) between the groups supplemented with 
prebiotics (GOS and FOS) and control group. At the end of the experiment weight 
gain the rats supplemented with prebiotics was similar (ranged ~ 110.53 to 
120.64g) compared with controls. Moreover, there was no statistically significant 
difference (p>0.05) in weight gain between rats supplemented with prebiotics. 
The statistical analysis revealed that the food intake non-significant 
differences between different groups (p>0.05) supplemented whit prebiotics and 
control. The food intake were similar between groups supplemented with 
prebiotics, the food intake ranged ~10–12 g/d No statistical significance differences 
were observed in Feed conversion rate (FCR) in groups supplemented with 
prebiotics (0.25) and control group (0.26). FCR was similar for rats supplemented 
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with prebiotic (0.25).  Rats remained healthy and no mortality was was recorded 
over experimental period. 
The means of the absolute weights of after 42 days supplementation with 
prebiotics are presented in Table 1. There was no significant difference (p>0.05) in 
the   absolute weights of organs (thymus, spleen, and liver) between the control 
groups and supplemented with prebiotics.  In addition, no significant difference was 
observed on the absolute weights of collected organs from the different groups of 
animals supplemented with prebiotics (Table 1). 
 
 
 
Table 1- Growth performance and absolute weight of organs of Wistar albino’s rats 
supplemented with prebiotics for 42 days. 
Performance 
parameters 
 
Control 
(Maltodextrin) 
 
Prebiotic 
 GOS 
 
Prebiotic 
FOS  
p-values 
Initial body weight (g)  
 
388.80±18.45 392.60±12.45 408.20±20.50 0.053 
Body weight gain (g)  
 
112.44±10.39 117.36±15.56 110.2±12.40 0.065 
Total Food intake (g)  
 
420.40±0.21 426.50±0.32 430.20±0.15 0.054 
1Feed conversion ratio  
 
0.26±0.04 0.25±0.05 0.25±0.12 0.632 
2
 Weight organs (g) 
 
   
 
Thymus  33.80±2.60 33.20± 3.20 30.10±2.30 0.523 
Spleen  74.60±3.10 73.10±1.40 70.50±2.70 0.852 
Liver  148.20±1.20 140.30±1.80 146.40±1.50 0.837 
Values are expressed as Mean ± SD  (n = 12). Groups did not differ, p>0.05. 
 1
 Feed conversion ratio = weight gain (g)/food intake (g). 
2
 Absolute weights of organs (g)   
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3.2 - Cecal Short-Chain Fatty Acid Concentrations, Molar Ratios and Cecal 
pH 
 The supplementation of prebiotics resulted in higher (p<0.05) cecal 
concentrations of acetate, propionate, butyrate compared with the control (Table 
3). Total cecal SCFA pools were higher (p<0.05) from supplementation of GOS 
and FOS compared with control. The cecal SCFA (acetate, propionate and 
butyrate) were higher (p< 0.05) in rats supplemented with FOS compared with the 
control and GOS. 
The supplementation with FOS resulted in higher (p<0.05) cecal butyrate 
concentrations compared with GOS treatment. The concentration of butyrate from 
14.3 ± 3.7 µmol/g cecal content in the FOS group  to 27.9 ± 12.6 µmol/g in the rats 
suplemented wiht GOS (p<0.01). Total cecal SCFA were dramatically higher 
(p<0.05) as a result of FOS consumption, which GOS consumption. 
The cecal SCFA concentration in the rats supplemented with FOS and GOS 
are in the order from:  acetate, propionate and  butyrate respectively. The molar 
ratio (%) of acetate, propionate and butyrate were 60.33; 24.42 and 15.25, 
respectively in cecum of rats supplemented with FOS and 62.57; 20.80 and 16.63, 
respectively in rats supplemented with GOS. The supplementations of GOS induce 
such a high molar ratio of butyrate when compared with FOS. 
 Cecal pH was lower (p<0.05) in rats supplemented GOS and FOS com 
pared with control. Nevertheless, the cecal ph values were similar between FOS 
and GOS. 
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Table 2 - Short-chain fatty acids (SCFA) concentration in cecal rats supplemented 
with prebiotics3-1. 
Item Treatments  
Cecal SCFA 
(µmol/g cecal 
content) 
Control 
(Maltodextrin) 
 
FOS GOS     p-value 
Acetato 15.22±2.69a 52.08±10.10b 36.97±7.93c p< 0.001 
Propionato 4.02±1.05a 19.67±5.78b 12.29±2.73c p< 0.005 
Butyrate 2.65±2.39a 14.58±3.45b 9.82±3.62c p< 0.005 
Total SCFA 21.89±11.10a 86.33±21.20b 59.08±16.50c p< 0.001 
Cecal pH 7.40a 6.10b 6.20b p< 0.001 
Values are mean ± SD (n=12)  
 FOS, fructo-oligosaccharides; GOS, Galacto-oligossacharides. 
 
abc
 Means in the same row not sharing superscript letters differ (p<0.05). 
  SCFA = short chain fatty acids 
*Total SCFA= acetate+propionate+butyrate. 
 
3.3 - Intestinal Morphometric Parameters of Duodenum,  Jejunum and Ileum. 
Morphological measurements of the duodenum, jejunum and ileum of rats 
are apresented in Table 3. No significant differences (p>0.05) were observed in the 
villus height, crypt depth, and villus height:/crypt depth (VH:CD) ratio between the 
group’s suplemented wiht prebiotics (FOS and GOS) compared with control group. 
Moreover, results were similar between the groups supplemented with prebiotics. 
In the Jejunum the villus height was significantly higher (p>0.05) and crypt 
depths were significantly lower (p>0.05) for the rats supplemented whit prebiotics 
(FOS and GOS) compared with control (Table 3). No significant differences 
(p>0.05) were observed in the villus height, crypt depth between groups 
supplemented with prebiotics. The VH:CD depth ratio was significantly higher 
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(p<0.05) for groups of animals supplemented with prebiotics. However, the 
differences in VH:CD ratio were not significant between groups supplemented with 
prebiotics.  
The Villus height and VH:CD ratio at the ileum were significantly higher 
(p<0.05) in the rats supplemented with prebiotic when compared with rats of 
control group. The crypt depths at the ileum were significantly lower for the rats 
suplemented with prebiotics compared with control group (p<0.05). The villus 
height, crypt depth and VH:CD ratio was similar (p>0.05) for both groups of 
animals supplemented with prebiotics (Table 3).   
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Table 3- Effects of FOS and GOS on the morphology of the intestinal mucosa in 
the duodenum, jejunum and ileum. 
 Groups 
Duodenum  
 
Control 
(Maltodextrin) 
 (250mg/kg) 
FOS 
(250mg/kg) 
GOS 
(250mg/kg) 
p- value  
 
Villus height 
(mm) 
 
3.30 ± 0.49a 3.32 ± 0.57a 3.21±0.61a  0.822 
Crypt depth 
(mm) 
 
1.52 ± 0.24a 1.56 ± 0.26a 1.58 ± 0.41a 0.853 
VH : CD ratio 
 
2.25±0.18a 2.20±0.29a 2.22±0.25a  0.836 
Jejunum  
 
 
Villus height 
(mm) 
 
3.28 ± 0.50b 5.08 ± 0.69a 5.16 ±0,69a 0.032 
Crypt depth 
(mm) 
 
1.43 ± 0.26a 2.45 ± 0.34b 2.32 ± 0,22b 0.030 
VH : CD ratio 
 
1.38±0.18b 2.32±0.32a 2.26±0,34a 0.026 
Ileum  
 
 
Villus height 
(mm) 
 
3.28 ± 0.50b 5.08 ± 0.69a 5.16 ±0,69a 0.032 
Crypt depth 
(mm) 
 
1.43 ± 0.26a 2.45 ± 0.34b 2.32 ± 0,22b 0.030 
VH : CD ratio 
 
1.38±0.18b 2.32±0.32a 2.26±0,34a 0.026 
Results are expressed as Mean ± SD (n= 12) 
a–bMeans within a row with different letters differ significantly (p< 0.05). 
*Count in area equivalent to 10 villosities (in triplicate) 
VH:CD = villus height/crypt depth 
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4 - Discussion 
There has been a growing interest in the nutritional and physicochemical 
properties of the Prebiotics. One reason for that interest is the recent development 
of the industrial production in order to satisfy the demand of these functional food 
ingredients. The purpose of this work was to study the effects of supplementation 
of prebiotics on growth performance, organ weight and on the morphology of the 
small intestine in rats Wistar.  
In the present study, results showed no significant differences among 
treatments, in feed intake, body weight, weight gain and feed conversion.  Our 
results, in agreement with previous studies, showed that when GOS was added in 
diets to Broiler Chickens [20] and diets to pig growing [21]. Prebiotic 
supplementation did not significantly affect body weight, body weight gain and feed 
intake. However, other researchers have previously demonstrated significant 
increases in body weight gain in broilers receiving diets supplemented with 
prebiotics [22, 23].    
The improvement in feed intake by dietary prebiotic supplementation often 
resulted in improved growth performance. However, in the present study, using the 
prebiotics specifics GOS and FOS, no differences were observed in feed intake 
and consequently in body weight and body weight gain between treatments. 
Inconsistent results in response to prebiotic supplementation may be due to 
differences in methods of preparing the supplement, different experimental 
condition, doses of prebiotic applied, animal species and study population (e.g. in 
age, weight or breed) composition of diets, duration of supplementation or other 
environmental conditions [22].   
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Previous studies, reported no significant difference in organ weight (the 
spleen, liver and kidneys) in rats supplemented with 5% FOS during 23 days [24]. 
Results were similar to the ones we found in the present study. Nevertheless, was 
observed   significant difference in lymphoid organs weight (thymus, spleen and 
bursa of Fabricius) in birds after supplementation with oligochitosans during 21 
days [25].   
In our study no pathological abnormalities were observed macroscopically in 
terms of external morphology, color and organ texture when they were collected to 
measure weight. These results are in agreement with previous studies, since they 
did not observed any microscopic and macroscopic anormalities in organs such as 
liver, pancreas, kidneys, spleen, and heart in rats supplemented with 5 to 10 % of 
FOS [26, 27].  The absence of significant difference among groups for the organ 
weight added to the absence of mortality suggested that prebiotic GOS was not 
toxic.  
The present study demonstrated that supplementation with prebiotics FOS 
and GOS increased cecal SCFA concentrations in rats. Previous studies reported 
that intake of selected oligosaccharides, especially FOS and GOS, improved 
concentrations of total cecal SCFAs including butyrate [28].   
Campbell et al [18], studying the effects of oligofructose, FOS and XOS at 
the 6% dietary level, on concentration of cecal SCFA, demonstrated the cecal 
SCFA were higher (p<0.05) in rats consuming oligosaccharides compared with the 
control and cellulose diet. The oligofructose and fructooligosaccharides containing 
diets resulted in higher cecal butyrate concentrations compared with the control, 
cellulose and xylooligosaccharide diets.  
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Similar results were reported by Younes et al. [29], demonstrated the rats 
fed FOS and XOS at the 7.5% dietary level to elevate the cecal total SCFA.  
Butyrate was those fed XOS, while these oligosaccharides differ in their chemical 
composition; they probably are fermented similarly by the microbiota of rats 
because of the presence of similar constituents (glucose and fructose) for 
fermentation [30].  
Human colonic bacteria ferment oligosaccharides to short-chain fatty acids 
(SCFA), mainly acetate, propionate, and butyrate. SCFA contribute to normal large 
bowel function and prevent pathology through their actions in the lumen and on the 
colonic musculature and vasculature and through their metabolism by colonocytes. 
Butyrate, in particular, is thought to play a role in maintaining a normal colonocyte 
population [31].   
In vitro studies as well as animal studies indicate that in particular 
propionate and butyrate have the potential to support the maintenance of a healthy 
gut and to reduce risk factors that are involved in the development of gut 
inflammation as well as colorectal cancer [32].    
 In the present study, were observed that butyrate was produced in a higher 
concentration in rats supplemented with FOS and GOS compared with control. 
Butyrate is a preferred substrate for colonocytes and appears to promote a normal 
phenotype in these cells. Fermentation of some oligossacharides types favors 
butyrate production. 
 The cecal pH values were lower (p<0.05) in cecum of the rats supplemented 
with oligosaccharides FOS and GOS   compared with the control group. An inverse 
relationship between the pH and SCFA concentration in the cecal contents of rats 
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were observed in this study. The pH values are lowered significantly and SCFC 
concentrations are increased in rats supplemented with oligosaccharides. Lower 
pH values (and raised SCFA) are believed to prevent the overgrowth of pH-
sensitive pathogenic bacteria [31].  
    The histological study showed that the supplementation of prebiotics FOS 
and GOS increased the villus height and VH: CD villus ratio and decreased crypt 
depth in the jejum and ileum compared with controls. However, no effects of 
suplementation of prebiotics were observed for villus height and crypt depth at the 
duodenum. No statistically significant differences were observed in the villus 
height, crypt depth and VH: CD ratio between the prebiotics FOS and GOS. 
The villus play a crucial role in the digestion and absorption processes of the 
small intestine, as villus increase surface area and are the first to make contact 
with nutrients in the lumen [33].  Higher values of crypt depth indicate more 
proliferative cell function to guarantee a suitable rate of epithelial renewal and high 
demand for new tissue [34].  
  The crypts of the villus contain several specialized cells such as absorptive 
cells, goblet cells, and regenerative cells that are responsible for the production of 
mucus and the replacement of old cells [35].   
Previous studies, reported that the inulin-containing diet resulted in greater 
villus height jejunal (p<0.05) and deeper crypts (p<0.01) than in control birds 
without affecting villus:crypt depth ratio [36].  Similarly, studies using 
supplementation of the prebiotic FOS, reported morphological differences (mucosal 
thickness, villus height, crypt depth and villus/crypt ratio) in broilers [37].  
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In weaned piglets, studies using  feed without additives as well as feed 
containing an antibiotic, a probiotic, a prebiotic and a symbiotic,  observed that the 
prebiotics provided an increase in the villus height and crypt depth in  pigs fed with 
a diet with the prebiotic than in those receiving a diet with the probiotic [38]. 
Similar results were observed in study the effect of the prebiotic 
mananoligosacharide (MOS) on the small intestine in broiler chicken, they 
concluded that the addition of MOS to the diets increased the longitudinal muscular 
and mucosa thickness resulting in a higher nutrient absorption surface area in the 
small intestine of broiler chicken at 21 and 42 days of age [39].  
 The increases in villus height/crypt depth ratio were observed of the three 
segments in the small intestine of rats supplemented with prebiotics. The villus 
height/crypt depth ratio is a useful criterion for estimating the likely digestive 
capacity of the small intestine [40].   
A decrease in the villus height/crypt depth ratio is considered deleterious for 
digestion and absorption, and vice versa. Prebiotics that increases the villus 
height/crypt depth ratio might also increase the hydrolytic capacity of the epithelium 
[41].  
The influence of the prebiotics on the intestinal mucosa can be related to the 
fact that they reach the colon, suffer bacterial action of the micro-flora and are 
fermented. This fermentation activity results in volatile short-chain fatty acids 
(SCFA), especially acetate, propionate, and butyrate [42, 28].   
That supplementation of oligossacharides FOS and GOS, improved 
concentrations of total cecal SCFAs including butyrate, the preferred energy 
source for colonocytes, resulting in a trophic effect in small intestine. 
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 These results were reported by Koruda et al. [30] in studies with rats 
observed the trophic effects of SCFA on epithelial cell proliferation. One of the 
most important properties of SCFA is their trophic effect on the intestinal 
epithelium. These trophic properties have important implications, particularly for 
patients receiving enteral or parenteral nutrition, and in maintaining the mucosal 
defence barrier against invading organisms [43].    
 These SCFA are the prime substrates for the energy metabolism in the 
colonocyte and they act as growth factors to the healthy epithelium. In normal cells 
butyrate has been shown to induce proliferation at the crypt base, enhancing a 
healthy tissue turnover and maintenance. In inflamed mucosa butyrate stimulates 
the regeneration of the diseased lining of the gut. In neoplastic cells butyrate 
inhibits proliferation at the crypt surface, the site of potential tumour development 
[43, 44].   
 The data indicate that FOS and GOS supplementation (250mg/kg/d) 
produced higher SCFA concentration in cecum and decrease pH. Furthermore, the 
supplementations resulted in an increase in the villus height and decreased crypt 
depth of intestinal mucosa of rats. These results   represent a valuable 
morphometric reference for future studies of small bowel in human. 
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5 - Conclusion 
In conclusion, the GOS produced by β-galactosidase from Scopulariopsis sp 
is likely to exert protective effects on the small intestine mucosa in rats. Therefore, 
this product might be promising as a food ingredient for functional foods. However, 
more studies should be performed in vivo to confirm their protective effects on the 
intestinal mucosa. 
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Abstract 
 
This study evaluated the concentrations of cecal SCFAs, cecal and fecal pH, 
concentrations of microbial population, small intestinal mucosal morphology of 
several oligosaccharides, using a rat model. Forty male Wistar rats were randomly 
assigned to one of the following five treatments for 42 days: Rats were respectively 
supplemented by gavage of Inulim, fructo-oligosaccharides (FOS) galacto-
oligosaccharides and GOS/FOS in ratio of 9:1 [250 mg/(Kg body weight/day). 
Control group were give gavage of physiological saline solution. The growth 
performance was not affected by suplemmentation of oligosaccharides. The 
concentration SCFAs in rats cecum were significantly increased (p<0,05) by intake 
oligosaccharides, especially GOS/FOS mixture ratio 9:1.  The pH cecal and fecal o 
was significantly lower in rats receiving the oligosaccharides. The Cecal 
bifidobacterium, lactobacillus and total anaerobes were higher whereas total 
aerobes were lower in rats supplemented with oligosaccharide compared with rats 
the control group. The oligosaccharides significantly increased (p<0.05) villus 
height, crypt/villus ratio and total mucosal thickness and and decreased crypt depth 
at the jejunum and ileum. In the present study, the indigestible oligosaccharides 
are fermentable in the gut, by providing SCFA, trophic effects on small intestine, 
lowering pH, and increasing bifidobacteria may be beneficial in improving 
gastrointestinal health. In conclusion, supplementation of indigestible 
oligosaccharides may be beneficial to gastrointestinal health. 
 
Keywords: Oligosaccharides, short-chain acids, Bifidobacterium, Lactobacillus, 
intestinal morphology, rats. 
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1 – Introduction 
 
Oligosaccharides are carbohydrates with a low degree of polymerization (DP) and 
consequently low molecular weight. They have been variously defined as including 
anything from 2 to 20 monosaccharide units. The concept of no-digestible (or 
nondigestible or unavailable) oligosaccharides (NDOs) originates from the 
anomeric C atom (C1 or C2) of the monosaccharide units of some dietary 
oligosaccharides has a configuration that makes their osidic bounds nondigestible 
to the hydrolytic activity of the human digestive enzyme (Roberfroid & Slavin, 
2000).  
 
The NDOs possess important physicochemical and physiological properties, and 
are claimed to behave as dietary fibers and prebiotics. (Mussato & Mancilha, 
2006). Commercially, oligosaccharides are produced by enzymic processes either 
by hydrolysis of polysaccharides or synthesis from smaller sugars. Because of their 
prebiotic properties, oligosaccharides have received much recent attention as 
functional food ingredients (Roberfroid, 1998; Cummings et al, 2001). 
 
 NDO pass through the small intestine tract. In the large intestine, are selectively 
fermented by bifidobacteria and lactobacilli, stimulating their growth, both of which 
are considered beneficial intestinal bacteria. (Cherbut et al., 1994; Roberfroid et al., 
2010).  
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The increased levels of beneficial bacteria in the gut resulting from the 
consumption of indigestible oligosaccharides are associated with a number of 
positive effects in the digestive and immune systems. These include the 
development of the mucosal barrier, production of short-chain fatty acids which 
reduce pH in the gut, activation of the immune system, metabolism of bile acids, 
and synthesis of several vitamins (Bruzzese et al., 2006).  
 
Prebiotics oligosaccharides currently commercialized as food ingredients include: 
fructo-oligossacharides, galacto-oligosaccharides, lactosucrose, isomalto-
oligosaccharides, gentio-oligossacharides and xilo-oligossacharides (Rastall, 
2002), However, only Inulin, Galacto-oligosaccharides (GOS) and fructo-
oligosaccharides (FOS) have an established prebiotic status, and their health 
effects have been extensively studied (Gibson et al., 2004; Roberfroid, 2007).  
 
 “Fructans” is a general term used for naturally occurring plant oligo – and 
polysaccharides. Belonging to fructans inulin (IN) and fructo-oligosaccharides 
(FOS) are plant-derived carbohydrates with the benefits of soluble dietary fiber and 
different chain lengths (degree of polymerization). (Lopez-Molina et al., 2005). 
GOS were recently defined as “a mixture of oligosaccharides occurring naturally in 
human milk, the commercial products are synthesized by the action of B-
galactosidase on lactose (Rabiu et al., 2001). 
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Galactooligosaccharides and fructooligosaccharides have been used to stimulate 
Bifidobacteria, and several human studies have demonstrated the prebiotic effect 
of these compounds (Gibson et al., 1995; Bouhnik et al, 1997).  
 
The genus Bifidobacterium, a major bacterial group in the gastrointestinal tract 
(GIT), accounts for up to 25% of the total culturable bacteria in adults (Sgliir et al, 
1998) and are generally considered to be health promoting and beneficial (Rao, 
1999). Much recent research has focused on bifidobacteria to establish the 
importance of these bacteria in influencing certain normal functions of the intestinal 
tract and in exploring their role in human health and diseases (Mitsuoka et al., 
1990). 
 
However, several important factors influence the total oligosaccharide effects in the 
bowel, particularly the nature of the oligosaccharides, the dose, the duration of the 
treatment, the place where their fermentation mainly occurs (proximal or distal 
colon) and the initial composition of intestinal microbiota (Delzene, 2003). 
 
There is a growing commercial interest in new non-digestible oligosaccharides for 
functional food ingredients. Also, it is essential intense scientific research for 
evaluating their functional traits. In this sense, the current study aimed evaluating 
prebiotic properties of the GOS produced by β-galactosidase from Scopulariopsis 
sp and compare prebiotic properties of GOS with commercially available prebiotic 
FOS (Raftilose®, Beneo, Belgium) and Inulin (Oraft-Raftiline ® Beneo, Belgium).  
 
  
209 
Was examined, the influence of different indigestible oligosaccharides: Inulin, FOS 
and GOS, on the concentrations of cecal SCFAs, cecal and fecal pH, 
concentrations of cecal microbial population and intestinal morphology in Wistar 
rats.  
 
2 - Materials and Methods 
 
2.1 - Oligosaccharides 
Two commercial oligosaccharides, GOS produced from lactose and GOS/FOS 
mixture were investigated for their effects on the intestine physiology of rats. The 
FOS (Raftilose P95) contain 95% oligofructose with Degree of Polymerisation (DP) 
between 2 and 8 and 5% of glucose, fructose and sucrose were obtained from 
ORAFTI (Belgium). The inulin (Oraft-Raftiline HPX, BENEO 100%) is a mixture of 
oligo- and polysaccharides with DP between 2 and 60. The commercial 
oligosaccharides Inulin and FOS were kindly donated by Orafti-Active Food 
Ingredients (Belgium). The galacto-oligossacharides (GOS) mixture used in this 
study was produced by transgalactosylation using β-galactosidase from 
Scopulariopsis sp on lactose. The main component of GOS is 4’ galactosyllactose 
and contains of the several oligosaccharides species (disaccharides, trisaccharides 
and tetrasaccharides) and lactose, glucose and galactose (Santos et al. 2009). 
 
2.2 - Animal and Treatments 
Forty male Wistar rats (Center of Bioterism – CEMIB. Unicamp (Campinas-SP, 
Brazil) weighing 385±12g was assigned randomly to one of five groups 
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(8rats/group). Treatment included: Control group were give gavage of physiological 
saline solution [2 mL/ (kg BW.d)]. Iunlin, FOS, GOS and GOS/FOS mixture in a 
ratio of 9:1 groups were rendered gavage of 250mg/mL corresponding 
oligosaccharides solution [2mL/ (kg BW.d)], respectively. The animals were 
allowed free access to water and commercial diet (PURINA®)  
 
During the period of adaptation (5 d), the rats were housed two per cage in a 
temperature-controlled room (22°C) with a 12-h cycl e of light and darkness. 
Following the adaptation phase, rats were housed individually in plastic boxes. The 
experimental protocol was reviewed and approved by the Institutional Committee 
for Ethics in Animal Experimentation (CEEA/IB/UNICAMP). The experimental 
lasted 42 days, and individual food consumption and weight gains of the rats were 
recorded daily. 
 
2.3 - Sample Collection 
At the termination of the experiment, the rats were anaesthetised with 
subcutaneous injection of ketamine-xylazine-acepromazine cocktail (1.4 ml/kg 
body wt) and killed by exsanguination through a cardiac puncture. After 
laparotomy, the cecum and colon with contents was removed. The Cecal contents 
were collected, pH measured, and a 0.5g aliquot immediately processed for SCFA 
analysis. The remaining cecal contents were immediately placed into a sterile 
assay tube for bacterial enumeration. After removal of the appropriate samples, the 
small intestines were cleaned with saline solution, and immersed in the fixing 
solution for subsequent histological analysis. The pH was measured in the fresh 
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stool sample using pHmeter  (Pack ph 21)  by homogenizing 2.0g of fecal sample 
in 3 w/v sterile H2O (pH 7.0) in a 10 ml centrifuge tube. 
 
2.4 Determination of the Concentrations of SCFA 
Cecal SCFA concentrations were determined in duplicate using the method   
described by of Smirick-Tjardes et al. (2003) with modification. Cecal contents 
were acidified with 250 g/L metaphosphoric acid using a mixture of 0.4g 
sample:0.8 mL acid:2.8 mL distilled H2O and centrifuged at 25,900 1g for 20 min. 
2), precipitated at room temperature for 30 min, and then centrifuged at 25,900 × g 
for 20 min. The supernatant was decanted and frozen at −20°C in microfuge tubes. 
After freezing, the supernatant was thawed and centrifuged in microfuge tubes at 
13,000 × g for 10 min. The supernatant was used in GC/MS analysis. 
 
The cecal digesta was analysed for SCFA concentration with the gas 
chromatography GC/MS (Agilent 5975C, inert MSD) equipped with a Nukol  
capillary columm (Supelco, 30m x 0.25mm x 0.25µm film thickness). The injection 
was performed in the splitless mode for 1 min at 220°C. Oven temperature was 
programmed at 100°C for 5 min, then increase to 200 °C at 8°C.min -1 and held for 1 
min at the final temperature. Injector and detector temperature was 200°C; the 
carrier gas was nitrogen at a flow rate of 25 mL/min. Volatile free acid standard mix 
(Supelco4697-U) was used as internal standard. Caecal SCFA pool size was 
calculated as the product of SCFA concentration in cecal digesta mass. 
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2.5 - Bacterial Enumeration 
Bacterial enumerations were determined using the method   described by Pan et 
al. (2009).  Samples for enumeration of selected genera of cecal bacteria were 
serially diluted 10-fold with peptone-water immediately after collection; 100 µl of the 
appropriate dilutions were inoculated onto duplicate plates using selective media 
for the enumeration of different bacteria. Bacteria were counted on plate count 
agar – PCA (Merck; total aerobes) Wilkins –chalgren agar (Difico; total anaerobes), 
Mac-Conkey agar   (Merck; Enterobacteriaceae), de Man, Rogosa and Sharp – 
MRS agar (Oxoid; Lactobacillus), and MRS agar (Oxoid; Bifidobacterium) 
 
Enumeration of Bifidobacterium was determined using the method   described by 
Moriya et al (2006). The Commercial MRS medium (Oxoid) was sterilised at 121ºC 
for 15min and was added the inhibitors and the aminoacid L-cysteine added. The 
inhibitors concentration in the final medium were: lithium chloride 3 mg/ mL, 
nalidixic acid 15 µ/mL, neomycin sulphate 100 µg/mL and paramomycin sulphate 
200 µg/mL. The L-cysteine concentration was 0.5 g/mL in the final medium. 
 
Plates were incubated at 37ºC aerobically or in anaerobic conditions (Anaerogen® - 
anaerobiosis generator from Oxoid), for 24 or 72 h as appropriate. Plates 
containing 20 to 200 colonies were enumerated. The microbial count data were 
expressed as colony forming units/g wet sample. The selectivity of the growth 
conditions was confirmed by microscopic examination.   
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2.6 - Preparation of Tissues 
The small intestine was carefully dissected distally to the stomach and proximal to 
the cecum.  Transversal sections (2cm) of the duodenum, jejunum, and ileum were 
washed in saline solution, and immersed in a fixing solution (formol 5%) for 24h for 
subsequent histological examination. The histological cuts were dehydrated in a 
series of crescent concentrations of alcohol, diafinized in xylol, and immersed into 
paraffin. Sections were cut (5 µm) on a microtome (Leica RM 2145) cut, and then 
stained with hematoxylin and eosin (HE staining). 
 
2.7 - Morphological Analysis 
For the morphometric study of intestinal mucosa, ZoomBrowser EX Imaging 
System software was used in conjunction with a microscope (Carl Zeiss, Germany) 
fitted with a video camera (Sony). The video camera transferred the image from 
the microscope to the computer screen. After capturing the images, the 
morphometric analysis was performed using the Image Tool Software. 
The height of the villus and the depth of the crypts and Total mucosal thickness 
were measured in well-guided longitudinal sections. The villosities length was 
measured the extension between the junction crypt-villi and the villosities ends. 
The crypt depth was measured between the junction crypt-villi and the crypt base. 
Total mucosal thickness were measured the extension from the top of the villus to 
the border over the muscularis mucosae (Figure 1). A total of 10 intact crypt-villus 
units were selected in triplicate for each intestinal cross-section (30 measurements 
for each sample) 
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Figure 1- Schematic diagram of an intestinal villus showing how the intestinal 
mucosal levels were measured in well-guided longitudinal sections (Pires et al., 
2003).  (1-2) Villus height, (2-3) Crypt depth 
 
 
 
 
2.8 - Statistical Analyses 
One-way analysis of variance was performed using the GRAPHPAD PRISM 5.0 
version (graphPad software, Inc., La  Jolla, CA, USA). Differences among means 
were tested using the Tukey test.  Values of less than 0.05 (p<0.05) were 
considered significant. 
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3 - Results and Discussion  
 
 
 
3.1 - Effects of Supplementation on Body Weight and Feed Intake 
No significant differences in feed intake or weight gain were noted throughout the 
study. The body weight and feed intake of the rats did not differ among the control, 
and groups Supplemented with oligosaccharide (data not shown). Feed intake was 
unaffected by oligosaccharides.  After 42 days of gavage, feed intake ranged ~20–
22 g/d with an average of 21.4 g/d and fluctuated daily, the groups supplemented 
with oligosaccharides (Inulin, FOS and GOS),  the total ration consumption was 
0.858; 0.862 and 861kg respectively per rats  and in the control group, and it was 
0.862 kg. No statistical differences in feed intake between groups Supplemented 
with oligosaccharide. In addition, there was no significant difference (p>0.05) in 
food conversion ratio between the groups supplemented with oligosaccharides and 
control group. 
 
Campbell et al. (1997) and Sakaguchi et al. (1998) also observed no difference in 
feed consumption in rats with the oligosaccharides added to the feed. There is 
considerable variation in the results reported by other researchers, since Vesna et 
al. (2007) reported on lower feed consumption in broilers supplemented with 
mannan-oligosaccharides (MOS) Similar results were obtained by Rosen (2007) 
reported on average lower feed consumption for birds fed MOS vs. controls, 
 
Initial body weights ranged from 384 to 386g in the groups Supplemented with 
oligosaccharides with final body gain from 445 to 452g. The body weights 
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increased over time for all groups supplemented and control.  The body gain was 
similar between control groups (450.5g) and supplemented. Morever, no significant 
differences in body weight were noted in the groups supplemented with different 
oligosaccharides.  
 
These results seem to confirm observations made by Campbell et al. (1997), 
showed that No significant differences in food intake and body weight in rats 
suplemented with different oligosaccharides (Oligofructose, FOS and XOS) and 
control group. Similar results were obtained by Younes et al. (1995), no observed 
significant differences in food intake or weight gain in rats feed diets containing 
7.5%  two oligosaccharides (fructo-oligosaccharide or xylo-oligosaccharide).  
 
These results indicate that the effects of oligosaccharides on body weight and food 
intake might be affected by differences in the animal model, animal gender, 
experimental period, supplemental method, and dose and type of oligosaccharide 
used 
 
3.2 - Cecal SCFAs Concentrations and pH Analysis 
 
All oligosaccharides significantly increased (p<0.05) the cecal concentration of total 
SCFA, acetate, propionate, and butyrate compared to the control (Table 1). The 
cecal concentration of total SCFAs was greatest (p<0.05) for the FOS compared 
with inulin and GOS. Moreover, the mixture of GOS/FOS had results in similar 
concentration of total SCFA compared with inulin, FOS and GOS. 
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Table 1- Concentration of short-chain fatty acids (SCFAs) in cecal contents and pH 
values in rats supplemented with different oligosaccharides for 42 days. 
Item Treatment 
SCFAs 
(µmol/g) 
 
Control     Inulin FOS GOS GOS/FOS   
 (9:1) 
p values 
Acetate 6,88±1,99a 28,18±11,82b 52,05±13,01bc 34,24±15,46b 33,75±6,96b p<0.0001 
Propionate 3,78± 0,65a 9,49± 5,43b 26,36±3.57bc 9,34± 4,63b 10,45± 5,72b p<0.0020 
Butyrate 2,64±1,93a 7,33± 3,8b 12,75± 9,26bc 7,33± 3,80b 7,28± 2,69b p<0.0042 
*Total 
SCFA 
13,30±2.19a 45,00±11.47b 91,16±19.96bc 50,83±15.02b 51,49±17.16b p<0.0032 
       
Fecal pH 7.7±0.28a 6.3±0,26b 6.2±0,18b 6.4±0,34b 6.2±0.39b p<0.0001 
Cecal pH 7.3±0.32a 5.7±0.52b 5.5±0.44b 6.0±0.37b 5.8±0.52b p<0.0001 
FOS: fructo-oligosaccharides; GOS: Galacto-oligosaccharides.  
Results are show as mean± SD (means of 8 rats). 
abc
 Means in the same row not sharing superscript letters differ (p<0.05). 
*Total SCFA =Acetate+Propionate+Butyrate 
 
 
All the three major short chain fatty acids (acetate, propionate, and butyrate) were 
significantly increased (p<0.05) the cecal concentration by oligosaccharides.  FOS 
resulted in greatest (p<0.05) concentrations of acetate among oligosaccharides. 
The mixture GOS/FOS resulted in a similar concentration of acetate (p<0.05) 
compared with inulin and GOS. 
 
 
Propionate production was higher (p<0.05) in rats supplemented with 
oligosaccharides. However, FOS resulted in greatest (p<0.05) concentrations of 
propionate among oligosaccharides. Propionate production was similar between 
oligosaccharides inulim, GOS and GOS/FOS mixture. 
 
  
218 
Oligosaccharides resulted in greatest (p<0.05) concentrations of butyrate 
compared to the control. The butyrate concentration was higher (p<0.05) in rats 
supplemented with FOS. However the Butyrate production was similar for inulim, 
GOS and GOS/FOS mixture.  Butyrate is the preferred energy substrate of 
colonocytes. In the present study the cecal SCFAs concentration   are in the order 
predicted from that equation, i.e., acetate > propionate > butyrate. 
 
Differences in the relative proportions of acetate, propionate and butyrate were 
observed between 5 groups experimental. The cecal SCFAs are produced in molar 
ratio (52:28:20) respectively in control group; inulin (62:21:17) respectively, FOS 
(57:23:20) respectively, GOS (67:18:15) respectively, GOS/FOS (65:20:15). 
Acetate was the predominant SCFA in the cecum in all rats.  Molar ratios of SCFA 
are probably a more reliable indicator of dietary changes than SCFA 
concentrations (Scheppach, 1994). The characterization of changes in the 
concentration of microbial products such as SCFA may reflect dietary effects and 
provides an indication of microbial Activity (Kleessen et al., 1997). 
 
Fecal pH was lower (p<0.05) in rats supplemented with oligosaccharides compared 
with control. Similarly, Cecal pH was lower (p<0.05) in rats supplemented with 
oligosaccharides compared with control. Moreover, cecal pH was dramatically 
lower (p<0.05) that fecal pH   in rats supplemented with oligosaccharides. 
 
In the present study, three types of oligosaccharides, inulin FOS and GOS were 
used to study the potential effects of on SCFA formation, using a rat model. The 
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oligosaccharides, inulin, FOS and GOS increased cecal concentration of cecal 
SCFA, especially FOS. The production rate and level of SCFA in the colon 
depends on the composition of the microbiota, the substrate availability, and the 
gut transit time. (Wong & Jenkins, 2007). 
 
The values of cecal SCFA concentration from this study are comparable with 
previous studies. Pan et al. (2009) investigating the effects of oligosaccharides 
FOS, GOS, MOS and COS on concentration of cecal SCFA demonstrated that 
SCFA in mice cecum were significantly increased by intake oligosaccharides. 
 
In studies employing different oligosaccharides, using a rat model, similar 
observations have been made by Campbell et al (1997), Nilsson et.al (2005) and 
Juskiewicz et al. (2006). However, in humans production of total colonic SCFA is 
difficult to determine. Human experimentation has been confined largely to fecal 
measurements, which are also limited, because more than 95% of the SCFA are 
rapidly absorbed and metabolised by the host. Probably for these reasons various 
studies were not able to show effects of different fermentable substrates on fecal 
SCFA concentrations (Topping & Clifton, 2001). 
 
The major fermentation products of indigestible oligosaccharides metabolism in 
large bowel are short chain fatty acids (SCFAs), mainly acetate, propionate and 
butyrate, are usually produced in a molar ratio of 60:20:20, respectively 
(Cummings, 1981). However, the concentrations and proportions of SCFA are 
dependent not only on the counts and activities of the bacterial species but also on 
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the environmental conditions such as luminal pH and the absorption rate of the 
SCFA in the gut (Cummings and Macfarlane, 1991). 
 
SCFA are rapidly absorbed from the colonic lumen by passive diffusion and anion 
exchange, and only 5-10% is excreted in the feces (Ruppin et al., 1980). Butyrate 
is the most interesting of the SCFA since; it regulates cell growth and differentiation 
of colonocyte. In addition to this trophic effect, butyrate stimulates the 
immunogenicity (sensitivity to the immune response) of the cells. The colonic 
microbiota has a considerable influence on the immune system of the host (Bornet 
et al., 2002). Propionate is largely taken up by the liver. Acetate enters the 
peripheral circulation to be metabolized by peripheral tissues (Wong et al., 2006; 
Hijova & Chmelarova, 2007).     
   
The SCFA acidify the luminal pH which suppresses the growth of pathogens and 
stimulation of sodium and water absorption, they also influence intestinal motility 
(Scheppach, 1994). The SCFAs have been associated with reduced risk of  
developing gastrointestinal disorders, including reduction of cancer risk, increase in 
mineral absorption, improvement in bowel habit, control of serum lipid and 
cholesterol level (Hijova &Chmelarova, 2007).  
 
The pH of cecum was significantly lower in rats receiving the oligosaccharides and 
GOS/FOS mixture in compared with control group. The fecal pH decreased after 
oral supplementation with oligosaccharides. The influence of the mixture GOS/FOS 
on the change in fecal pH was significant (p<0.05). The reduction in pH value was 
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a result of microflora action utilizing oligosaccharides and producing fermentation 
end-products like lactic and short-chain fatty acids 
 
 In rats, fermentation is essentially localized in the cecum. The cecum has the 
highest level of SCFA available for absorption/utilization. As a result of 
fermentation, pH decreases. There are several results available indicating that 
SCFA and pH influence the physiological role of intestinal cells. 
 
3.3 - Effects of Oligosaccharides on Microbial Population 
 
The effects of supplementation of the oligosaccharides on cecal microflora are 
presented in Table 2.  In the present study, the cecal concentration of 
Bifidobacterium and Lactobacillus were greatest (p<0.05) as a result of 
suplementation of oligossacharides. However, there was no significant difference 
in and lactobacillus counts among the oligosaccharides groups. 
 
Total aerobes were lower (p<0.05) due to ingestion of oligosaccharides compared 
with control group, whereas total anaerobes were higher (p<0.05) for rats 
suplemented with oligossacharides compared with control group. Cecal 
concentrations of the E.coli were lower (p<0.05) for rats supplemented with 
oligossacharides compared with control group. 
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Table 2- Effects of oligosaccharides in cecal microbial population. 
log10 CFU/g 
wet contents 
Treatment 
 
Control Inulim FOS GOS GOS/FOS 
(9:1) 
p- values 
Bifidobacterium 7.8±0.22a 9.2±0.36b 9.8±0.25b 9.4±0.32b 9.8±0.20b 0.0001 
Lactobacillus 6.2±0.20a 8.4±0.23b 8.6±0.52b 8.5±0.55b 8.2±0.36b 0.0122 
E.coli 7.8±0.55a 6.2±0.36b 6.3±0.58b 6.5±0.28b 6.3±0.61b 0.0138 
Total aerobes 8.4±0.62a 7.2±0.26b 6.8±0.52b 6.6±0.56b 6.9±0.38b 0.0001 
Total 
anaerobes 
7.8±0.2a 10.2±0.6b 10.5±0.7b 10.1±0.3b 10.2±0.8b 0.0001 
FOS: fructo-oligosaccharides; GOS: Galacto-oligosaccharides, CFU, colony-forming units. 
Results are show as mean±SD, n=8. 
Means in a row without a common letter differ, p<0.05 
 
 
 
In the present study, no significant differences were observed in in cecal population 
of the Bifidobacterium and Lactobacillus in group supplemented with mixture of 
GOS/FOS (9:1). Results were similar when compared with others oligosaccharides 
(inulin, FOS or GOS). 
 
Infant formula supplementation with a prebiotic mixture (90% short-chain galacto-
oligosaccharides (scGOS) and 10% long-chain FOS (lcFOS) leads to increased 
numbers of the fecal Bifidobacterium  and Lactobacillus. Several studies 
demonstrated that this mixture modulated the entire microbiota closer to the 
intestinal flora composition found in breast-fed infants (Moro et al., 2002). 
 
Marked differences in the rat cecal and colonic microflora in response to different 
indigestible oligossacharides also were reported by other authors (Campel et 
al.1993; Pan et al 2009).  
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Pan et al. (2009) reported significant differences in the cecal microbiota of rats 
supplemented whit oligosaccharides. After 14 d of gavage, the concentrations of 
Bifidobacterium and Lactobacillus in the cecum were higher (P<0.05) in each 
oligosaccharide group than in the control group. These results confirm that 
indigestible oligossacharides has the potential for changing the composition of the 
intestinal microflora. 
 
It was demonstrated that the intakes of indigestible oligosaccharides FOS, 
oligofructose and xylooligosaccharide led to significant increase in Bifidobacterium 
and Lactobacillus (Campbell et al., 1997).  
 
Several in vivo studies demonstrate that diets that supply oligosaccharides (e.g., 
inulin, FOS, and GOS) selectively increase the intestinal tract population of 
bifidobacteria in animals and humans (Delzenne, & Roberfroid, 1994, Hsu et al., 
2004; Hsu et al., 2004). The indigestible oligossacharides may benefit 
gastrointestinal tract health via fermentation and proliferation of desirable bacterial 
species (Campbell et al., 1997). 
 
A number of physicochemical and microbial factors can influence the pattern and 
the extent of fermentation of appropriate bacterial substrates. These include 
competition for nutrients, the physicochemical environment of the large gut (e.g., 
oxidation-reduction potential, pH, SCFA, and lactate concentrations), various host 
conditions (e.g., intestinal motility, antibacterial compounds), metabolic interactions 
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among bacteria, and changes in the fermentation strategy of bacterial species 
(Macfarlane & Cummings, 1991; Kleessen et al., 1997). 
 
Also, a study by Tuohy et al. (2001) demonstrated that that the dose and the 
duration of oligosaccharide intake, the place where fermentation mainly occurs 
(proximal or distal colon), as well as the initial composition of fecal flora, are 
important factors influencing the extent of the prebiotic effect, i.e. the increase in 
bifidobacteria. 
 
The colonic microflora should change in response to gross nutritional shifts (e.g., 
weaning), progressive change (such as aging), or variations in food intake. In aged 
persons, Escherichia coli, streptococci, and clostridia increase and bifidobacteria 
decrease further (Mitsuoka et al., 1996; Topping & Clifton, 2001).  
 
The effect of oligosaccharides on histological measurements of the duodenum, 
jejunum and ileum mucosa of rats is summarized in Table 3. In the present study, 
no significant differences in villus height in the duodenum were observed in rats 
supplemented whit oligosaccharides. However, the villus height was significantly 
increased (p<0.05) after 42 days oral supplementation with oligosaccharides 
versus control.  
 
No significant differences were observed in villus height among groups 
supplemented with oligosaccharides or mixture of GOS/FOS. The crypts of the 
villus contain several specialized cells such as absorptive cells, goblet cells, and 
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regenerative cells that are responsible for the production of mucus and the 
replacement of old cells (Ayabe et al., 2000;  Solis de los Santos et al., 2007 ). 
 
In the present study, we observed significant increases in crypt depth in the 
jejunum and ileum in rats supplemented whit oligosaccharides compared with 
control group. However, there was no difference in crypt depth in the duodenum 
among groups supplemented and control. Crypt depth was similar (p>0.05) and 
jejunum and ileum between groups supplemented with oligosaccharides and 
mixture GOS/FOS.  
 
 According to Silva et al. (2010), higher values of crypt depth indicate more 
proliferative cell function to guarantee a suitable rate of epithelial renewal and high 
demand for new tissue. 
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Table 3. Effects of oligosaccharides on the morphology of the intestinal mucosa   
at different sites in the small intestine. 
 Treatment 
Site Control Inulin FOS GOS GOS/FOS 
Villus height 
(mm) 
3.48±2.26 3.42±2.87 3.17±2.75 3.46±2.14 3.28±2.75 
Duodenum 3.79±3.20 5.79±2.17 5.58±4.15 5.89±3.75 5.87±4.10 
Jejunum 3.53±1.20 5.38±3.35 5.74±2.75 5.62±3.73 5.69±3.33 
Ileum 
     
Crypt depth 
(mm) 
     
Duodenum 1.36±0.78 1.34±0.56 1.28±0.55 1.39±0.74 1.16±0.52 
Jejunum 1.82±2.15 2.06±5.30 2.34±6.03 2.19±3.65 2.06±2.12 
Ileum 1.76±8.30 2.28±6.45 2,10±8.01 2.19±6.23 2.30±8.08 
Villus height/ 
crypt depth 
     
Duodenum 1.58±0.06 1.62±0.07 1.42±0.03 1.75±0.8 1.55±0.06 
Jejunum 1.78±2.21 2.86±2.36 2.38±2.57 2.65±4.75 2.84±2.45 
Ileum 1.48±3.75 2.53±8.20 2.44±7.32 2.65±4.72 2.37±4.40 
Results are show as mean±SD 
Means within a row with different letters differ significantly (p<0.05). 
Means represent 8 rats per treatment; there was one sample for each of the three intestinal 
segments per rat, three cross-sections per sample, 24 cross-sections for each of the three intestinal 
segments per treatment, and 10 measurements per cross-section for a total of 240 measurements 
for each of the three intestinal segments per treatment. 
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The crypt/villus ratio in the jejunum and ileum were significantly higher for the rats 
supplemented with oligosaccharides versus control. The ratio villus height to crypt 
length in the normal small intestine varies from about 3:1 to 5:1. 
 
This result concurs with results found in earlier experiments. Xu et al. (2003) no 
observed significant differences for villus height, crypt depth, or microvillus height 
at the duodenum. By contrast, addition of 4.0g/ kg FOS significantly increased ileal 
villus height, jejunal and ileal microvillus height, and villus-height-to-cryptdepth 
ratios at the jejunum and ileum and decreased crypt depth at the jejunum and 
ileum 
 
 
Solis de los Santos et al. (2005) observed significantly increased in villus height 
and and crypt depth the duodenum and Ileum in broilers supplemented with 
prebiotics. Similarly, Budiño et al. (2005). It was found that the density and length 
of duodenal villus was higher in pigs fed a diet with the prebiotic than in those 
receiving a diet with the probiotic.  
 
Silva et al. (2009) evaluated the effect of yeast extract or prebiotic on performance 
and intestinal morphometry of broiler chickens and observed the prebiotic 
increased in the villus height and crypt depth in the three intestinal regions. 
Nevertheless, data in the present study disagree from those reported by Leforestier 
et al. (2009) studying the effect of the GOS ingestion on small intestinal mucosal 
morphology in mice, no detectable effect on the intestine villus height.  
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Dietary factors increase the height of intestinal villi as well as the number and 
depth of crypts (Mroz 2001) Nutritional factors, such as short-chain organic acids, 
may directly affect intestinal morphology, stimulating the proliferation of intestinal 
epithelial cells (Sakata et al. 1995; Ichikawa et al. 2002). 
 
Oligosaccharides indigestible increased the production rate of SCFA (acetate, 
propionate and butyrate) in the colon. The SCFA are metabolites of bacterial 
fermentation, which stimulate epithelial cell proliferation in the gut (Ichikawa et al., 
1999). The most important of these short-chain fatty acids is butyrate. 
 
 Butyrate plays a key role in colonic epithelium homeostasis, is rapidly absorbed in 
the epithelium and is thought to stimulate proliferation, is a principal energy source 
for epithelial cell, also believed to protect against colon cancer as it inhibits DNA 
synthesis and induces cell differentiation (Gonçalves et al., 2011). By producing a 
greater concentration of butyrate, the preferred energy source for colonocytes, a 
trophic effect may be resulted within the gastrointestinal tract (Pan et al., 2009). 
 
It is likely that the trophic effects of the oligossacharides are due to the ability of the 
oligossacharides  create a more favorable intestinal microbial environment and are 
not a direct action of oligossacharides on the intestinal tissue (Xu et al., 2003). 
 
The intestinal tract can be anatomically divided into two well-defined segments: the 
small intestine and the large intestine or colon. The small intestine is subdivided 
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into three proximal-distal segments: the duodenum, jejunum, and ileum. The 
absorptive surface area of the small intestine is dramatically increased by 
numerous finger-like protrusions that point toward the lumen, the so-called villi, and 
invaginations into the submucosa known as the crypts of Lieberkühn. 
 
 The mucosa of the large intestine lacks villi; crypts invaginate deep into the 
submucosa, Crypts are responsible for the proliferation of epithelial cells (Barker et 
al., 2008). The small intestinal epithelium consists of four principal cell types 
deriving from one multipotent stem cell: enterocytes, goblet, enteroendocrine, and 
Paneth cells.  (Sancho et al. 2003)  
 
Accordingly, the trophic effect of indigestible oligosaccharides on the small 
intestine is assigned the production of SCFAs, principally butyrate. SCFA are 
metabolized rapidly by colonocytes and are major respiratory fuels and trophic to 
the small bowel and colon (Topping & Clifton, 2001). 
 
 In vivo studies with rats have documented the   trophic effects of SCFA on 
epithelial cell proliferation (Frankel et al. 1994, Koruda et al.  1988). These trophic 
properties have important physiological implications in addition to maintaining the 
mucosal defense barrier against invading organism (Salminen et al., 1998). 
 
These findings suggest that oligosaccharide supplementation could modify the 
population and metabolic characteristics of the gastrointestinal bacteria, which 
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might in turn modulate enteric functions and provide resistance to colorectal 
cancers (Buddington et al., 2002). 
 
The beneficial action of indigestible oligosaccharides on the villus height and crypt 
depth in jejunum and ileum was probably influenced by production of SCFA 
(acetate, propionate and butyrate) in the colon.  
 
These results preliminary suggest that GOS produced by β-galactosidase from 
Scopulariopsis sp have prebiotic potential, could have potential in the development 
of new functional product. However, further studies of the effects of these 
oligosaccharides on intestinal microbiota, morphological of the small intestinal 
mucosa and concentration of SCFA are necessary to sustain this beneficial health 
effects. 
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4 - Conclusions 
In conclusion, from this study we can conclude that GOS produced by β-
galactosidase from Scopulariopsis sp can exert beneficial effects in the 
gastrointestinal tract, by providing SCFA, lowering pH, increasing bifidobacteria 
and beneficial changes in intestinal architecture. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
232 
5 - Acknowledgements 
We thank for Mariana Pimentel and Gustavo Molina their assistance in analyses. 
The financial support provided by the CAPES (Coordenação de Aperfeiçoamento 
de. Pessoal de Nível Superior), is gratefully acknowledged. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
233 
6 - References 
Ayabe, T., D. P. Satchell, C. L. Wilson, W. C. Parks, M. E. Selsted, and Ouelette, 
A. J. (2000). Secretion of microbicidal defensins by intestinal Paneth cells in 
response to bacteria. Nat. Immunol. 1:113–118. 
 
Barker, N., Wetering, M.V and Clevers, H (2008). Genes Dev.  22: 1856-1864. 
doi:10.1101/gad.1674008. 
 
Bornet, F.R.J., Maeflah, K., Menanteau, J. (2002). Enhancement of Gut Immune 
Functions by Short-Chain Fructooligosaccharides and Reduction of Colon Cancer 
Risk. Bioscience Microflora vol. 2 (1), 55-62. 
 
Budiño, F.E.L., Thomaz, M.C., Kronka, R.N. et al (2005). Effect of probiotic and, or 
prebiotic inclusion in weaned piglet diets on structure and ultra-structure of small 
intestine. Braz. Arch. Biol. Technol., v. 48, p. 921-929.  
 
Buddington, K. K. Donahoo. J.B and   Buddington, R.K (2002). Dietary 
Oligofructose and Inulin  Protect Mice from Enteric and Systemic Pathogens and 
Tumor Inducers. J. Nutr. V. 132, p. 472-4 
 
Bouhnik, Y., Flourié, B., d’Agay-Abensour, L, et al. (1997). Administration of 
transgalacto-oligosaccharides increases fecal Bifidobacteria and modifies colonic 
fermentation metabolism in healthy humans. J Nutr. 127:444–8. 
 
Bruzzese, E., Volpicelli, M., Squaglia, M., Tartaglione, A., Guarino, A (2006). 
Impact of prebiotics on human health. Dig Liver Dis. 38 Suppl 2:S283–S287.  
 
Campbell, J.M., Fahey, G.C., & Wolf, B.W. (1997). Selected indigestible 
oligosaccharides affect large bowel mass, cecal and fecal short-chain fatty acids, 
PH and microflora in rats J. Nutr. 127:130-136. 
 
  
234 
Cummings, J. H. (1995). Short chain fatty acids. In: Human Colonic Bacteria: Role 
in Nutrition, Physiology and Pathology. G. R. Gibson and G. T. Macfarlane (Eds). 
CRC Press, Boca Raton, FL, pp. 101–130. 
 
Cummings, J. H.,  MacFarlane, G. T., Englyst, H. N.  (2001). Prebiotic digestion 
and fermentation. Am. J. Clin. Nutr.  73, 415S– 420S. 
 
Cherbut, C., Desravannes, S., Schnee, M., Rival, M., Galmiche, J., Delortlaval, J. 
(1994). Involvement of small intestinal motility in blood glucose response to dietary 
fibre in man. British Journal of Nutrition 71, 675–685.  
 
Delzenne, N. M. & Roberfroid, M. R. (1994). Physiological effects of non-digestible 
oligosaccharides. Lebensm. Wiss. Technol. 27: 1–6. 
 
Delzene, N.M. (2003). Oligosaccharides: state of the art. Nutrition society, 62,177-
182- DOI:10.1079/PNS2002225 
 
Frankel, W. L., Zhang, W., Singh, A., Klurfeld, D. M., Don, S., Sakata T., Modlin, 
I., Rombeau, J. L.  (1994).  Mediation of the trophic effects of short-chain fatty 
acids on the rat jejunum and colon. Gastroenterology 106:375–380. 
  
Gibson, G.R., Probert, H.M., Van Loo, J., Roberfroid, M.B., Rastall, R.A. (2004). 
Dietary modulation of the human colonic microbiota: updating the concept of 
prebiotics. Nutrition Research Reviews 17: 259-275. 
 
Gibson, G.R., Beatty, E.R., Wang, X. et al. (1995). Selective stimulation of 
Bifidobacteria in the human colon by oligofructose and inulin. Gastroenterology 
1995;108:975–82 
 
  
235 
Gonçalves, P., Gregorio, I., Martel F. (2011). The short-chain fatty acid butyrate is 
a substrate of breast cancer resistance protein. Am J Physiol Cell 
Physiol. 301:(5) C984-C994; 
 
Hijova, E., Chmelarova, A. (2007). Short chain fatty acids and colonic health. 
Bratisl Lek Listy. 108(8):354-8. 
 
Hsu, C., Liao, J., Chung, Y., Hsieh, C., Chan, Y. (2004). Xylooligosaccharides and 
Fructooligosaccharides Affect the Intestinal Microbiota and Precancerous Colonic 
Lesion Development in Rats. J. Nutr. 134: 1523–1528, 
 
Ichikawa, H., Kuroiwa, T., Inagaki, A., Shineha, R., Nishihira, T., Satomi, S., 
Sakata,  T. (1999).  Probiotic bacteria stimulate gut epithelial cell proliferation in rat. 
Dig Dis Sci. (10):2119-23. 
 
Ichikawa, H., Shineha, R., Satomi, S., Sakata, T. (2002). Gastric or recital 
instillation of short-chain fatty AIDS stimulates epithelial cell proliferation on small 
land large intestine in rats. Dig Dis Sci 47: 1141-1146   
 
Juśkiewicz, J., Zduńczyk, Z and Jankowski, J. (2006). Growth performance and 
metabolic response of the gastrointestinal tract of turkeys to diets with different 
levels of mannanoligosaccharide. W. Poult. Sci. J. 62:612-625. 
 
Kleessen, B., Sykura, B., Zunft, H. J. & Blaut, M. (1997). Effects of inulin and 
lactose on fecal microflora, microbial activity, and bowel habit in elderly 
constipated persons. Am. J. Clin. Nutr. 65: 1397–1402 
 
Kleessen, B.,  Stoof, G. Proll, J Schmiedl, D. Noack, J and Blaut, M. (1997). 
Feeding resistant starch affects fecal and cecal microflora and short-chain fatty 
acids in rats. J Anin Sci.   75:2453-2462. 
 
  
236 
Koruda, M. J., Rolandelli, R. H.,  Settle, R. G.  (1988). Effect of parenteral nutrition 
supplemented with short-chain fatty acids on adaption to massive small bowel 
resection. Gastroenterology, 95:715–720. 
 
Leforestier, G., Blais, A., Blachier, F., Baglieri, A.M., Gay, A.M.D., Perrin, E., Tome, 
D. (2009).  Effects of galacto-oligosaccharide ingestion on the mucosa-associated 
mucins and sucrase activity in the small intestine of mice. Eur J Nutr.  48:457–64. 
 
Lopez-Molina, D., Nawarro-Martinez, M.D., Melgarejo, F.R., Hiner, A., Chazarra S., 
Rodriguez-Lopez, J.N. (2005). Molecular properties and prebiotic effect of inulin 
obtained from artichoke (Cynara scolymus L). Phytochemistry,  66, 1476–1484 
 
Macfarlane, G.T & Cummings, J.H (1991). The colonic flora, fermentation and 
large bowel digestive function. In The Large Intestine: Physiology, Pathophysiology 
and Disease, pp. 51–92 [SF Phillips, JH Pemberton and RG Shorter, editors]. New 
York: Raven Press Ltd. 
 
Mitsuoka, T. (1992). Intestinal flora and aging. Nutr Rev, New York, v.50, n.12, 
p.438-446. 
 
Mitsuoka, T. (1990). Bifidobacteria and their role in human health. Journal   of  
Industrial  Microbiology,  6:  263-268 
 
Moriya, J., Fachin, L., Gândara, A.L.N., Viotto, W.H. (2006).  Evaluation of culture 
media for counts of Bifidobacterium animalis in the presence  of yoghurt bacteria. 
Braz. J. Microb., 37: 516-520 
 
Moro, G., Minoli, I., Mosca, M., Fanaro, S., Jelinek, J., Stahl, B., Boehm, G. 
(2002).Dosage-Related Bifidogenic Effects of Galacto- and Fructooligosaccharides 
in Formula-Fed Term Infants. Journal of Pediatric Gastroenterology and Nutrition. 
Volume 34 - Issue 3 - pp 291-295.  
  
237 
Mussatto, S.I., Mancilha, I.M. (2007). Non-digestible oligossacharides: A review. 
Carbohydrate Polymers (68), 587-597. 
 
Mroz, Z. (2001). Some developments on Dutch nutritional approaches to protect 
piglets against post-weaning gastrointestinal disorders in the absence of in-feed 
antibiotics. J Anim Feed Sci 10 (suppl. 1): 153-167 
 
Nilsson, U. and Nyman, M. (2005). Short-chain fatty acid formation in the hindgut 
of rats fed oligosaccharides varying in monomeric composition, degree of 
polymerisation and solubility. British Journal of Nutrition. 94, 705–713 DOI: 
10.1079/BJN20051531 
 
Pan, X., Chen, F., Wu, T., Zhao, Z. (2009). Prebiotic oligosaccharides change the 
concentrations of short-chain fatty acids and the microbial population of mouse 
bowel. J Zhejiang Univ Sci B.  April; 10(4): 258–63.doi:  10.1631/jzus.B0820261 
 
Pires, A.L.G., Silveira, T.R., Silva, V.D. (2003). Digital morphometric and 
stereologic analysis of small intestinal mucosa in well-nourished and malnourished 
children with persistent diarrhea. J. Pediatr. 79(4):329-36. 
 
Rao, V. (2001) The prebiotic properties of oligofructose at low intake level. Nutrition 
Research 21, 843–848. 
 
Rabiu, B.A., Jay, A.J., Gibson, G.R. and Rastall, R.A. (2001). Synthesis and 
Fermentation Properties of Novel Galacto-Oligosaccharides by β-Galactosidases 
from Bifidobacterium Species. Appl Environ Microbiol.  June; 67(6): 2526–2530. 
doi:  10.1128/AEM.67.6.2526-2530.2001 
 
Rastall, R.A.,  Maitin, V. (2002). Prebiotics and synbiotics: towards   the   next 
generation Current Opinion in  Biotechnology, n. 13, p. 490-496. 
 
  
238 
Roberfroid, M. B. (1998) Prebiotics and synbiotics: concepts and nutricional 
properties.  British Journal of Nutrition, v. 80 (suppl.), p. S197-S202, 1998. 
 
Roberfroid, M.B., Slavin, J. (2000). Nondigestible oligosaccharides. Crit Rev Food 
Sci Nutr. 40(6):461-80. 
 
Roberfroid, M.B. (2007). Prebiotics: the concept revisited. Journal of  Nutrition 137 
(Suppl.): 830S-837S. 
 
Roberfroid, M.B., Gibson, G.R., Hoyles, L., McCartney, A.L., Rastall, R., Rowland, 
I., Wolvers, D., Watzl, B., Szajewska, H., Stahl, B., Guarner, F., Respondek, F.,  
Whelan, K., Coxam, V., Davicco, M.J., Leotoing, L., Wittrant, Y., Delzenne, N.M., 
Cani, P.D., Neyrinck, A.M. and Meheust, A., (2010). Prebiotic effects: metabolic 
and health benefits.  British Journal of Nutrition, 104, S1-S63. 
 
Rosen, G.D. (2007). Holo-analysis of the efficacy of Bio-Mos® in broiler nutrition. 
Br. Poult. Sci. 48, 21-26. 
 
Ruppin,  H.,  Bar-Meir,  S.,  Soergel,  K.H., Wood,  C.M., Schmitt,  M.G. (1980).  
Absorption of short-chain fatty acids by the colon. Gastroenterol. 78: 1500-1507. 
 
Santos, R., Simiqueli, A.P.R  and  Pastore, G.M. (2009). Produção de 
galactooligossacarídeo por Scopulariopis sp.  Ciênc. Tecnol. Aliment. vol.29, n.3, 
pp. 682-689. ISSN 0101-2061. 
 
Sancho, E., Batlle, E., and Clevers, H. (2003). Live and let die in the intestinal 
epithelium. Curr. Opin. Cell Biol. 15: 763–770. 
 
Salminen, S., Bouley, C., Boutron-Ruault,  M.C. et  al. (1998).  Functional food and 
science gastrointestinal physiology and function. Br J. Nutr.  80:S147-S171. 
 
  
239 
Sakata, T., Adachi, M., Hashida, M., Sato, N., Kojima, T. (1995). Effect of n-butyric 
acid on epithelial cell proliferation of pig colonic mucosa in short-term culture. Deut 
Tierarztl Woch 102: 163-164.   
 
Sakaguchi, E., Sakoda, C., Toramaru, Y. (1998). Caecal fermentation and energy 
accumulation in the rat fed on indigestible Oligosaccharides. British Journal of 
Nutrition.  80, 469–476. 
 
Silva, V.K., Silva, J.D.T., Gravena, R.A., Marques, R.H., Hada, F.H., Moraes, V.M. 
(2010). Yeast extract and prebiotic in pre-initial phase diet for broiler chickens 
raised under different temperatures. R. Bras. Zootec., v.39, n.1, p.165-174. 
 
Sghir, A., J. M. Chow, and R. I. Mackie. (1998). Continuous culture selection of 
bifidobacteria and lactobacilli from human faecal samples using fructo-
oligosaccharides as selective substrate. J. Appl Micro. 85:769-777. 
 
Scheppach, W. (1998). Butyrate and the epithelium of the large intestine. Proc. 
ofthe Proyibre Cons-Functional Properties of Non-digestible Carbohydrates, 
Guillon et al. teds), Lisbon, Portugal.  
 
Solis de los Santos, F.,  Farnell, M. B., Tellez, G., Balog, J. M., Anthony, N. B., 
Torres-Rodriguez, A., Higgins, S., Hargis, B. M.,  Donoghue,  A. M. (2005). Effect 
of prebiotic on gut development and ascites incidence of broilers reared in a 
hypoxic environment. Poult. Sci. 84:1092–1100. 
 
Solis de los Santos, F., Donoghue, A. M.,  Farnell, M.B, Huff, G.R., Donoghue, 
D.J.(2007).Gastrointestinal Maturation is Accelerated in Turkey Poults 
Supplemented with a Mannan-Oligosaccharide Yeast Extract (Alphamune). Poultry 
Science 86:921–930. 
 
  
240 
Silva, V.K., Silva, J.D.T., Gravena, R.A et al.(2009).Desempenho de frangos de 
corte de 1 a 21 dias de idade alimentados com rações contendo extrato de 
leveduras e prebiótico e criados em diferentes temperaturas.Revista Brasileira de 
Zootecnia, v.38, n.4, p.690-696. 
 
Smiricky-Tjardes, M. R., Grieshop, C. M., Flickinger, E. A., Bauer, L. L., Fahey, G. 
C. Jr. (2003).  Dietary galactooligosaccharides affect ileal and total-tract nutrient 
digestibility, ileal and fecal bacterial concentrations, and ileal fermentative 
characteristics of growing pigs. J. Anim. Sci. 81:2535–2545. 
 
Topping, D. L., Clifton, P.M. (2001). Short-Chain Fatty Acids and Human Colonic 
Function: Roles of Resistant Starch and Nonstarch Polysaccharides. Physiol 
Ver.  vol. 81 no. 3 1031-1064. 
 
Tuohy, K.M., Kolida, S., Lustenberger, A.,  Gibson, G.R. (2001) The prebiotic 
effects of biscuits containing partially hydrolyzed guar gum and 
fructooligosaccharides — a human volunteer study. British Journal of Nutrition 86, 
341– 348. 
 
Vesna, T., Lazarevic, M., Sinovec, Z., Tokik, A. (2007).  The influence of different 
feed aditives to performance and immune response in broiler Chicken. Acta 
Veterinária, v. 57, n. 2-3, p. 217-229. 
 
Wong, J.M.W., de  Souza,  R.,  Kendall, C.W.C., Emam, A., Jenkins,  D.J.A. 
(2006). Colonic health: fermentation and short chain fatty acids. J.Clin. 
Gastroenterol. 40: 235-243. 
 
Wong, J. M. W., Jenkins, D. J. A. (2007). Carbohydrate Digestibility and Metabolic 
Effects. J. Nutr.  vol. 137 no. 112539S-2546S. 
 
  
241 
XU,  Z.R., Hu, C.H., Xia, M.S., Zhan, X.A and Wang, M.Q. (2003).  Effects of 
Dietary Fructooligosaccharide on Digestive Enzyme Activities, Intestinal Microflora 
and Morphology of Male Broilers. Poultry Science 82:1030–1036 
 
Younes, H., Garleb, K., Behr, S., Remesy, C. & Demigne, C. (1995). Fermentable 
fibers or oligosaccharides reduce urinary nitrogen excretion by increasing urea 
disposal in the rat cecum. J. Nutr. 125: 1010 –1016. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
242 
CONCLUSÕES GERAIS E PERSPECTIVAS FUTURAS 
 
 
 O presente trabalho foi desenvolvido com o objetivo de avaliar as 
propriedades funcionais e efeitos prebióticos dos galacto-oligosacarídeos (GOS) 
produzido pela ação da enzima β-galactosidase produzida pelo fungo 
Scopulariopsis sp. Os experimentos foram realizados in vitro e in vivo utilizando 
ratos wistar como modelo animal e permitiram as seguintes conclusões. 
 
 
● Os GOS produzido pela ação da enzima β-galactosidase extraída do fungo 
Scopulariopsis sp  demonstrou características prebióticas. Não foi hidrolisado 
pelas enzimas digestivas, foi seletivamente fermentado no colon pelas bactérias 
fecais e convertido em ácidos graxos de cadeia curta: acetato, butirato e 
propionato (analisados por cromatografia gasosa). 
 
● De acordo com os resultados obtidos os GOS não produziram efeitos adversos 
(tóxicos) mesmo quando ingerido em doses elevadas no modelo experimental 
utilizado. 
 
● A suplementação de GOS promoveu um aumento significativo na população de 
bifidobacterias e lactobacilos e inibiu o crescimento de bacteria patogênica (E.coli), 
e aumentou a concentração de ácidos graxos de cadeia curta no ceco e 
conseqüentemente promoveu uma redução no pH cecal e fecal 
 
  
243 
 
● O estudo histológico demonstrou que a suplementação de GOS promoveu um 
aumento na altura das vilosidades e na relação altura de vilo/profundidade de 
cripta e diminui a profundidade das criptas no jejuno e íleo, promovendo 
mudanças benéficas na arquitetura intestinal, sendo uma das características para 
análise de absorção de nutrientes associadas a produção de AGCC. 
 
● Desta forma, os GOS produzidos pela β-galactosidase por Scopulariopsis sp 
promoveu varias alterações fisiológicas benéficas no trato-gastrointestinal. 
 
● De acordo com os resultados obtidos, pode se concluir que os GOS produzidos 
pela  β-galactosidase por Scopulariopsis  sp pode ser uma nova fonte de 
ingrediente alimentar  funcional, pois apresenta características cientificamente 
comprovada de propriedades funcionais e efeitos prebióticos. 
 
● No entanto, novos estudos são necessários para verificar quais os 
oligossacarídeos presentes são responsáveis pelos efeitos benéficos à saúde, já 
que se trata de uma mistura diferente aos demais. 
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ANEXO I - Parecer do Comitê de Ética 
 
 
